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Abstract
Protein therapeutics like insulin and glucagon-like peptide-1 analogues are currently used
as injectable medications for the treatment of diabetes mellitus. An orally administered protein
therapeutic is predicted to increase patient adherence to medication and bring a patient closer to
metabolic norms through direct effects on hepatic glucose production. The major problem facing
oral delivery of protein therapeutics is gastrointestinal tract hydrolysis/proteolysis and the
inability to passage the enterocyte. Herein we report the potential use of vitamin B12 for the oral
delivery of protein therapeutics.
We first investigated the ability of insulin to accommodate the attachment of B12 at the
B1 vs. B29 amino acid position. The insulinotropic profile of both conjugates was evaluated in
streptozotocin induced diabetic rats. Oral administration of the conjugates produced significant
drops in blood glucose levels, compared to an orally administered insulin control, but no
significant difference was observed between conjugates. We also report, for the first time, a dose
dependent response of a B12-insulin conjugate. We then explored the implications of B12
conjugation on the biological activity of the potent peptide glucagon-like peptide-1 (7-36) amide,
with a K34R amino acid substitution. Various in vitro bioassays utilizing human embryonic
kidney cells and human pancreatic islets were conducted and indicated B12 has a minimally
negative effect on GLP-1 biological activity. Finally we modified the structure of B12 for future
conjugation work. The modification of the 5’hydroxyl group of the ribose unit of B12 to a
carboxylic acid is predicted to benefit the field of B12 conjugation significantly with the ability to
produce higher yielding and more stable B12 conjugates.

The Path to an Orally Administered Protein Therapeutic for the
Treatment of Diabetes Mellitus
By
Susan Clardy-James
B.S. Chemistry, Millikin University 2008

DISSERTATION
Submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy in Chemistry
in the Graduate School of Syracuse University
December 2012

Copyright 2012 © Susan Clardy-James
All rights reserved

Acknowledgements
It would not have been possible to write this thesis without the guidance and support of many
kind people around me, to only some of whom it is possible to give particular mention here.
I am truly indebted and thankful to my advisor, Professor Robert P. Doyle, whose
encouragement, wisdom and commitment to the highest standards inspired and motivated me to
become the scientist I am today. I will forever be thankful for his patience, guidance and support
throughout my time at Syracuse University. I could not have imagined having a better advisor
and mentor for my Ph. D studies and am incredibly grateful to have had the opportunity to work
with him.
I would like to thank all of the individuals in the Doyle lab. Each one brought a different
perspective that helped me grow and learn in unexpected ways. I especially want to thank
Professor Nadia Marino for the wonderful conversation about research, life and the future. I also
want to thank Professor G. G. Holz, Dr. Colin Leech and Dr. Oleg Chepurny for allowing me the
opportunity learn a new skill, in a new lab.
I would also like to thank my friends and family for their love and support. My dearest
friend, Jessica Seely, for being there any time even with thousands of miles between us. My
parents, Theresa and Richard Clardy, for always loving me and encouraging me to never stop
learning. My brother, Richard Clardy Jr., for putting things into perspective and reminding that
there is a world outside the lab. Last but far from least, my husband, Stephen James, for his
tireless devotion and complete understanding through the good and bad times. I am without a
doubt blessed to have such an amazing support system and am truly thankful to all of them.

iv

Table of Contents
Page
Chapter 1 General Introduction

1

1.1 Diabetes Mellitus

1

1.2 Injectable Peptides and Proteins for the Treatment of Diabetes Mellitus

2

1.2.1 Insulin

3

1.2.1.1 History and Discovery

3

1.2.1.2 Biosynthesis and Secretion of Insulin

4

1.2.1.3 Structure and Sequence of Bovine Insulin

8

1.2.1.4 The Insulin Receptor

10

1.2.2 Glucagon-Like Peptide-1

12

1.2.2.1 Discovery of the Incretin Effect

12

1.2.2.2 Biosynthesis and Secretion

13

1.2.2.3 Structure and Sequence of Human GLP-1

15

1.2.2.4 The Glucagon-Like Peptide Receptor

16

1.3 A Pursuit of a Noninvasive Peptide/Protein Treatment for Diabetes Mellitus
1.3.1 Strategies for Oral Delivery of Peptides and Proteins
1.4 Vitamin B12

17
19
20

1.4.1 History

20

1.4.2 Structure and Chemistry of Vitamin B12

21

1.4.3 Physiological Roles of B12

23

1.4.4 The Dietary Uptake Pathway Overview

25

1.4.5 Haptocorrin

27

v

1.4.6 Intrinsic Factor

27

1.4.7 Cubilin and Amnionless

29

1.4.8 Transcobalamin

31

1.4.9 Megalin and TCblR/CD320

34

1.5 Using the B12 Pathway for Drug Delivery
1.5.1 Targeted Delivery

35
35

1.5.1.1 The Use of B12 for Imaging

37

1.5.1.2 Vitamin B12 Therapeutics

38

1.5.2 Oral Delivery of Peptides and Proteins

40

1.6 Points of Modification on B12

40

1.7 Summary

43

1.8 References

43

Chapter 2 Investigating the B12 Uptake Pathway for the Oral Delivery of Insulin

54

2.1 Introduction

54

2.2 Results and Discussion

58

2.2.1 Synthesis of B12-B1Insulin (1) and B12-B29Insulin (2)

57

2.2.2 MALDI-ToF Mass Spectrometry

62

2.2.3 Electronic Absorption Spectroscopy

65

2.2.4 In vivo experimentation

66

2.3 Conclusion

72

2.4 References

74

Chapter 3 Exploring the effect of B12 on Glucagon-Like Peptide-1 Biological Activity
3.1 Introduction

77
77

vi

3.2 Results and Discussion

80

3.2.1 Synthesis and Purification of B12-K34R-GLP-1 (7-36) amide (3)

80

3.2.2 MALDI-ToF Mass Spectrometry

82

3.2.3 In vitro Experimentation

83

3.3 Conclusion

90

3.4 References

90

Chapter 4 Synthesis of a B12 Derivative Capable of Amide Bond Formation

93

4.1 Introduction

93

4.2 Results and Discussion

95

4.2.1 Synthesis of B12 5’-carboxylic acid (4)

95

4.2.2 1D and 2D NMR analysis of 4

100

4.2.3 Synthesis of B12 5’-carboxylic acid-benzylamine (5)

104

4.3 Conclusion

110

4.4 References

110

Chapter 5 Experimental Procedure

113

5.1 Materials and Methods

113

5.2 Experimental Procedure

114

5.2.1 Synthesis of B12-B1Insulin (1)

114

5.2.2 Synthesis of B12-B29Insulin (2)

115

5.2.3 Synthesis of B12-K34R-GLP-1(7-36) amide (3)

116

5.2.4 Synthesis of B12-5’-carboxylic acid (4)

116

5.2.5 Synthesis of B12 5’-carboxylic acid-benzylamine (5)

117

5.3 In vitro Experimentation of 3

118

vii

5.3.1 Cell Cultures

118

5.3.2 Luciferase Assay

118

5.3.3 Fura-2 Assay

118

5.3.4 Insulin Secretion in Human Pancreatic Islets

119

5.4 In vivo Experimentation of 1 and 2

120

5.5 References

120

Chapter 6 Future Work

122

6.1 Vitamin B12

122

6.2 Glucagon-Like Peptide-1

127

6.3 C-peptide

128

6.4 References

129

Appendix A Publications arising from this work in chronological order

viii

List of Figures
Page
Figure 1.

The primary treatment goal for DM is to maintain glycemic control

2

(indicated as normal glucose level). Glycemic control in a patient
with diabetes can be challenging since the proper amount of insulin
must be administered after meals. Not injecting enough or injecting
too much insulin will result in hyperglycemia or hypoglycemia,
respectively. While persistent hyperglycemia causes microvascular
complications, hypoglycemia can cause diabetic coma or death.
Figure 2.

The subcellular organization of the insulin secretory pathway.

5

Figure 3.

The post-translational modifications of preproinsulin, which results

6

in active monomeric insulin and C-peptide.
Figure 4.

Glucose induced insulin secretion (GSIS) is regulated by three

8

pathways: triggering pathway, metabolic amplify pathway and
neurohormonal amplify pathway. Gs: Gs α subunit, AC:
adenyl cyclase.
Figure 5.

A representation of the primary structure of bovine insulin including
the disulfide bonds formed between the A- and B-chains and the Achain intrachain disulfide bond.

ix

9

Figure 6.

A carton representation of the domain organization within the

11

homodimeric insulin receptor. L1, L2: first and second leucine-richrepeat domains, CR: cysteine-rich region, Fn0-1-2: fibronectin domains,
Ins: Insulin insert domain, TM/JM: trans- and juxta-membrane regions,
TK: tyrosine kinase domain and CT: C-terminal domain.
Figure 7.

The primary structure of human GLP-1 (7-36) amide. The C-terminal

15

amidation has been shown to increase plasma stability.
Figure 8.

The secondary structure of GLP-1 (7-36) amide determined by

16

solution NMR. Lys 26 (indicated as ball and stick) has been identified
as the best position for conjugation.85 Protein data bank ID: 1D0R.
Modified using RCSB PDB protein workshop software 3.9.
Figure 9.

An illustration of the physical barriers and available pathways for

18

oral drug delivery in the intestines.
Figure 10.

Structure of B12 with a variable R group shown to the left. Three of

22

the more common forms of B12 (cyanocobalman, methylcobalamin and
adenosylcobalamin) are shown to the right.
Figure 11.

Outline of methionine synthase (Enz) catalytic cycle, which involves
two methyl transfer half-reactions: homocysteine to methionine and N5methyltetrahydrofolate to tetrahydrofolate.

x

24

Figure 12.

An overview of the B12 uptake pathway as outlined by a recent 2012

26

review. The transfer of B12 from IF to TCII is currently being debated as
discussed in section 1.4.7 and shown in Figure 15. Image is reproduced
from reference 120 with permission of Nature Publishing Group. MRP1:
multidrug resistance protein 1.
Figure 13.

Ribbon diagram of IF-B12 complex with the B12 shown in ball and stick.

29

Used with permission of National Academy of Science from reference
129.
Figure 14.

The structure of CUB 5-8 (left, blue) interacting with IF bound to B12

31

(right, green and pink). The interaction is calcium (red sphere) dependent.
The image is reproduced from reference 125 with permission from Nature
Publishing Group.
Figure 15.

There are currently two theories involving the export of B12. a)

32

Seetharam et al. present B12 bound to TCII in the cell while more
recently b) Nexo et al. have established an alternative export system
involving MRP1. Images used from references 146 (a) and 120 (b) with
permission from Cambridge University Press and Nature Publishing
Group, respectively.
Figure 16.

A representation of the TCII-B12 complex. The TCII α-domain is shown 33
on the bottom (red) with the β-domain on top (blue). The B12 molecule is
shown in ball and stick and found sandwiched between the two domains
(orange). Reprinted from reference 132 with permission of National
Academy of Science.

xi

Figure 17.

Conjugation can occur at any of the functional groups (indicated in

42

shaded shapes) without loss of binding by the three uptake proteins.
Figure 18.

A basic representation of the B12 dietary uptake pathway.

55

Figure 19.

The three amine groups available for conjugation on the bovine insulin

57

structure are indicated. Conjugation at the GlyA1 has previously been
shown to eliminate biological activity, therefore only the PheB1 and
LysB29 are available for conjugation.
Figure 20.

The activation of B12 occurs at the 5’-hydroxyl group of the ribose

59

with the aid of CDT. B12 Act = CDT activated B12.
Figure 21.

The synthetic route of 1 and 2 are outlined.

60

Figure 22.

The RP-HPLC spectra of a BOC protected insulin plus B12 reaction

61

monitored at 254 nm.
Figure 23.

The RP-HPLC spectra of an FMOC protected insulin plus B12 reaction

62

monitored at 360 nm (Dash, indicating B12 is present) and 254 nm
(Solid, indicating insulin is present).
Figure 24.

A representative MALDI-Tof MS spectrum of DTT reduced 1 or 2
shows mass at 4754 m/z representing [B12-CN+H]+attached to the
B chain of insulin. Absent is B12 attached to the A strand, 3694 m/z.

xii

63

Figure 25.

(a) MALDI-Tof MS spectrum of reduced and tryptically digested

64

1 produces a 2286 m/z fragment consistent with [B12-CN+H]+
attached to the LysB29 position. (b) Reduced and tryptically digested
2 produces a 3844 m/z fragment consistent with [B12-CN+H]+ at the
N-terminus of the B strand, as expected with PheB1 conjugation.
Figure 26.

The “typical” absorption spectra of CNCbl. The predominate bands

65

highlighted (α, β, and γ) are due to spin allowed intraligand charge
transfers of the corrin ring.
Figure 27.

The electronic absorption spectra of B12-insulin conjugate contain

66

the characteristic B12 peaks and insulin peak.
Figure 28.

Relative (% change from pre-gavage) blood glucose concentration

67

following administration of 1 at concentrations of 10-9 M, 10-7 M
and 10-5 M.
Figure 29.

Relative (% pre-gavage) blood glucose concentration following

68

administration of free insulin (n=4), 1 (n=6) and 2 (n=6).
Figure 30.

MD simulation of TCII bound to 1. TCII structure: α-domain (red);
β-domain (dark blue); unstructured linkage between domains (green).
Structure of 1: B12 (yellow ball and stick) with Co (III) (blue sphere);
Insulin B-chain (yellow ribbon); A-chain (light blue ribbon). The
structure was produced using the GROMACS software package with
GROMOS96 (53a6) united-atom force field by collaborator Dr.
Damien Allis at Syracuse University.

xiii

70

Figure 31.

A representative structure of 1 bound within TCII. The structure was

72

produced from a molecular dynamic simulation performed using the
same software as previously described in Figure 30 by collaborator
Dr. Damien Allis at Syracuse University.
Figure 32.

GLP-1 (7-36) amide was purchased with N-terminal FMOC protection

80

and K34R amino acid substitution (purple) which will be referred to as
FMOC-K34R-GLP-1. These modifications allow for site directed B12
conjugation at the Lys26 (blue).
Figure 33.

RP-HPLC chromatogram showing separation of unconjugated B12 and

82

K34R-GLP-1 (7-36) amide from B12 conjugated K34R-GLP-1 (7-36)
amide with detection at 254 nm (solid line) and 360 nm (dash line).
Absence of B12 absorption at 360 nm indicated the peak at retention
time (Tr) ~ 24 mins is unconjugated K34R-GLP-1 (7-36) amide now
with two FMOC units, while the peak at Tr ~ 20 mins is B12 conjugated
K34R-GLP-1 (7-36) amide with one FMOC.
Figure 34.

MALDI-ToF MS spectrum of 3 after FMOC removal showing the

83

presence of a prominent peak at 4682 m/z representing a 1:1
B12-K34R-GLP (7-36) amide.
Figure 35.

A basic depiction of the intercellular mechanisms of the GLP-1R,
which were monitored for in vitro assays described in section 3.2.5.
RYR: ryanodine receptor; ER: endoplasmic reticulum; CRE: cAMP
response element. RIP-1-CRE-Luc: rat insulin 1 promoter-cAMP
response element-luciferase reporter.

xiv

84

Figure 36.

The fold increase of luciferase activity was determined for 3 and

85

K34R-GLP-1 (7-36) amide after HEK-GLP-1 cells were transfected
with a RIP1-CRE-Luc reporter and were exposure to 3 for 4 hrs.
3 produced a concentration dependent response with an EC50 of
4.5 nM, while K34R-GLP-1 (7-36) amide had an EC50 of 4.1 nM.
Figure 37.

Fura-2 determinations of intercellular [Ca2+] were obtained in

87

HEK-GLP-1R cells that express endogenous P2Y purinergic receptors.
Note that both forms of GLP-1 potentiated the action of ADP to mobilize
intracellular [Ca2+] and that native GLP-1 was slightly more potent than
3. Data are averaged from 12 wells for each data point and similar results
were obtained in four independent plates with three different batches of 3.
Figure 38.

Pure human pancreatic islets isolated from digested pancreatic tissues,

88

as seen under a microscope. Image reprinted from reference 31 with
permission of Baishideng Publishing Group Co.
Figure 39.

Static incubation assays using human pancreatic islets. Islets were
exposed to KRB containing 2.8 mM glucose for 30 min and were
then exposed to KRB containing 16.7 mM glucose with GLP-1 or 3
or without test substance. GSIS resulted in a 1.4 fold insulin secretion
while a 2.1 fold increase was observed for 3, which is comparable to
GLP-1 (2.8 fold).

xv

89

Figure 40.

Potential sites available for carboxylic acid formation that also maintain, 94
at least in part, B12 uptake protein recognition and binding are indicated
in red. The atom numbering scheme used for future NMR discussion
(see section 4.2.2) is also indicated.

Figure 41.

The structure of 2-iodoxybenzoic acid (IBX).

95

Figure 42.

Purposed mechanism for the formation of 4 utilizing IBX and 2-

96

hydroxypyridine (HYP).
Figure 43.

The RP-HPLC spectra of 4 (Tr = 13.5 mins.) monitored at 360 nm.

98

Unreacted B12 and 5’aldehyde co-elute at ~ Tr = 6 mins as indicated
by MALDI-ToF MS.
Figure 44.

MALDI-ToF MS spectrum of HPLC peak at Tr = 14 mins indicating 4

99

([M-CN]+ 1343.5 m/z) with angiotensin as an internal reference.
Figure 45.

Absorbance spectrum of 4 in 35 % HPLC mobile phase B.

100

Figure 46.

500 MHz 1H NMR spectrum of 4.

101

Figure 47.

500 MHz 1H-13C HSQC NMR spectrum of 4.

101

Figure 48.

500 MHz 1H-13C HMBC NMR spectrum of 4.

102

Figure 49.

500 MHz 1H NMR spectrum of B12 (CNCbl).

103

Figure 50.

Portion of HSQC of 4 (right) and B12( left) highlighting the loss of

104

protons (δH = 3.75 and 3.92) due to oxidation at the R5 carbon
(δC = 63.3) in the 4.
Figure 51.

Synthesis of 5.

105

xvi

Figure 52.

Purification of the conjugate was established by RP-HPLC using

105

an SAX column with a gradient from 100% water to 35% MeCN:
phosphate buffer pH 2.
Figure 53.

MALDI-ToF MS spectrum of 5 ([M-CN+H]+ 1432.5). Angiotensin

106

was used as an internal reference (not shown).
Figure 54.

500 MHz 1H NMR spectrum of 5.

107

Figure 55.

500 MHz 1H-13C HSQC NMR spectrum 5.

107

Figure 56.

500 MHz 1H-13C HMBC of 5.

108

Figure 57.

Analysis of the 5 by 2D heteronuclear NMR spectroscopy. A. The

108

atom numbering scheme for the benzylamine attached to the R5 of
B12 by an amide bond. B. Signal assignments made from HSQC. C.
Signal assignments made from HMBC (Both 1H and 13C assignment
for CA were made by HSQC).
Figure 58.

Rendering of B12-insulin (yellow-blue) bound by TCII (red and dark

123

blue) produced by collaborator Dr. Damien Allis at Syracuse
University. It is possible for such a structure to bind either the TCII
receptor CD320 or the insulin receptorCD220 as indicated. The image
was altered from 2 with permission of The Royal Society of Chemistry
(RSC) on behalf of the Centre National de la Recherche Scientifique
(CNRS).
Figure 59.

Structure of B12 with side chain propionamides indicated. Conversion
of the propionamide at the b position to a carboxylic acid is cited as
reducing TCII protein binding of B12.

xvii

124

Figure 60.

RP-HPLC of B12 b carboxylic acid derivative.

125

Figure 61.

Competitive binding study of human TCII vs. mouse TCII with

126

B12-Insulin (AKP1), B12 b carboxylic acid-insulin (AKP2), B12 b
carboxylic acid (Acid) and control B12 from two sources (B12 USA
and B12 DK).

xviii

List of Tables
Page
36

Table 1.

B12-small molecule conjugates

Table 2.

Optimization of the Reaction Conditions for 4.

96

Table 3.

1

108

H and 13C chemical shifts for the B12 5’-carboxylic acid (B12CA),

B12 5’-carboxylic acid benzylamine (B12CABA) and B12 (CNCbl)
in D2O [500 MHz].

xix

List of Abbreviations
aa

Amino acid

AC

Adenyl cyclase

AdoCbl

Adensylcobalamin

ADP

Adenosine diphosphate

ANTIDE

Luteinizing hormone releasing hormone antagonists

ATP

Adenosine triphosphate

AUC

Area under the curve

B12

Vitamin B12, cobalamin

B12Act

B12 activated by CDT

BOC

t-butyloxycarbonyl

cAMP

Cyclic adenosine monophosphate

CD

Circular dichroism

CD220

Insulin receptor

CDC

Center for Disease Control and Prevention

CDI

1, 1'-carbonyldiimidazole

cDNA

Complementary deoxyribonucleic acid

xx

CDT

1, 1’-carbonyl-di-(1, 2, 4-triazole)

CH3CN

Acetonitrile

CHCA

α-cyano-4-hydroxycinnamic acid

CICR

Calcium induced calcium release

CNCbl

Cyanocobalamin

CNRS

Centre National de la Recherche Scientifique

CoA

Coenzyme A

CPE

Carboxypeptidase E

CR

Cysteine-rich region

CRE

cAMP response element

CT

C-terminal domain

CUB

Components C1r/C1s, the sea urchin protein Uegf, and bone
morphogenic protein-1

DAG

Diacylglycerol

DCC

N,N'- dicyclohexylcarbodiimide

DM

Diabetes mellitus

DMB

5,6-dimethylbenzimidazole

DMF

Dimethylformamide
xxi

DMSO

Dimethyl sulfoxide

DPP-IV

Dipeptidyl peptidase IV

DTPA

Diethylenetriamine-N,N,N',N",N" -pentaacetic acid

DTT

Dithiothreitol

EAS

Electronic absorption spectrometry

ECD

Extracellular domain

EC50

Half maximal effective concentration

EDAC

1-ethyl-3-(3-dimethylaminopropyl)carbodiimide

EDC

Ethyl-3-(3-dimethylaminopropyl)carbodiimide

EGF

Epidermal growth factor

Enz

Methionine synthase

EPO

Erythropoietin

ER

Endoplasmic reticulum

Et2O

Diethyl ether

FBS

Fetal bovine serum

FMOC-K34R-GLP-1

Glucagon-like peptide (7-36) amide with a K34R amino acid
substitution and N-terminal FMOC protection

FMOC-OSu

N-(9-Fluorenylmethoxycarbonyloxy)succinimide
xxii

Fn0-1-2

Fibronectin domains

Fura-2 AM

Fura-2 acetoxymethyl ester

G-CSF

Granulocyte-colony stimulating factor

GIIS

Glucose induced insulin secretion

GIP

Glucose-dependent insulinotropic polypeptide

GIT

Gastrointestinal tract

GLP-1

Glucagon like peptide-1

GLP-1R

Glucagon-like-peptide-1 receptor

GPCR

G protein-coupled receptor

GRP

Gastrin-releasing peptide

Gs

Gs alpha subunit

GSIS

Glucose stimulated insulin secretion

HC

Haptocorrin

HEK-293

Human embryonic kidney

HEK-GLP-1R

HEK-293 cells stably expressing the human GLP-1 receptor

HOBt

1-hydroxybenzotriazole

HPMA

Lysine-modified-hydroxypropyl-methacrylamide

xxiii

hr

Hour

HYP

2-hydroxypyridine

IBX

2-iodoxybenzoic acid

ICR

Islet Cell Resource

IF

Intrinsic factor

Ins

Insulin insert domain

IP3

Inositol 1,4,5-triphosphate

JM

Juxtamembrane regions

K34R-GLP-1

Glucagon-like peptide-1 (7-36) amide with a K34R amino acid
substitution

KRB

Krebs-ringer buffer

L1

First leucine-rich-repeat domains

L2

Second leucine-rich-repeat domains

LDL

Low density lipoprotein

LMBD1

Lipocalin receptor like protein

Luc

Luciferase

MALDI-ToF

Matrix assisted laser desorption ionization time of flight

MeCbl

Methylcobalamin
xxiv

min

Minutes

MRP1

Multidrug resistance protein 1

MS

Mass spectrometry

MWCO

Molecular weight cutoff

NMR

Nuclear magnetic resonance

NO

Nitric oxide

NOCbl

Nitrosylcobalamin

PC 1/3

Prohormone convertases 1/3

PC 2

Prohormone convertases 2

PEG

Poly(ethylene glycol)

RER

Rough endoplasmic reticulum

RIP1-CRE

Promoter region of the rat insulin 1 gene a cAMP response element

RIP1-CRE-Luc

Rat insulin 1 promoter-cAMP response element-luciferase reporter

RNR

Ribonucleotides reductase

RP-HPLC

Reverse-phase high pressure liquid chromatography

RSC

The Royal Society of Chemistry

RYR

Ryanodine receptor

xxv

STZ

Streptozotocin

T1D

Type I diabetes mellitus

T2D

Type II diabetes mellitus

TBTU

O-(Benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium
tetrafluoroborate

TCII

Transcobalamin II

TEA

Triethylamine

TFA

Trifluoroacetic acid

TK

Tyrosine kinase domain

TM

Transmembrane regions

Tr

Retention time

TSTU

((N,N,N′,N′-Tetramethyl-O-(N-succinimidyl) uronium
tetrafluoroborate

TTHA

triethylenetetramine-N,N,N',N",N"',N"'-hexacetic acid

TZD

Thiazolidinedione

xxvi

Chapter 1 General Introduction
1.1 Diabetes Mellitus
Diabetes mellitus (DM) is a series of diseases characterized by the body’s inability to
produce (type I, T1D) or properly use (type II, T2D) the hormone insulin, resulting in
abnormally high blood glucose levels.1 T1D accounts for 5-10% of all newly diagnosed cases
and is a result of the body’s immune system destroying pancreatic β cells,2, 3 which are the only
cells in the body capable of producing insulin. In addition to genetic factors, environmental
conditions have also been described as risk factors for T1D.2, 4 There is no known prevention for
T1D and it is usually diagnosed in people younger than 30.2 In T2D, there is an inability to
produce enough insulin to meet the body’s insulin sensitivity level. As the disease progresses,
pancreatic β cell mass declines and the insulin deficiency increases. The onset of T2D is usually
later in life, although it has recently been diagnosed in children.1, 5, 6 T2D is much more prevalent
then T1D, accounting for 90-95% of all new cases. Research suggests physical inactivity and
excess body weight increases your risk for T2D.7-11
According to a study conducted in 2011 by the Center for Disease Control and Prevention
(CDC), 8.3% of the United States’ population is affected by DM.1 The number of DM cases is
expected to increase significantly in the coming years, if current trends continue.1 DM is
currently the third leading cause of death in the United States, just behind cancer and heart
disease.1, 12 The high morbidity rate associated with DM has been attributed to the microvascular
(retinopathy, nephropathy, and neuropathy) and macrovascular (cardiovascular disease)
complications that result due to prolonged hyperglycemia.13 The annual diabetes-related
spending in the United States is also expected to increase from $113 billion to $336 billion by

1

2034.14 The increasing prevalence and growing costs associated with DM has made it a major
healthcare concern in the United States today.11, 12, 14
1.2 Injectable Peptides and Proteins for the Treatment of DM
One of the primary goals for the treatment of DM is achieving and maintaining metabolic
norms in regards to blood glucose levels (see Figure 1).15 Fluctuation in blood glucose levels
often leads to serious health complications including retinopathy, nephropathy, and neuropathy,
as previously mentioned.13

Figure 1. The primary treatment goal for DM is to maintain glycemic control (indicated as
normal glucose level). Glycemic control in a patient with diabetes can be challenging since the
proper amount of insulin must be administered after meals. Not injecting enough or injecting too
much insulin will result in hyperglycemia or hypoglycemia, respectively. While persistent
hyperglycemia causes microvascular complications, hypoglycemia can cause diabetic coma or
death.13, 16
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Patients with T1D require an exogenous source of insulin, often administered by
subcutaneous injection, to maintain normal glycemic levels. In T2D the body still produces
insulin, but the cells are unable to use it efficiently. The initial treatment for T2D is diet,
exercise and oral anti-diabetic medications such as metformin,17 sulphonylureas,18 and
thiazolidinedione (TZD)19 in an attempt to slow or reverse the disease. These oral treatments
lose efficacy over time as the disease progresses and a transition to injectable medications is then
required.20, 21 Injectable insulin has been the primary medication for DM since its discovery in
1922.15 Recent research has focused on the importance of incretin peptides like glucagon like
peptide-1 (GLP-1) for the co-management of DM.22, 23
1.2.1 Insulin
1.2.1.1 History and Discovery
A number of important scientific observations led to the ultimate discovery of insulin in
1922 by Canadian scientists Frederick Banting, Charles Best, John Macleod and Bertram
Collip.24-26 In 1869, Paul Langerhans, a German medical student, observed a cluster of cells
within the pancreatic tissues that did not have a reported function. This cluster would later be
named the ‘islets of Langerhans’, and include insulin secreting β cells. Twenty years later, Oskar
Minkowski and Joseph van Mering determined removing the pancreas of a dog resulted in
diabetes, but ligating the duct through which pancreatic juices flow to the intestines only resulted
in minor digestive problems, but not diabetes. This suggested the pancreas had at least two
functions and one of them involved the regulation of glucose.27
It was Dr. Frederick Banting that hypothesized that pancreatic digestive juice may be
harmful to the pancreatic secretion produced by the islets of Langerhans. Banting convinced
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Professor John Macleod at the University of Toronto to fund his idea and he began work in 1921.
As a surgeon, Banting was able to ligate the pancreatic ducts prior to extraction of the pancreas.
His work led to the successful isolation of insulin. The insulin extract was first tested in diabetic
dogs with great success.28 The first attempt to inject the extract in humans, however, failed.
With the help of biochemist Bertram Collip, the extract was further purified and used
successfully in the treatment of a 14 year old diabetic patient in 1922.21, 28 The news of the
successful treatment of diabetes with insulin rapidly spread and in 1923 Banting and Macleod
won the Nobel Prize in Physiology or Medicine. Banting decided to share his cash award with
Best and Macleod shared his cash award with Collip.
1.2.1.2 Biosynthesis and Secretion of Insulin
Insulin is produced in the pancreatic β cells of the islets of Langerhans. The process
involves multiple steps beginning with the prohormones ‘preproinsulin’ and ‘proinsulin’ (see
Figure 2).29 Initially, insulin mRNA is translated into the single chain precursor preproinsulin,
which contains a 24 amino acid (aa), hydrophobic signal peptide directing the chain to the rough
endoplasmic reticulum (RER).28, 30, 31 Shortly after entering the RER, a signal peptidase removes
the signal peptide, forming proinsulin.
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Figure 2. The subcellular organization of the insulin secretory pathway.

Proinsulin consists of a carboxyl-terminal A-chain, an amino-terminal B-chain, and a
connecting peptide as the C-peptide (see Figure 3).31 In the RER lumen, proinsulin folds and
three intrachain disulfide bonds form, linking residues 25-54 (B-chain) and residues 90-110 (Achain) and giving insulin its native structure. The folding process is believed to be aided by a
connecting segment at residue 55-89 (C-peptide), which is subsequently removed.31 Once
folded, proinsulin is shuttled to the Golgi apparatus and is packaged into secretary vesicles. In
the vesicles, proinsulin is cleaved by the prohormone convertases 1/3 (PC1/3), 2 (PC 2) and
carboxypeptidase E (CPE), finally generating active insulin and C-peptide.28, 32 PC1/3 and PC2
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cleave between residue 32 and 33 at the C-peptide/B-chain junction and residue 65 and 66 at the
C-peptide/A-chain.33 The removal of extra basic residues at the C-terminal end of the B-chain
and C-terminal end of C-peptide occurs by CPE.

Figure 3. The post-translational modifications of preproinsulin, which results in active
monomeric insulin and C-peptide.

Pancreatic β cells secrete insulin in a tightly regulated fashion to ensure glucose
homeostasis.34 The mechanism for insulin secretion is a complex process involving the
integration of intracellular and extracellular components and is still not completely understood
(see Figure 4). Nutrients, hormones, and neurotransmitters have all been shown to directly
6

stimulate insulin secretion.35, 36 Glucose is the most important physiological regulator of insulin
secretion. Calcium, adenosine triphosphate (ATP), cyclic adenosine monophosphate (cAMP)
and phospholipid-derived molecules such as diacylglycerol (DAG) and inositol 1,4,5triphosphate (IP3) have all been identified as key intracellular components as well.35-37
Glucose induced insulin secretion (GIIS) occurs by three different pathways: the
triggering pathway (KATP channel-dependent pathway), the metabolic amplifying pathway (KATP
channel-independent pathway) and the neurohormonal amplifying pathway.38 During the
triggering pathway, intracellular transported glucose is metabolized causing an increase in ATP
concentration and subsequent closure of ATP sensitive K+ channels, which causes depolarization
of the cell membrane and opens calcium channels, allowing calcium influx. The rise in
intracellular [Ca2+] triggers the fusion of insulin granules to the plasma membrane. The
mechanism of the metabolic amplifying pathway is less understood and believed to be more
complex. It is known that the triggering pathway most be operational and there must be an
increase in intercellular [Ca2+] levels for the metabolic amplifying pathway to occur.34 In
addition to glucose stimulation, hormonal inputs are important for normal regulation of insulin
and occur by the neurohormonal amplifying pathway, which has recently been studied and is
summarized in Figure 4.39
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Figure 4. Glucose induced insulin secretion (GSIS) is regulated by three pathways: triggering
pathway, metabolic amplify pathway and neurohormonal amplify pathway.38 Gs: Gs α subunit,
AC: adenyl cyclase.

1.2.1.3 Structure and Sequence of Bovine Insulin
In 1955, insulin became the first protein to be fully sequenced, winning Frederick Sanger
the 1959 Nobel Prize for Chemistry.40 Insulin’s primary structure consists of two polypeptide
chains, a 30 aa B-chain and a 21 aa A-chain (see Figure 5).41 The amino acids are referred to by
the letter of the chain (A or B) and the position within the chain. The aa sequence of insulin is
highly conserved among different species, which allows the cross species use of insulin, for the
most part.42 For research purposes the use of cross species insulin as a screen for biological
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purpose is appropriate and well-studied.42 However, a transition to clinical use requires the use
of human insulin to prevent immunological issues.43, 44
Bovine insulin, which was the source of insulin used for the work presented here, differs
from human insulin by three aa: alanine for threonine at A8, valine for isoleucine at A10, and
alanine for threonine at B30.43 The difference in aa does not alter the highly conversed
secondary structure of the insulin.42 The insulin structure contains one intra-chain disulfide bond
connecting residues 6 to 11 of the A-chain (A6-A11) and two inter-chain disulfide bonds linking
the A- and B-chain (A7-B7 and A20-B19) (see Figure 5).41 The secondary structure of insulin
includes a helical section between residues B9 and B19, as well as a N-terminal helix (A1-A8)
linked to an antiparallel C-terminal helix (A12-20).45, 46
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Figure 5. A representation of the primary structure of bovine insulin including the disulfide
bonds formed between the A- and B-chains and the A-chain intrachain disulfide bond.

Insulin self-associates into dimers at micromolar concentrations, which is the
concentration found in β cells during expression, suggesting dimers may be present in the
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endoplasmic reticulum.29 The residues involved in dimerization are all located in the B-chain
and have been identified as B8, B9, B12, B13, B16, B23-B29.45 Insulin further associates into
hexamers at millimolar concentration in the presences of zinc ions.47 Insulin is stored as a
hexamer in vacuoles of the β cells when blood glucose levels are low. When blood glucose is
elevated, the hexamers are released into the blood where they dissociate into dimers and
monomers. The dimer and hexamer formation is important for stabilization during storage.48
The cellular actions of insulin are initiated by monomeric insulin binding to its plasma
membrane receptor.29
1.2.1.4 The Insulin Receptor
The insulin receptor (CD220) is part of the receptor tyrosine kinase superfamily and is
present on virtually all mammalian cells, although the concentration of CD220 varies across
different cells.29 CD220 is a heterotetrameric glycoprotein consisting of two extracellular αdomains and two membrane spanning β-domains. The domains are connected by disulfide bonds
forming a β-α-α-β structure. In simplest terms, insulin binds to an extracellular α-domain and
causes phosphorylation of an intercellular β-domain.49
The crystal structure of the CD220 ectodomain was published in 2006 and provided
valuable information about the structural organization of the receptor (summarized in Figure 6)
and domains involved in insulin binding.50 The crystal structure of CD220-insulin complex has
not yet been acquired, but the CD220 crystal structure combined with various experiments
involving insulin analogues has provided a basis for a reasonable CD220-insulin binding
model.49 The insulin residues involved in receptor binding include residues A1, A2, A3, A5,
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A19, A21, B12, B16, and B23-26.51-53 It has also been suggested that residues A13 and B17 are
involved in receptor binding.29

Figure 6. A carton representation of the domain organization within the homodimeric insulin
receptor. L1, L2: first and second leucine-rich-repeat domains, CR: cysteine-rich region, Fn0-1-2:
fibronectin domains, Ins: Insulin insert domain, TM/JM: trans- and juxta-membrane regions, TK:
tyrosine kinase domain and CT: C-terminal domain.

11

1.2.2 Glucagon-Like Peptide-1
Glucagon-like-peptide-1 (GLP-1) is a gut hormone, produced in intestinal L cells, that
increases the amount of insulin secreted from pancreatic β cells in response to ingested nutrients,
also known as an incretin (see section 1.2.2.1). Orally delivered glucose produces a dramatic
increase in the secretion of insulin compared to injected glucose.54 This response to oral glucose
is referred to as the incretin effect and accounts for 70% of the total postprandial insulin
secretion.55
The role of GLP-1 in the postprandial homeostasis of glucose was established in the late
1980s and early 1990s.56, 57 Recent preclinical and clinical research has established GLP-1’s role
in increasing satiety,58-62 promoting modest weight loss,63 improving β cell function,64, 65 and
preserving β cell mass by inducing proliferation,65, 66 which may help to slow or reverse the
progression of T2D.66 The insulinotropic activity of GLP-1 is glucose dependent, making it an
ideal treatment for hyperglycemia, since hypoglycemia is unlikely to occur as a result of
treatment.67, 68
1.2.2.1 Discovery of the Incretin Effect
It was first speculated in the early 1900s that there was a component in the gut that was
released after oral ingestion of nutrients, which caused insulin secretion.55, 69 Zunz and Labarre
were able to extract an intestinal component that produced a lowering of glucose levels in dogs.70
They introduced the term “incretin” to describe the extract. Several other groups pursued the gut
component with some reports of the presence of glucose lower abilities.54, 70, 71 However, Loew
and colleagues reported the inability to lower blood glucose levels in dogs with the extract and
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interest in the extract quickly declined.70 It was later determined that Loew’s experiments
involved fasting animals, which would not respond to the glucose dependent GLP-1.70
Interest in the extract rekindled in 1960s with the development of a reliable
radioimmunoassay for insulin, by Yalow and Berson.72 The ability to measure the circulating
levels of insulin allowed researchers to determine the action of glucose alone could not account
completely for the insulin secretion. In 1969, Creutzfeldt defined the criteria for an incretin as 1)
nutrients like carbohydrates must cause incretin secretion and 2) at physiological levels, elevated
blood glucose levels must cause it to stimulate insulin secretion.70 The first incretin, glucosedependent insulinotropic polypeptide (GIP) was identified in the 1970s. In the 1980s, with the
help of complementary deoxyribonucleic acid (cDNA) cloning, GLP-1 was identified.70
1.2.2.2 Biosynthesis and Secretion
GLP-1 is produced in the intestinal L cells, which are located in the ileum and colon.73, 74
As with insulin, the synthesis of GLP-1 involves a larger precursor, which is then
posttranslationally modified to the functional form. The process begins with the prohormones
“preproglucagon” and “proglucagon”. The preproglucagon has a signal peptide directing it to
the secretory pathway, which is quickly removed to produce proglucagon. Posttranslational
cleavage of proglucagon is organ specific with PC2 producing glucagon in pancreatic α cells and
PC1/3 producing GLP-1 in intestinal L cells.74
GLP-1 was originally synthesized and tested as 36 and 37 aa peptides, GLP-1 (1-36)
amide and GLP-1 (1-37), respectively.70 The sequences were based on a predicted
posttranslational modification based on the understanding that PCs cleave a prohormone to the
active hormone at a dibasic aa sequence.70 Therefore, the cleavage was assumed to occur
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between the Lys and Arg resulting in a 37 or 36 aa peptide, depending on the presence or
absence of the Gly residue at the C-terminus. C-terminal amidation of peptide hormones is
common and involves the oxidation of a C-terminal Gly, resulting in the conversion of a
carboxyl to an amide on the preceding aa.75 The conversion to the amide does not occur
completely, resulting in non-amidated and amidated peptide.75 Amidation of the GLP-1
enhances the survival of GLP-1 in plasma. 75, 76
After early tests determined the GLP-1 (1-36) amide and (1-37) isoforms had no
insulinotropic effects, reanalysis of the aa sequence determined His7 should be the N-terminal
amino acid.70, 75 The reanalysis was based on alignment of other membranes of the glucagon
superfamily of peptides. Testing of GLP-1 (7-36) amide and GLP-1 (7-37) confirmed the
truncated forms were indeed the insulinotropic forms of the peptide.70 The functions of the GLP1 isoforms GLP-1 (1-36) amide and (1-37) are still unknown. There are two biologically active
forms of GLP-1: GLP-1 (7-37) and GLP-1 (7-36) amide, and both are found in the circulation of
humans. GLP-1 (7-36) amide is the predominant form, accounting for typically 80% of
circulating GLP-1. 75, 77
GLP-1 secretion is stimulated by ingested nutrients and occurs in a biphasic pattern.78
Initially there is a rapid increase in the circulating GLP-1 level at 15-30 min after nutrient
ingestion, followed by a second minor increase of GLP-1 at 90-120 min.78, 79 The second
increase of GLP-1 is believed to be a result of nutrients interacting directly with the L cell to
cause GLP-1 secretion. Absence of L cells in the small intestines suggests the initial GLP-1
secretion is mediated indirectly, rather than by direct L cell contact with nutrients. Brubaker et
al. proposed a mechanism involving the neuro/endocrine pathway for the indirect mediation of
GLP-1 secretion.80 It was proposed that nutrients in the duodenum activate a proximal-distal
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neuro/endocrine loop, which stimulates GLP-1 secretion from L cells in the ileum and colon.
The incretin hormone GIP, the neurotransmitter acetylcholine and neuropeptide gastrin-releasing
peptide (GRP) have all been identified as key regulators of GLP-1 secretion involved in the
proximal-distal neuro/endocrine loop.80
1.2.2.3 Structure and Sequence of Human GLP-1
GLP-1 is a 3.3 kDa peptide containing 30 aa residues (see Figure 7). The primary
structure is highly conserved in mammalian species.70 The conservation of GLP-1 reflects the
fact that basically the entire aa sequence is required for full biological activity. Removal or
addition of amino acids at the N-terminus of the GLP-1 (7-36) amide or GLP-1 (7-37) results in
a dramatic loss of receptor binding and biological activity.70 Addition of an aa residue at the Cterminal also results in a significant reduction in biological activity.70

Figure 7. The primary structure of human GLP-1 (7-36) amide.81 The C-terminal amidation has
been shown to increase plasma stability.75
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Site specific mutation studies identified the following amino acids as important for
receptor binding and activity: 1 (His), 4 (Gly), 6 (Phe), 7 (Thr), 9 ( Asp), 22 (Phe) and 23 (Ile).82,
83

NMR studies of the structure of GLP-1 identified the N-terminus as a randam coil from

residues 1-7, two helical segments at residues 7-14 and 18-29 and a linker region at 15-17 (see
Figure 8).84

Figure 8. The secondary structure of GLP-1 (7-36) amide determined by solution NMR. Lys 26
(indicated as ball and stick) has been identified as the best position for conjugation.85 Protein
data bank ID: 1D0R. Modified using RCSB PDB protein workshop software 3.9.

1.2.2.4 The Glucagon-like Peptide Receptor
The therapeutic potential of GLP-1 receptor (GLP-1R) targeting for the treatment of T2D
has been validated through extensive basic, clinical and translational research.63, 67, 68, 79, 86 GLP-1
mediates its insulinotropic effects by binding to GLP-1Rs on pancreatic β cells. The GLP-1R is
a seven-transmembrane class B heterotrimeric G protein-coupled receptor (GPCR). The B class
is a subfamily of GPCR distinguishable by a large N-terminal extracellular domain (ECD),
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which are typically 120 residues long and contain six highly conserved cysteine residues.87 The
ECD is responsible for peptide recognition and selective binding. GLP-1R’s ECD is composed
of an N-terminal α-helix, two anti-parallel β strands, and a final lobe composed of two additional
anti-parallel β sheets and a short α-helical region.88
The X-ray crystal structure (2.1 Å resolution) of GLP-1 bound to the ECD of GLP-1R
identified GLP-1 (7-36) amide as a continuous α helix from amino acid residues 13 to 33, with a
kink around residue 22.76 Interaction between the ECD and GLP-1 were noted between residues
24 and 33. Specifically, the hydrophobic face of GLP-1’s α-helix interacts with ECD at residues
24, 25, 28, 29, 32 and 33.76
1.3 A Pursuit of a Noninvasive Peptide/Protein Treatment for Diabetes Mellitus
The oral delivery of peptides and protein is a major goal for therapeutics.89 Early work to
develop an oral route focused primarily on a desire to increase patient adherence to medication
and quality of life.90 Recent research has evolved to place new emphasis on the physiological
importance of an orally administered peptide or protein,90, 91 with such delivery postulated to
bring a patient closer to metabolic norms through direct effects on hepatic glucose production.89
The major problem facing oral delivery of peptides and proteins is gastrointestinal tract (GIT)
hydrolysis/proteolysis and the inability to passage the enterocyte.92
The initial barrier for oral delivery of peptide and proteins is the enzymatic barrier.89
Pepsin is the major enzyme found in the stomach and is a key element in digestion. In the
intestines there are three major proteases responsible for further digestion: trypsin, chymotrypsin
and carboxypeptidase. Degradation of the peptide/protein by proteolysis will result in a reduced
bioavailability.89
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If the peptide/protein makes it through the proteolytic barrier, the next major barrier is a
physical barrier produced by the mucin lining of the intestines. Mucus plays an important role in
determining the absorption and bioavailability of orally administered drugs.93 The intestinal wall
is the next barrier for drug delivery and is also a physical barrier. Drug delivery is focused on
the mucous layer of the intestinal wall, which is comprised of villi that extend out from the
epithelial lining and are responsible for absorption of the majority of nutrients.94 Adsorption of
nutrients from the intestine can occur by two major pathways: transcellular and paracellular (see
Figure 9).

Figure 9. An illustration of the physical barriers and available pathways for oral drug delivery
in the intestines.

The transcellular pathway involves passive or active diffusion through the intestinal
epithelial cells, while the paracellular pathway takes place in the interstitial space between the
epithelial cells. In transcellular passive diffusion, small nutrients can cross through nonspecific
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permeability pathways. Larger nutrients, like vitamin B12, must use a receptor mediated uptake
pathway to utilize the transcellular route.89 The paracellular route is regulated by epithelial tight
junction proteins and is only open to small solutes, ions and water.95 The tight junctions are
important for keeping the cells tightly bound to one another.
1.3.1 Strategies for Oral Delivery of Peptides and Proteins
Numerous strategies have been attempted to overcome the barriers associated with oral
delivery of peptides/proteins. The methods most commonly used include the use of enzyme
inhibitors,93, 96-98 encapsulation,99, 100 chemical modification101 and/or absorption enhancers.102-104
While there have been great strides towards the delivery of oral peptides/proteins because of
these strategies, all of the methods have negative aspects that have kept them from reaching a
clinical level.102
Early research focused on the use of enzyme inhibitors to reduce the rate of proteolytic
degradation of orally delivered peptides/proteins.98 The potential for this technique was
demonstrated by the use of a duck ovomucoid, which provided insulin 100% protection from
trypsin and chymotrypsin.93 The major concern with the use of enzyme inhibitors is the potential
side effects associated with continuous use including the potential for alteration to the body’s
metabolism.102
Absorption enhancers work by altering the permeability of the cell membrane and include
surfactants, chelating agents, zonular occludens toxin, and fatty acids.102 Detergents and
surfactants disrupt the lipid bilayer of the cell membrane, enhancing the trancellular pathway.94,
95

Chelating agents and zonular occludens toxin disrupts the integrity of the tight junctions

enhancing the paracellular pathway.103, 104 A major drawback to the use of absorption enhancers
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is that by altering the permeability of the cell membrane potential toxins and pathogens have
access to the circulatory system.102
Various encapsulation techniques, including emulsions, liposomes, microsphere, and
nanoparticles, have been attempted to protect peptides/protein.99, 101, 105 Nanoparticle based
peptide and protein drugs have gained a lot of attention in recent years. Nanoparticles are
usually designed to deliver a large encapsulated load of peptide/protein to the intestines where a
trigger (often pH based) releases the load for uptake at the intestinal wall.99, 106 The difficulties
with the use of nanoparticles include the lack of specific control of drug release and the potential
for buildup of non-degradable particles in tissues.99, 102
Chemical modification of peptides/protein includes amino substitution, to eliminate
recognition sites of proteases or the attachment of various chemical moieties that are known to
protect the peptide or protein from proteolysis.101, 106-109 One example of attachment of a chemical
moiety is the addition of PEG, which has the ability to protect peptides and proteins from
intestinal proteolysis as well as alter the interactions of the molecular with blood proteins,
allowing for an increase in systemic circulation time.101, 106-109
1.4 Vitamin B12
1.4.1 History
The early history of vitamin B12 (B12) belongs entirely to the field of medicine and the
treatment of pernicious anemia. Pernicious anemia was first described in 1824 and was an
incurable and usually fatal disease.110 In 1920, Whipple discovered a diet of raw liver could
regenerate the red blood cells of anemic dogs and in 1926, Minot and Murphy reported the same
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findings in anemic patients.111 This discovery won all three the 1934 Nobel Prize in Physiology
and Medicine.110
In 1948, B12 was isolated from the liver and determined to be the compound responsible
for the improvement in pernicious anemia. The isolation was performed by two independent
groups, Folkers and coworkers at Merck Laboratories in the U.S. and Smith and Parker at Glaxo
Laboratories in the U.K.112, 113 The X-ray crystal structure of B12 was obtained in 1955 by
Dorothy Hodgkin.110, 114 This complex crystal structure of B12 won Hodgkin the 1964 Nobel
Prize for Chemistry. In 1972, Woodward and Eschenmoser reported the total synthesis of B12.115
It took over 100 scientists eleven years to complete this feat.116 Since these early years,
thousands of papers have been published on the chemistry and biochemistry B12.
1.4.2 Structure and Chemistry of Vitamin B12
B12, or cobalamin, is the most structurally complex cofactor existing in nature.116 B12 is a
member of a family of cob(III)alamin species all of which are comprised of a cobalt (III) ion
equatorially coordinated to four pyrrolic nitrogens of a corrin ring (see Figure 10).117 The corrin
ring is similar to the more commonly known porphyrin structure but with a greater degree of
saturation and increased sp3 carbons, which confers greater flexibility.117 In addition, there is
greater asymmetry to the corrin ring compared to a porphyrin, due to the fusion of the A and D
rings resulting in a 15-carbon ring structure over the porphyrin 16-carbon structure.117
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Figure 10. Structure of B12 with a variable R group shown to the left. Three of the more
common forms of B12 (cyanocobalman, methylcobalamin and adenosylcobalamin) are shown to
the right.

In humans, the cobalt atom is further bound to a 5,6-dimethylbenzimidazole (DMB) base
at the α-axial position.117 The identity of the base varies in different species.117 DMB is
connected to the D-ring of the corrin ring by a ribose-phosphate-amide bond linkage formed
through the f amide side chain. The functional group attached at the upper β position of the
cobalt ion, depicted as R in Figure 10, is variable depending on the type of cob(III)alamin
species. The most common cob(III)alamin used in research and nutriceuticals is cyanocobalamin
(see Figure 10, R = CN, CNCbl).118 CNCbl is not the biological active form of cob(III)alamin
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but is readily converted to the biologically active forms, methylcobalamin (R= CH3, MeCbl) and
adensylcobalamin (R= 5’-deoxyadenosyl, AdoCbl) in the human body.119
The use of B12 as a cofactor is a result of the ability of the cobalt atom to change
oxidations states.116 In AdoCbl, the cobalt atom is converted from Co3+ to Co2+ (cob(II)alamin)
by homolytic cleavage of the Co-C bond. In MeCbl, heterolytic cleave of the Co-C bond results
in a Co+ (cob(I)alamin) species.116
1.4.3 Physiological Roles of B12
B12 plays an important role in the normal functioning of the brain and nervous system
(myelin production), the formation of blood (tetrahydrofolate production), DNA synthesis
(ribonucleotides reductase (RNR) conversion of ribonucleotides to deoxyribonucleotides), and
fatty acid synthesis and energy production.120-122 Many of B12 functions can be replaced by folic
acid (vitamin B9) but two enzymes absolutely require B12 as a cofactor, methylmalonyl
coenzyme A mutase and methionine synthase.122
Cytosolic methionine synthase is a MeCbl-dependent methyl transferase responsible for
the formation of methionine by methylation of homocysteine.123 The process is a catalytic cycle
involving two methyl transfer half-reactions, outlined in Figure 11. The cobalt-bound methyl
group of MeCbl is transferred to homocysteine, forming methionine and an enzyme-bound
cob(I)alamin.124 This highly nucleophilic cob(I)alamin then acquires the methyl group of N5methyltetrahydrofolate, forming tetrahydrofolate and MeCbl.123 Tetrahydrofolate is essential for
the production of purines and pyrimidines in DNA synthesis.123
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Figure 11. Outline of methionine synthase (Enz) catalytic cycle, which involves two methyl
transfer half-reactions: homocysteine to methionine and N5-methyltetrahydrofolate to
tetrahydrofolate.

Methylmalonyl Coenzyme A mutase is an AdoCbl-dependent enzyme, which catalyzes
the rearrangement of methylmalony-CoA to succinyl-CoA.124 This rearrangement occurs by the
exchange of a hydrogen atom from the methyl group with the carbonyl-CoA group on the
adjacent carbon. This conversion from methylmalonyl-CoA to succinyl-CoA is an important
step in the degradation of branched-chain amino acids, and odd-chain fatty acids.124
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1.4.4 The Dietary Uptake Pathway Overview
B12 is vital for the survival of all living organisms and is only synthesized naturally by
bacteria, so mammals must acquire the vitamin through their diet.123 As a result, the body uses a
complex uptake mechanism involving three soluble transport proteins (haptocorrin (HC),
intrinsic factor (IF) and transcobalamin II (TCII)) to ensure successful isolation of B12.120 The
uptake pathway also utilizes four receptors (cubilin, amnionless, megalin, and TCblR/CD320),
which only recognize a B12 transport protein when bound to B12. Any disruption in the uptake
pathway is known to result in a B12 deficiency.120 In the most basic terms, the uptake pathway
begins with the protection of B12 from the acidic environment of the stomach by HC, followed
by the receptor mediated uptake of IF bound to B12 in the intestines and B12 delivery to the cell
by TCII (see Figure 12).
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Figure 12. An overview of the B12 uptake pathway as outlined by a recent 2012 review.120 The
transfer of B12 from IF to TCII is currently being debated as discussed in section 1.4.7 and shown
in Figure 15. Image is reproduced from reference 120 with permission of Nature Publishing
Group. MRP1: multidrug resistance protein 1.

A number of important publications have been received in recent years providing a
clearer picture of the exact mechanism of B12 transport.125-132 There are still areas of the pathway
that are not completely understood and some areas of the pathway that are controversial in the
B12 field. What follows is a review of the current understanding of the B12 uptake pathway:
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1.4.5 Haptocorrin
HC is a 45.6 kDa glycoprotein primarily secreted in human saliva at concentration of 50
nM.133 The predominant function of HC is the transport of B12 through the acidic environment of
the stomach and into the duodenum.134 In the duodenum, an increase in pH causes the release of
B12 and pancreatic proteases cleave the HC. The release and break down of HC results in the
transfer of ~80% of bound B12 to IF.135
In the blood plasma, HC is believed to be responsible for the removal of partially
synthesized or degraded B12.136 HC is the only known B12 transport protein capable of binding
corrinoids, which are a large group of compounds containing the corrin ring with coordinated
cobalt. Approximately 40% of plasma corrinoids are a B12 analogue unable to serve as a
cofactor. Due to HC presence in breast milk, tears and salvia, it was suggested that haptocorrin
may also have antibacterial functions118 but a recent paper contradicts this hypothesis.128
HC is the least understood of the B12 transport protein. It was recently established that
HC is not present in all species, which was an extremely important finding as a number of B12
studies are conducted in nonhuman subjects.127 No crystal structure has been reported, but the
structure of HC is predicted to be very similar to IF (see section 1.4.5).137 The recombinant
expression of human haptocorrin was recently reported in human embryonic kidney (HEK)
cells.138 This successful expression will allow researchers the ability to produce and more
extensively study HC in the coming years.
1.4.6 Intrinsic Factor
The second B12 transport protein in the series, IF is a highly glycosylated protein secreted
in the parietal cells and is crucial for B12 transport across the intestinal wall.125 IF binds B12 in
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the large intestines after proteases degrade HC and the pancreas secretes a bicarbonate solution
that neutralizes the acidic stomach content.138 IF can only bind B12 and is reported to be the first
filter in the B12 uptake pathway.122 The IF-B12 complex crosses the intestinal wall in the ileum by
receptor mediated endocytosis via the cubam receptor complex.125, 139 The cubam receptor
complex consists of two receptors cubilin and amnionless (see section 1.4.6).139 Once in the
lysosome, IF is degraded by cathepsin L and B12 is released.140,120 B12 is transported across the
lysosomal membrane with the aid of the lipocalin membrane receptor like protein LMBD1.130
Once B12 is in the cytoplasm, there is debate as to how B12 leaves the cell, which will be
discussed in section 1.4.7.
The crystal structure of IF bound to B12, at 2.6-Å resolution was published in 2007,
providing a picture of how the 60 kDa protein binds B12 (see Figure 13).129 The structure of IF is
very similar to the structure of TCII, which was reported in 2006 and is discussed in section
1.4.7.132 IF contains 399 aa residues plus 15% carbohydrate and is comprised of two domains, a
270 residues α domain and a 110 residue β domain. 129 As the names suggest, the α domain is an
intertwined α6/α6 helical barrel and the β domain is a cluster of β strands (see Figure 13). The
B12 binding site is located between the α and β domains and about 19% of the B12 is solvent
exposed when bound by IF.129 There are five residues from the α domain (His73, Tyr115,
Asp153, Asp204, and Gln252) and four residues from the β domain (Ser347, Val352, Phe370,
and Leu377) that form direct hydrogen bonds with B12.129 The B12 DMB group is maintained in
a hydrophobic environment made up of a β-hairpin molded by residues 343-352 of the β
domain.129
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Figure 13. Ribbon diagram of IF-B12 complex with the B12 shown in ball and stick. Used with
permission of National Academy of Science from reference 129.

1.4.7 Cubilin and Amnionless
The transport of B12 across the intestinal wall occurs in the terminal ileum with the aid of
IF and the cubam receptor complex.125, 139, 141 The cubam receptor complex consists of two coexpressed receptors in the apical membrane of the ileum: cubilin and amnionless.139 The cubilin
receptor is a 460 kDa glycoprotein and is comprised of eight epidermal growth factor (EGF)-like
repeats followed by 27 complement CUB (components C1r/C1s, the sea urchin protein Uegf, and
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bone morphogenic protein-1) domains.125 The CUB domains are the ligand binding region and
accounts for 85% of the receptor.125 Cubilin has domains for the binding of a number of ligands
including vitamins, lipids and hormones.142
The IF-B12 complex binds to the CUB 5-8 domains and the interaction is calcium
dependent.125, 143 B12 and IF are only recognized by the CUB domain as a complex.142 A recent
crystal structure of the CUB 5-8 domains bound to IF-B12 identified both α and β domains of IF
interacting with the CUB domains (see Figure 14).125 Specifically residues 25-299 of the IF α
domain interact directly with CUB 6 domain and residues 308-417 of IF β domain interact
directly with the CUB 8 domain.125 The internalization of CUB bound to IF-B12 is facilitated by
amnionless, a 48 kDa transmembrane protein.139 Amnionless contains internalization signals
within its cytosolic domain known to induce endocytosis by clathrin-coated buds.125
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Figure 14. The structure of CUB 5-8 (left, blue) interacting with IF bound to B12 (right, green
and pink). The interaction is calcium (red sphere) dependent. The image is reproduced from
reference 125 with permission from Nature Publishing Group.

1.4.8 Transcobalamin
TCII is the primary B12 transporter in the blood serum and is responsible for the delivery
of B12 to the cells by facilitating binding of B12 to the TCblR/CD320 receptor.120 TCII is the only
nonglycosylated B12 transport protein, known to date and is believed to be secreted from the
vascular endothelium.144 When and where TCII binds B12 is still debated.126, 145 In the early
2000s, Alpers and Seetharam proposed the transfer from IF to TCII occurs within the enterocyte
(see Figure 15a).145, 146 Just recently, research has demonstrated the ability of B12, with the aid of
MRP1, to leave the enterocyte free of a transport protein (see Figure 15b).126 Further work needs
to be done to determine when TCII binds B12. What is known for sure is TCII is bound to B12 in
the blood serum and transports B12 to the TCblR/CD320 or megalin receptor (discussed in
section 1.4.9).137
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Figure 15. There are currently two theories involving the export of B12. a) Seetharam et al.
present B12 bound to TCII in the cell while more recently b) Nexo et al. have established an
alternative export system involving MRP1. Images used from references 146 (a) and 120 (b)
with permission from Cambridge University Press and Nature Publishing Group, respectively.

TCII was the first transport protein crystallized and the structure revealed a number of
important details about points of modification on B12 including the presence of hydrogen bond
formation between various residues in TCII and B12’s phosphate moiety and side chains of the
corrin ring.132 The crystal structure also showed that TCII does not completely encompass B12
upon binding, and leaves an exposed section of the vitamin accessible to solvent. The 1.4 nm
solvent accessible pocket of B12 bound to TCII shows the phosphate and ribose hydroxyl groups
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are left protruding into the solvent, but only the 5’-hydroxyl of the ribose group is open to the
environment enough that it can easily accommodate the conjugation of large molecules (see
Figure 16).132

Figure 16. A representation of the TCII-B12 complex. The TCII α-domain is shown on the
bottom (red) with the β-domain on top (blue). The B12 molecule is shown in ball and stick and
found sandwiched between the two domains (orange). Reprinted from reference 132 with
permission of National Academy of Science.
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1.4.9 Megalin and TCblR/CD320
The TCII-B12 complex is recognized by two cell-surface TCII receptors: TCblR/CD320
and megalin. The renal filtration and reuptake of B12 occurs in the kidney with the aid of TCII
and the receptor megalin.142, 147 Megalin is a 600 kDa LDL-receptor family protein.148 The TCIIB12 complex binds to megalin with high affinity and internalizes the complex, preventing loss of
B12.149
In the bloodstream, TCII transports B12 to the cell, where the TCII-B12 complex is
recognized by a newly identified receptor, TCblR/CD320.150 TCblR/CD320 is a 58 kDa
transmembrane protein that belongs to the low density lipoprotein (LDL) receptor family.
TCblR/CD320 is present on the cell surface of virtually all tissue and a soluble form of the
receptor has recently been identified in the bloodstream.151 The expression of the TCblR/CD320
receptor has been linked to the proliferative and differentiation status of the cell. The levels of
TCblR/CD320 expression increase when cells are dividing, which relates to the fact that B12 is
essential for DNA synthesis.123 Endocytosis of the TCII-B12 complex results in the degradation
of TCII in the lysosome and the release of B12. Once the B12 is released it can be stored in the
cell, used as a cofactor or leave the cell.120
In contrast to TCII, haptocorrin seems to have a less important role in B12 delivery to
cells, although haptocorrin that lacks terminal sialic acid is known to be rapidly cleared by the
asialoglycoprotein receptor in the liver.138, 152 The role of this receptor is believed to be involved
in degradation of HC. A receptor for sialylated HC has not been identified.138

34

1.5 Using the B12 Pathway for Drug Delivery
The use of B12 for drug delivery is focused in two main areas of research: targeted
delivery of therapeutic and imaging agents and increased oral bioavailability of peptides and
proteins. B12 has been utilized for the delivery of imaging agents and therapeutic drugs for the
treatment and diagnosis of cancer, due to the increased need for B12 in rapidly dividing cells.153
The increase in bioavailability of peptides and proteins is based on the potential the B12 uptake
pathway has for overcoming the major barriers to oral delivery of peptides and proteins.154 The
following section will be a review of the field of B12 drug delivery.
1.5.1 Targeted delivery
Upon delivery to the blood stream, a B12 conjugate will typically be acquired by TCII, as
previously discussed in section 1.4.5.120 In cancer therapy/imaging, the hypothesis for B12 based
targeted delivery has historically been that increased TCblR/CD320 expression (as much as 3- to
26- fold in certain patients)155 in a variety of cancers such as testis, breast, ovarian, thyroid,
uterine, and brain cancer would provide sufficient selectivity over healthy cells.155 The increase
in TCblR/CD320 expression in cancer cells has led to the production of both small organic and
inorganic B12 conjugates with various applications in medicinal chemistry, which will be briefly
discussed in this section and can be found in Table 1.
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Table 1. B12-small molecule conjugates.
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1.5.1.1 The Use of B12 for Imaging
Early investigators demonstrated that cobalt radionuclides (57Co, 58Co, 60Co) could be
used to label B12 for imaging.144, 156 The half-life of the radionuclide, however, required the
dosage for humans to be too small for successful external images to be taken and the radioactive
compounds were shown to accumulate in the liver, pancreas, and kidneys, leading to organ
damage.157 In an attempt to overcome these issues, a number of additional radionuclides
including 111In (2.8 days; 0.245 MeV-γ),157 131I (8 hrs; 364 keV-γ, 606 keV-β)158 and 99mTc (6.02
hrs; 140 keV-γ)159 have been conjugated to B12 for labeling purposes. Unfortunately, these
experiments still resulted in undesired organ accumulation, limiting the amount of drug delivered
to cancerous cells and demonstrating high background uptake in healthy cells.157, 159, 160
Several fluorescent B12 imaging agents have also been synthesized.161, 161-163 The first
reported fluorescent B12 analogues utilized the β-axial position of the Co (III) ion for conjugation
of the fluorophores (Fluorescein, napthofluorescein and Oregon Green), but low Co-C bond
dissociation energy (~37 kcal/mol) caused the molecules to suffer from photochemical
instability.164 A shift in conjugation sites to 5’-hydroxyl group of the ribose moiety162 and the
addition of a rigid linker provided more stable B12 fluorescent moiety with an increase in
fluorescent lifetime.163 An increase in the overall fluorescence quantum yield was observed with
the use of a rigid linker over a flexible linker because the rigid linker orients the fluorophore
away from the corrin ring of B12, minimizing through space intramolecular interactions.163 The
fluorescent agents are expected to be suitable as tumor markers to aid surgeons during surgery to
remove the tumors, but no data supporting this claim has been published to date.163 The imaging
agents will most likely suffer from nonselective TCII uptake in vivo.
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In an attempt to overcome background uptake, HC has more recently been targeted since
receptors for haptocorrin are also overexpressed in a number of cancer lines.165, 166 To target HC
over TCII, Alberto et al. disrupted the interactions between B12 and TCII by utilizing the b
propionamide site after modification to the b monocarboxylic acid. 167 This is a considerable
breakthrough for B12 based cancer therapeutics since it demonstrates one of the often stated
problems of using B12 systems, namely non-specific cell uptake, can be addressed, at least
towards cancer cell lines with de novo HC expression.
1.5.1.2 Vitamin B12 Therapeutics
Nitrosylcobalamin (NOCbl) is a B12 derivative with nitric oxide (NO), a molecule known
to induce apoptosis, as the β-axial ligand.168 Once in the cell, the NO detaches from B12 and has
the potential to causes direct damage to DNA and inhibits cellular metabolism, leading to
necrosis and apoptosis.169 In 2002, Bauer et al. analyzed 22 human tumor cell lines and two nontumor cell lines and concluded NOCbl had a greater selectivity for tumor cells and the tumor
cells were more sensitive to the NOCbl.169 The NOCbl was determined to inhibit tumor growth
in vitro and in vivo by activation of the extrinsic apoptotic pathway.168, 170
Colchicine is a cytotoxic agent, which disrupts mitosis by binding to tubulin and
inhibiting microtubule polymerization.171 The use of colchicine suffers from a lack of selectivity
for cancer cell among a field of healthy cells, resulting in undesired side effects.171 In 2004,
Grissom et al. employed B12 to deliver colchicine specifically to cancerous cells.171 Using an
acid labile hydrazone linker, colchicine was attached to the β axial ligand of B12. The linker
allowed for a pH-dependent release of colchicine in acidic conditions.171 Once taken into the cell
via the B12 receptors, colchicine was released to interact with microtubules but showed a ten-fold
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decrease in toxicity.171 In vivo experimentation demonstrating selectivity for cancer cells was
not performed.
In 2009, Siega et al. determined it was possible to deliver Gd3+ to cancer cells by
conjugation to B12.172 By using the metal chelating agent DTPA, a B12–Gd3+ conjugate was
constructed. The Gd3+ moiety conjugated to the 5’-hydroxyl group of the ribose moiety of the
B12 did not affect the binding of the B12 transport proteins.172 Viability tests on human
myelogenous leukaemia K562 cells incubated with the conjugate showed a significant decrease
in cell viability compared to those incubated with the B12 parent compound and/or the Gd3+ ion
alone.172 Given that this system utilized conjugation at the 5’-hydroxyl group of the ribose
moiety, allowing TCII recognition, it can be postulated that this system, if tested in vivo, will
give poor tumor specificity as well.
B12 can act as a ligand for cisplatin by formation of a cyanide-bridged species between
the β-axial ligand of B12 and Pt.173 B12–cisplatin conjugate retain a labile chloride ligand that can
be exchanged with ligands such as guanine, allowing the conjugate to behave in a similar way to
cisplatin.173 In 2008, Alberto et al. synthesized a number of prodrugs around the {B12-CN-Pt-R}
moiety.174 Using an in vitro adenosylation assay from Salmonella enteric, the group was able to
show that Co (III) was reduced to Co (II) and the Pt (II) complex was released.174 In 2011, the
preliminary in vitro cytotoxicity of the {B12-CN-Pt-R} conjugate suggested a lower activity (IC50
between 8 and 88 M) than for cisplatin alone.175 It is hypothesized that the limited B12 uptake
capacity is most likely to blame.175 Studies on the effects of the uptake capacity on concentration
are underway.175
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1.5.2 Oral Delivery of Peptides and Proteins
The investigation of B12 for the oral delivery of peptides and proteins began in the early
1990s with the work of Russell-Jones.176, 177 In an attempt to establish a route of oral delivery for
peptide and proteins, in general, Russell-Jones and co-workers conjugated B12 to a wide range of
peptides and proteins between 1994 and 1999.176-178 The initial conjugate involved the
attachment of luteinizing hormone releasing hormone antagonists (ANTIDE) to the B12 e
carboxylic acid derivative.176 Exploration of the spacer units established the ability to attach two
biological active molecules. B12 was also determined to increase solubility of the protein.155
Later the same year, work with granulocyte-colony stimulating factor (G-CSF) and
erythropoietin (EPO) established the ability of B12 to deliver a biological active protein orally in
an IF-dependent fashion in vitro and in vivo.177
A number of issues with the B12 uptake pathway were determined with these early studies
including the reduction of biological activity of the peptides or proteins, although sometime only
slight.176 It was also determined the B12 uptake pathway had a limited uptake capacity (~1 nM
per dose in humans) and so the system was restricted to highly active compounds.92 It was also
stated that the system had no way of protecting the protein from proteolysis.92
1.6 Points of Modification on B12
Knowledge of the binding between B12 and its various transport proteins is critical if a
B12 conjugate is to be successfully translated from bench to bedside. In the last five years there
has been an explosion of critical structural data related to the B12 uptake pathway with the
publication of the IF,129 TCII132 and cubilin(5-8)-IF-B12 structures.125 Researchers have a better
understanding of how B12 interacts with its transport proteins, and how these transport proteins
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interact with their receptors. The implications this can have on drug delivery and sites of
potential conjugation can then be better detailed, rationalized and hence optimized.
The B12 and the molecule of interest can be: (1) coupled directly together, (2) held apart
by ‘spacer’ units to produce distance between the B12 and drug or (3) carriers can be conjugated
to B12 with the desired drug contained, unconjugated, within this carrier. Several functional
groups are readily available for modification on B12 including propionamides, ethylamides,
hydroxyl groups, the cobalt (III) ion and a phosphate moiety.153 Only a few modifications are
capable of maintaining the recognition of all three transport proteins needed to utilize the full B12
uptake pathway effectively in an oral manner.137
The size of the drug is important when considering the location for conjugation as well as
the transport proteins being utilized since all three transport proteins are not created equally.
Conjugation of drugs resulting in the recognition of all three transport proteins has been
successful with B12 at three major sites: (1) to the peripheral corrin ring e propionamide176; (2) to
the 5’-hydroxy of the ribose 163; and (3) to the cobalt metal (see Figure 17).170, 179
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Figure 17. Conjugation can occur at any of the functional groups (indicated in shaded shapes)
without loss of binding by the three uptake proteins.
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1.7 Summary
An orally administered peptide/protein medication is important for increasing patient
adherence to therapy as well as the physiological importance of mimicking the natural pathway
of the peptide/protein.90 The uptake pathway of B12 makes for an excellent candidate for the oral
delivery of molecules because it has the potential to overcome the major problems associated
with oral delivery. Before the full potential of the B12 uptake pathway can be realized, however,
concerns about the pathway that have been brought to light in recent years, including the limited
uptake capacity (~1.5-2.0 μg per dose in humans), need to be addressed.
The work presented here is based on the hypothesis that the B12 uptake pathway can be
used to orally deliver active peptides and proteins. To address this hypothesis, three important
goals will be set (1) Gaining a better understanding of the previously designed B12-insulin
conjugation system through the reexamination of the reaction conditions, alternative conjugation
sites on insulin and modification of the B12 structure (2) Understanding the impact B12
conjugation and the B12 uptake pathway has on peptide/protein function (3) Appreciate the
limitation of the B12 uptake pathway and explore peptides suitable for B12 delivery.
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Chapter 2 Investigating the B12 Uptake Pathway for the Oral Delivery of Insulin
2.1 Introduction
The oral delivery of insulin at clinically significant and controllable levels is a major goal
in the treatment of DM.1, 2 The removal of insulin injections is predicted to increase patient
adherence to insulin therapy and increase patient’s quality of life.2,

3

Side effects of current

insulin therapy include weight gain and hypoglycaemia, which have been correlated with the
over-insulization of the periphery due to subcutaneous injections.4
Insulin is naturally secreted from pancreatic β cells directly into the portal vein and is
then shuttled to the liver.4 During first pass through the liver, up to 70% of secreted insulin is
extracted by insulin receptors located on the liver.5-7 The insulin extraction by the liver results in
a higher concentration of insulin in the portal vein compared to the systemic circulation.4
Subcutaneous injections bypass this first pass through the liver and result in an unnaturally
higher concentration of insulin in the systemic circulation than in the portal vein. The oral route
of administration is postulated to mimic the natural route of insulin secretion with absorption
from the GIT into the portal vein.4
The major problems facing oral delivery of peptides/proteins are hydrolysis/proteolysis in
the GIT and an inefficient uptake mechanism for large peptides or proteins from the GIT (see
section 1.3 for a more detailed discussion).8 We are interested in the use of the B12 dietary
uptake pathway to address these hurdles to oral delivery.
The B12 dietary uptake pathway (discussed in detail in sections 1.4.4-1.4.9) utilizes a
series of transport proteins and receptor to protect and shuttle the B12 from the mouth, across the
intestines, and to the cell where it is utilized as a cofactor (see Figure 18). For the oral delivery
of peptides and proteins, we are primarily interested in the two transport proteins, HC and IF,
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and the intestinal IF dependent cubam complex. HC is important for the protection of B12 in the
mouth/stomach and facilitates the transport of B12 to the intestines, where the second transport
protein IF transports the B12 across the intestinal wall with the aid of the cubam complex (see
section 1.4.7).9

Figure 18. A basic representation of the B12 dietary uptake pathway.

Previously, Petrus et al. reported on the development and characterization of an orally
active B12-insulin conjugate with hypoglycemic properties in the streptozotocin (STZ)-induced
diabetic rat model.10 The oral administration of the B12-insulin conjugate resulted in a 4.7 fold
greater decrease in blood glucose levels compared to orally administrated insulin in the STZ rat
model. It was determined that the B12-insulin’s glucose lowering ability was a result of the use
of the B12 uptake pathway. This determination was based on experimentation with co55

administration of excess B12 and the conjugate, which resulted in a loss of glucose lowering
ability.10
Results from the initial work with B12-insulin,10 stimulated further study into the
implications of the B12 conjugation on insulin’s ability to bind to its receptor (CD220) using
immune-electron microscopy and molecular dynamics simulation.11 What is clear from the
results obtained to date is that (i) B12 can deliver insulin to rat blood serum at levels significantly
greater than the same administered concentration of ‘free’ insulin, and (ii) The B12-insulin
conjugate can still dock to CD220, insulin receptor and thus trigger glucose uptake, even when
bound to TCII.
The use of the B12 pathway to deliver a clinically relevant bolus of insulin, or fast- acting
insulin usually given with a meal,12 is not possible however, given both the limited uptake
capacity (1.5-2.0 μg per dose)13 of the pathway and the relatively slow uptake time for serum
delivery (~ several hours).8 The possibility of developing an oral, long acting basal therapy is
more feasible, where a low level of long acting insulin is required and an initial uptake delay is
not critical.12
The earlier results with insulin10, 11 have been highly encouraging and we have become
focused on investigating and improving in vivo residency of B12-insulin conjugates. Before such
an area can be fully explored however, knowledge of (i) the effects of B12 conjugation on the two
main sites suitable for such on insulin (vide infra) and (ii) dose-response of B12-insulin
conjugates needed to be addressed. These important factors are discussed in this report.
Insulin has two primary sites available for conjugation (the Nα-amino group of
phenylalanine B1 (PheB1) and the Nε-amino group of lysine B29 (LysB29)), which allow
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biological function to be maintained (see Figure 19).14 It is not completely understood which
position is more suitable for modification.15, 16 Significant differences between both positions
upon B12 conjugation would be of great importance given the limited B12 uptake capacity and the
need therefore to optimize such a conjugate.

Figure 19. The three amine groups available for conjugation on the bovine insulin structure are
indicated. Conjugation at the GlyA1 has previously been shown to eliminate biological activity,
therefore only the PheB1 and LysB29 are available for conjugation.

The original conjugate utilized the LysB29 position for B12 attachment based on the
understanding that this amino acid is involved in the dimerization of insulin.16-18 Insulin is more
stable as a hexamer, but the monomer is the only biological active form.17 Therefore, the
suppression of dimerization and subsequent hexamerization would result in faster absorption of
the conjugate.17 It has been reported that conjugation at the LysB29 position results in a
reduction in biological activity due to the close proximity to the insulin receptor binding site.15
Therefore, moving B12 further away from the binding site could result in an increase in biological
activity.
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We describe herein the synthesis, characterization, and purification of a new B12-insulin
conjugate (1), which is attached at insulin PheB1 (Figure 19). The use of PheB1 for attachment
of B12 is also predicted to eliminate self-association of the insulin molecule because PheB1 is
involved in insulin hexamerization.15 We hypothesize that this new conjugate may result in an
increase in insulin’s biological activity, while maintaining the B12 uptake capabilities due to the
position of B12 attachment in relation to the insulin receptor binding region. The synthetic route
of the previously investigated B12-insulin (B12 bound to insulin LysB29, 2)10 was updated to
increase yield and mimic as close as possible the synthetic route for the new B12-insulin (B12
bound to insulin PheB1, 1).
Both 1 and 2 were coupled at the B12-ribose hydroxyl group through a carbamate linker.
Insulinotropic properties of 1 and 2 were evaluated in vivo in STZ induced diabetic rats.
Molecular dynamics simulation studies were used to help rationalize the results. We also report
for the first time the ability of a B12-insulin conjugate to exhibit dose dependence in STZ diabetic
rats.
2.2 Results and Discussion
2.2.1 Synthesis of B12-B1Insulin (1) and B12-B29Insulin (2)
Reaction of B12 with 1, 1’-carbonyl-di-(1, 2, 4-triazole) (CDT) furnished an activated
ester at the 5’-hydroxyl group (Figure 20), as previously reported by Russell-Jones et al.19
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Figure 20. The activation of B12 occurs at the 5’-hydroxyl group of the ribose with the aid of
CDT. B12Act = CDT activated B12.

The synthetic procedures for 1 and 2 were identical unless otherwise noted (see Figure
21). The activated B12 was added to a slowly stirring solution of bovine insulin in dimethyl
sulfoxide (DMSO) with 0.1% triethylamine (TEA). The site directed B12 conjugation utilizes the
established difference in reactivity of the amino groups (LysB29 >GlyA1 >> PheB1) of insulin
at pH 9.5.16 For 1, the more reactive LysB29 and GlyA1 were initially protected with tbutyloxycarbonyl (BOC) to allow for specific conjugation of B12 at the unprotected PheB1
residue as previously described by Kim et al.16 2 was synthesized without need for a protecting
group due to the high level of reactivity of LysB29 under the reaction conditions chosen.
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Figure 21. The synthetic route of 1 and 2 are outlined.

Both reactions were extracted with the addition of diethyl ether and centrifugation. The
products were isolated by analytical reverse-phase high pressure liquid chromatography (RPHPLC). Purification proved challenging due to the similarity in hydrophobicity of unconjugated
insulin and B12 conjugated insulin. For 1, the BOC protection was adequate to produce a
separation between B12 conjugated and free insulin (see Figure 22). At a pressure of 71 bar,
HPLC yielded a dark red fraction at rt = 1.4 min, pink fractions at 7.4 and 8.5 and clear fractions
at rt=7.6, 8.1, 9.0 and 9.7. The pink fraction at 7.4 is B12 attached at the GlyA1 position with
BOC at the LysB29. However, baseline separation was not achieved and the sample contained
60

BOC-Insulin, which eluted at 7.6. The pink fraction at 8.4 is B12 attached at PheB1-BOC2Insulin and the clear fraction at 9.0 is BOC3-Insulin.

Figure 22. The RP-HPLC spectra of a BOC protected insulin plus B12 reaction monitored at 254
nm.

For 2, addition of an excess of N-(9-Fluorenylmethoxycarbonyloxy) succinimide
(FMOC-OSu) was used to aid in purification. The FMOC moiety increases the retention time of
the unconjugated (hence, unprotected) insulin allowing for separation (see Figure 23).
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Figure 23. The RP-HPLC spectra of an FMOC protected insulin plus B12 reaction monitored at
360 nm (Dash, indicating B12 is present) and 254 nm (Solid, indicating insulin is present).

Following HPLC purification, the protecting groups (BOC or FMOC) were removed with
trifluoroacetic acid (TFA) (1) or piperidine (2) and dialyzed against 5 L of H2O overnight in
7000 MWCO dialysis tubing.
2.2.2 MALDI-ToF Mass Spectrometry
Matrix assisted laser desorption ionization time of flight (MALDI-ToF) mass
spectrometry (MS) detects ions. Therefore, the neutrally charged B12 must fragment in order to
produce detectable species. Experimentation with cyanocobalamin demonstrated fragmentation
of B12 occurs with the initial loss of the cyanide group. This is believed to result from the
hemolytic cleavage of the Co-CN bond and subsequent protonation of the negatively-charged
phosphate producing a [B12-CN+H]+ species with a 1329 m/z.20
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The exact site of B12 conjugation was verified by MALDI-ToF MS analysis of reduced
and digested fragments of 1 and 2. The conjugates were first treated with dithiothreitol (DTT) to
reduce the interchain disulfide bonds linking the A- and B-chain. MS analysis of the reduced
conjugates displayed m/z values of 2339 and 4755 corresponding to unmodified A-chain and
[B12-CN+H]+ bound to the B-chain, respectively (see Figure 24).

Figure 24. A representative MALDI-Tof MS spectrum of DTT reduced 1 or 2 shows mass at
4754 m/z representing [B12-CN+H]+attached to the B chain of insulin. Absent is B12 attached to
the A strand, 3694 m/z.

To verify the specific B chain site, reduced conjugates were treated with trypsin, which
cleaves peptides at the carbonyl side of arginine or lysine, except when followed by proline.21
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Reduced and digested 1 displayed a m/z of 3844 corresponding to B1-B22 plus [B12-CN+H]+
indicating conjugation at the B1 site (see Figure 25 b). While, reduced and digested 2 displayed
a m/z of 2286 corresponding to B23-B30 plus [B12-CN+H]+, indicating attachment at the B29
site (see Figure 25 a).

Figure 25. (a) MALDI-Tof MS spectrum of reduced and tryptically digested 1 produces a 2286
m/z fragment consistent with [B12-CN+H]+ attached to the LysB29 position. (b) Reduced and
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tryptically digested 2 produces a 3844 m/z fragment consistent with [B12-CN+H]+ at the Nterminus of the B strand, as expected with PheB1 conjugation.

2.2.3 Electronic Absorption Spectrometry
B12 (CNCbl) has a distinguishable electronic absorption spectrum, which provides
experimental data on the nature of the axial ligands, the cobalt oxidation state and the
concentration of the B12 solution. The absorption spectrum, seen in Figure 26, is characterized
by two prominent bands, the α/β in the visible region and the γ band in the UV region. All the
prominent bands above 300 nm have been attributed to π to π* transition of the corrin ring.22
Electronic absorption spectroscopy is a useful technique to determine the initial effects of
synthesis on the vitamin B12 structure and the overall yield of the reaction.

Figure 26. The “typical” absorption spectra of CNCbl. The predominate bands highlighted (α,
β, and γ) are due to spin allowed intraligand charge transfers of the corrin ring.
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Representative absorption spectrum for the B12 insulin conjugate is shown in Figure 27.
From this spectrum we can determine the B12 is a Co (III) “base on” species and using BeerLambert law the concentration of the solution and subsequent yield of the reaction can be
determined using an extinction coefficient of 27500 M-1 cm-1 for the band at 361 nm.

Figure 27. The electronic absorption spectra of B12-insulin conjugates contain the characteristic
B12 peaks and insulin peak.

2.2.4 In vivo experimentation
The dose dependent effect of 1 on blood glucose was assessed in STZ-rats and the results
are shown in Figure 28. 1 was administered at concentrations of 10-9 M (n=3), 10-7 M (n=3) and
10-5 M (n=2). Area under the curve (AUC) was calculated for each dose as 1387 ± 297, 795 ±
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202 and 125 ± 15 mmol/l 240 min below pre-gavage blood glucose concentration for 10-9 M, 10-7
M and 10-5 M doses, respectively. AUC of raw data identified a significant difference between
10-9 M and 10-5 M conditions, but there were no significant differences between the other
concentrations. The data presented in Figure 28 demonstrates the ability of the conjugate to
produce a dose dependent reduction in blood glucose. An increase in concentration from 10-9 M
to 10-5 M resulted in an increase of 10-20% drop in blood glucose.
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Figure 28. Relative (% change from pre-gavage) blood glucose concentration following
administration of 1 at concentrations of 10-9 M, 10-7 M and 10-5 M ( n = 3).
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Comparison of the conjugates was assessed by measuring blood glucose concentration
following oral delivery of 1 and 2 (see Figure 29). AUC transformation showed a significant
difference (p=0.03) between 1 and free insulin control, consistent with that observed in our
earlier report.12 Of interest here is that no significant difference in glucose drop (p=0.53) was
observed between 1 and 2. Both produced similar and greater drops over free insulin of the same
orally administered concentration. This data differs from previous literature15, 18 that suggests
conjugation position alters the biological activity of insulin and was not what we expected. We
believe our findings may be explained by components of the B12 uptake pathway, making this
result not in conflict with these earlier findings but rather suggesting a unique result tied to the
use of B12 in insulin conjugation.
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Figure 29. Relative (% pre-gavage) blood glucose concentration following administration of
free insulin (n=4), 1 (n=6) and 2 (n=6).

To help explain the biological similarities between conjugates, molecular dynamic (MD)
simulations of TCII interacting with 1 was performed by collaborator Dr. Damian Allis of
Syracuse University (see Figure 30). Previous MD simulations, performed by Dr. Damian Allis,
of 2 interacting with TCII11, 23 indicated that the lysine side chain provided an adequate tether
length to place the unstructured insulin B-chain region (residues B20-B30) beyond the steric
congestion of the B12 bound TCII structure.

Furthermore, the B20-B30 tail provides

considerable length for placing the most structured region of the insulin molecule (the complete
A-chain and B7-B19 B-chain region) far from the α and β domains of TCII, thereby not
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impacting the binding geometry of the B12 in its internal TCII pocket or the interaction of insulin
with the insulin receptor.
Formation of 1 places the B12 several residues from the structured region of insulin (the
complete A-chain and B7-B19 B-chain region), but the effective separation of the structured
insulin region from the TCII binding area is not obvious from the components themselves given
(i) the inability to predict whether an accommodation for the B12 binding within its pocket will
occur by insulin unfolding of the B1-B7 region and (ii) the inability to predict if the
phenylalanine side chain itself would serve as a source of steric congestion to disrupt B12 binding
in its pocket (in 2, the lysine side chain is itself the tether region between B12 and insulin).
Insights into the nature of the B12-insulin/TCII interaction upon PheB1 conjugation come from a
15 ns simulation of 1 interacting with the TCII complex. A representative of the geometry of 1
during these simulations is shown and labeled in Figure 30 and 31.
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Figure 30. MD simulation of TCII bound to 1. TCII structure: α-domain (red); β-domain (dark
blue); unstructured linkage between domains (green). Structure of 1: B12 (yellow ball and stick)
with Co (III) (blue sphere); Insulin B-chain (yellow ribbon); A-chain (light blue ribbon). The
structure was produced using the GROMACS software package with GROMOS96 (53a6)
united-atom force field by collaborator Dr. Damien Allis at Syracuse University.24

From the MD simulation we are able to see that the PheB1-CysB7 (B1-B7) region of the
B-chain is unfolded from its unmodified, native α helix geometry (see Figure 31).

The
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disruption of α helical structure extends slightly past the disulfide linkage (CysB7). The result of
this unfolding is that the B1-B7 residues become the long tether that separates the insulin core
from TCII upon binding of the B12-insulin conjugate. This tether originates from an otherwise
stable α helix and is slightly longer than half of the length of the B20-B30 tether in the previous
study. The retention of the B12 within its binding pocket with no observable deformation of this
pocket indicates that the B1-B7 tether is long enough to separate the two larger fragments. It is
this uncoiling of the B1-B7 region, induced upon binding by B12 uptake proteins that possibly
explains why both sites on insulin ultimately equate in function and why such differences were
not observed before.
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Figure 31. A representative structure of 1 bound within TCII. The structure was produced from
a molecular dynamic simulation performed using the same software as previously described in
Figure 30 by collaborator Dr. Damien Allis at Syracuse University.24

2.3 Conclusion
We report herein on the synthesis, purification and characterization of a new B12 insulin
conjugate attached at the insulin PheB1 position. The hypoglycemic properties resulting from
oral administration (gavage) of such a conjugate in STZ diabetic rats was similar to that noted in
a B12-insulin conjugate covalently linked at the insulin LysB29 residue,10 demonstrating the
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availability of both positions of insulin for, at least, B12 attachment. A possible rationale for this
result is put forward from MD simulations, which suggest there is forced un-coiling of the
insulin molecule at either the N- or C-terminal B strand insulin regions, depending on B12
conjugation, upon B12 binding protein interaction with 1 or 2. We also conclude that there is a
dose dependent response that can be observed for B12-insulin conjugates with doses of conjugate
greater than 10-9 M necessary to observe a drop in glucose.
In our earlier report on the oral activity of 2, it was demonstrated that the blood glucose
reduction could be blocked by the addition of a large excess of free B12.10 However, the
administered amount of conjugate (13.56 μg B12) was in great excess of the expected B12 uptake
capacity of the rat (1.5-2.0 μg per dose),13 signifying an alternative or additional mechanism for
the response may be possible. Given the presence of an insulin receptor in the intestine,25 it may
be that there is an alternate receptor at play in the uptake of B12-insulin. While the intestinal
insulin receptor was not the intended target for our conjugates it is possible that the conjugation
of B12 has resulted in predominantly monomeric insulin (necessary for CD220 binding) capable
of interacting with the intestinal insulin receptor.
It is also possible that B12 conjugation is greatly improving insulin stability, presumably
as IF-B12-insulin formed in situ. This hypothesis is more consistent with the observed glucose
drop along with observed dose-dependent response. The blocking of uptake by large excess of
B12 would not then be a consequence of cubam binding competition but rather prevention of IF
binding and any associated protection. It is also possible that the excess B12 altered the
oligerimization of the conjugate (‘modifying the formulation’) disrupting any B12 uptake and/or
insulin receptor binding in the intestine. If such a route through the insulin receptor is made
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available by B12 conjugation it would be a paradigm shift in our viewing of the exploiting of B12
for oral protein delivery.
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Chapter 3 Exploring the effect of B12 on glucagon-like peptide-1 biological activity
3.1 Introduction
DM is characterized by a deficiency in pancreatic β cell function and mass.1 In T1D, an
autoimmune disease has completely destroyed β cells and the body is no longer able to produce
the hormone insulin.2 T1D will not be discussed further in this chapter. In T2D, the pancreatic β
cells are not producing enough insulin to meet the body’s insulin demand and as the disease
progresses, the loss of β cell mass increases the insulin deficiency. A primary goal of research in
T2D diabetes is increasing the amount of functional insulin secreting β cells and slowing or
stopping the progression of the disease.1
GLP-1 (7-36) amide is a 30 amino acid amidated peptide, often referred to as GLP-1, that
has gained a lot of attention in recent years because of its physiological role in the growth of β
cells and suppression of β cell apoptosis.3 GLP-1 also has a wide variety of physiological roles
centered on the postprandial homeostasis of glucose, including the secretion and promotion of
insulin and suppression of glucagon production.4, 5 GLP-1’s insulinotropic functions are glucose
dependent, making it an ideal treatment for hyperglycemia since hypoglycemia is unlikely to
occur.4-6 Furthermore, GLP-1 has been associated with appetite suppression,7 which is an
important observation considering T2D is highly associated with obesity.8
There are two biologically active forms of GLP-1: GLP-1 (7-36) amide and GLP-1 (737), which refers to the amino acid residues making up the structure and whether the C-terminal
is amidated (see section 1.2.2.2). The C-terminal amidation is the prominent form of GLP-1 in
circulation, with the amidation predicted to increase stability.9, 10
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The therapeutic potential of GLP-1 receptor (GLP-1R) targeting for the treatment of T2D
has been validated through extensive basic, clinical and translational research.11, 12 The
therapeutic use of GLP-1 is limited by a short half-life (1-2 min), due primarily to degradation by
the enzyme dipeptidyl peptidase IV (DPP-IV).4 There is however currently a GLP-1 based
therapeutic available for the treatment of diabetes known as liraglutide.13 Liraglutide is an
injectable medication that exhibits an increased resistance to DPP-4 degradation due to the
addition of a fatty acid moiety at Lys26.13 Although effective for the treatment of T2D,13 the
injectable liraglutide does not have the ability to mimic the natural secretion of GLP-1, which
may have physiological benefits yet to be observed.
GLP-1 is secreted from intestinal L cells in response to orally ingested fats and
carbohydrates and enters the systemic circulation via intestinal capillaries draining into the
hepatic portal vein.14 GLP-1 is rapidly degraded by DPP-IV and only 10-15% of secreted GLP-1
makes it intact into the systemic circulation.14 GLP-1 is therefore believed to be most
concentrated in the intestinal extracellular space and hepatic portal vein. While it has been
established that the physiological effects of GLP-1 are a result of interaction with the GLP-1R, it
is unclear the exact mechanism and population of GLP-1Rs responsible for the various
physiological effects.15 GLP-1R is expressed on the vagal afferent fibers of gastrointestinal and
hepatoportal origin, pancreatic β cells and within CNS neurons.15
As the potential of GLP-1 therapeutics is realized, a drug delivery system that can mimic
the physiologic route of endogenous secretion is essential in fully understanding the mechanism
of the GLP-1.16 It has been reported that GLP-1 acts on the afferent receptors near the site of
secretion.7 Since native GLP-1 is secreted by the intestinal L cells, an orally delivered GLP-1
would have the potential to mimic the full physiological effects of native GLP-1.16
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As a peptide, GLP-1 cannot be delivered orally due to degradation and proteolysis in the
gastrointestinal tract.17 The B12 uptake pathway, previously discussed in chapter 1 (section
1.4.4), has the potential to overcome these barriers and orally deliver GLP-1. The full potential
of the B12 uptake pathway as a delivery system has yet to be fully realized. A number of
limitations to this delivery strategy have been identified in recent years, including a limited
uptake capacity and slow delivery rate, which has discouraged research into this area.18 The
critical component to the success of the B12 delivery approach is the use of a peptide that has a
therapeutic window within the B12 uptake capacity .
Using the B12 pathway for the delivery of peptides has a number of major advantages
over other delivery systems including oral delivery, no known toxicity and the ability to cross the
blood-brain barrier.19, 20 The limited uptake capacity of the B12 uptake pathway refers to the
transfer of B12 from the ileum to the systemic circulation through IF-mediated endocytosis via
the cubilin receptor (see section 1.4.7 for discussion on the cubilin). It is important to note that
cubilin recycles every few hours, and as such, multiple dosing (e.g., morning and evening) may
be adopted to increase the quantity of peptide absorbed throughout the day.21 This recycling may
also be important when considering dietary B12 competition.
We have previously demonstrated the ability to use B12 to orally delivery clinically
relevant amounts of the appetite suppressant peptide tyrosine tyrosine (PYY).22 To adapt this
uptake pathway for the delivery of GLP-1, recognition and affinity for the various binding B12
transport proteins must be maintained and the biological potency of the GLP-1 must not be
diminished. We are now exploring in depth the effect of B12 conjugation on the biological
potency of GLP-1 in an attempt to demonstrate the true potential of the uptake pathway for the
delivery potent peptides and proteins.
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3.2 Results and Discussion
3.2.1 Synthesis and Purification of B12-K34R-GLP-1 (7-36) amide (3)
GLP-1 (7-36) amide has three amine groups (N-terminal, Lys26 and Lys34) available for
conjugation. For our lead conjugate, the peptide was purchased with modifications (amino acid
substitution K34R, and FMOC protection of the N-terminal amine (FMOC-K34R-GLP-1)) to aid
in selective conjugation at the Lys26 (Figure 32). No significant reduction in biological activity
has been shown for conjugation at the Lys26.23, 24 Commercially available Liraglutide has the
same amino acid substitution24, 25 and the FMOC protection was removed after synthesis.

Figure 32. GLP-1 (7-36) amide was purchased with N-terminal FMOC protection and K34R
amino acid substitution (34) which will be referred to as FMOC-K34R-GLP-1 or K34R-GLP-1
when the FMOC is removed. These modifications allow for site directed B12 conjugation at the
Lys26 (26).
Modifications at the 5’-hydroxyl group of B12 have been repeatedly shown to maintain
binding with the transport proteins vital for oral B12 uptake.22, 26, 27 Reaction of B12 with 1,1’carbonyl-di-(1,2,4-triazole) in DMSO at room temperature for 5 minutes furnished an activated
ester at the 5’-hydroxyl group. An excess of activated B12 was then added to a slowly stirring
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solution of FMOC-K34R-GLP-1 in DMSO with 0.1% TEA. The reaction proceeded for 3 hrs
before an excess of FMOC-OSu was added to help with purification, as described below.
The reaction was extracted by diethyl ether addition and centrifugation. The product was
isolated on a C18 analytical column using reverse phase HPLC. Unreacted B12 was easily
separated from FMOC-K34R-GLP-1, however purification of unconjugated FMOC-K34R-GLP1 and B12 conjugated FMOC-K34R-GLP-1 proved challenging due to the similarity in
hydrophobicity.

The addition of excess FMOC-OSu was used to aid in purification, as

previously reported for a B12 insulin conjugate.27 The FMOC moiety increases the retention time
of the unconjugated (hence, unprotected) FMOC-K34R-GLP-1, allowing for separation (see
Figure 33). Following HPLC purification, the protecting group was removed with piperidine and
dialyzed against 5 L of H2O overnight in 3500 MWCO dialysis tubing. A 10% yield of 3 was
calculated using electronic EAS with an extinction coefficient of 27500 M-1 cm-1 at 361 nm,
corresponding to the B12 γ band, as described in section 2.2.3.

Figure 33. RP-HPLC chromatogram showing separation of unconjugated B12 and K34R-GLP-1
from B12 conjugated K34R-GLP-1 with detection at 254 nm (solid line) and 360 nm (dash line).
81

Absence of B12 absorption at 360 nm indicated the peak at retention time (Tr) ~ 24 mins is
unconjugated K34R-GLP-1 now with two FMOC units, while the peak at Tr ~ 20 mins is B12
conjugated K34R-GLP-1 with one FMOC.

3.2.2 MALDI-ToF Mass Spectrometry
B12-FMOC-K34R-GLP-1 was identified as the peak at a Tr of 20 by MALDI-Tof MS.
The peak at 4682 m/z represents a 1:1 [B12-CN+H]+ K34R-GLP-1 conjugate (see Figure 34).
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Figure 34. MALDI-ToF MS spectrum of 3 after FMOC removal showing the presence of a
prominent peak at 4682 m/z representing a 1:1 B12-K34R-GLP (7-36) amide.

3.2.3 In vitro Experimentation
GLP-1 mediates its insulinotropic effects by binding to specific GLP-1 receptors on the
pancreatic β cells and stimulating cAMP formation, calcium induced calcium release (CICR) and
insulin secretion (see Figure 35).15 The effect of B12 conjugation on GLP-1 physiological
function (cAMP production, CICR and insulin secretion) was studied in HEK-293 cells stably
expressing the human GLP-1 receptor (HEK-GLP-1R) and isolated human pancreatic islets.
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Figure 35. A basic depiction of the intercellular mechanisms of the GLP-1R, which were
monitored for in vitro assays described in section 3.2.5. RYR: ryanodine receptor; ER:
endoplasmic reticulum; CRE: cAMP response element. RIP-1-CRE-Luc: rat insulin 1 promotercAMP response element-luciferase reporter.

To determine the ability of the conjugate to perform as a cAMP elevating agent, HEKGLP-1R cells were transfected with a reporter construct containing the coding sequence for the
luciferase (Luc) enzyme and a promoter incorporating a cAMP response element originally
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identified within the 5’ promoter region of the rat insulin 1 gene (RIP1-CRE).28 This cAMPresponsive Luc reporter (RIP1-CRE-Luc) can be used to determine the effect of agonist for G
protein-coupled receptors positively linked to cAMP production, such as the GLP-1 receptor.28
The level of Luc activity was determined in whole-cell lysates by Luc-catalyzed oxidation of
luciferin, which generated photons detected by a photomultiplier tube. After exposure to the drug
for 4 hrs, Luc activity was determined and shown to be concentration dependent with an EC50 of
4.4 nM (see Figure 36). These findings were comparable to that found for K34R-GLP-1 with an
EC50 of 4.1 nM (see Figure 36). B12 was not shown to produce any response in the luciferase
assay. The EC50 values suggest the B12 has little negative effect on the potency of the GLP-1, an
important and highly positive result.

Figure 36. The fold increase of luciferase activity was determined for 3 and K34R-GLP-1 after
HEK-GLP-1 cells were transfected with a RIP1-CRE-Luc reporter and were exposed to 3 for 4
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hrs. 3 produced a concentration dependent response with an EC50 of 4.4 nM, while K34R-GLP-1
had an EC50 of 4.1 nM.
The stimulatory effects of GLP-1 on pancreatic islet insulin secretion have been
attributed to the capability to increase levels of cytosolic [Ca2+] in β cells.15, 29 GLP-1 produces a
rise in cytosolic [Ca2+] by promoting CICR from intracellular storages.15 The ability of 3 to
facilitate an increase in cytosolic [Ca2+] was assessed in HEK-GLP-1R cells that express
endogenous P2Y purinergic receptors using a fura-2 assay. Fura-2 is a widely used ratiometric
fluorescent dye which is used to determine intercellular levels of calcium. Fura-2 determinations
of [Ca2+] were obtained in a 2-step injection protocol were 3 (A) or native GLP-1 (B) was
administered to each well after baseline recording for 100 s. After a further 200 s the P2Y
receptor agonist adenosine diphosphate (ADP) (10 nM) was added and the ratio of Fura 2 was
recorded. Both forms of GLP-1 potentiated the action of ADP to mobilize intracellular [Ca2+]
and native GLP-1 was slightly more potent than 3 (see Figure 37).
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Figure 37. Fura-2 determinations of intercellular [Ca2+] were obtained in HEK-GLP-1R cells
that express endogenous P2Y purinergic receptors. Note that both forms of GLP-1 potentiated
the action of ADP to mobilize intracellular [Ca2+] and that native GLP-1 was slightly more potent
than 3. Data are averaged from 12 wells for each data point and similar results were obtained in
four independent plates with three different batches of 3.
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Since its formation in 2001, the national Islet Cell Resource (ICR) Center Consortium has
provided isolated human pancreatic islets (see Figure 38) for clinical and basic research while
also working to develop methods to perfect the isolation of islets for human transplantations.30
Human pancreatic islets are a critical tool for diabetes researchers. Human islets have provided
invaluable information about the cellular biology of the pancreas and the pathology of diabetes.
Furthermore, the uniqueness of the human pancreatic biology is an invaluable tool for the
development of therapeutics for the treatment of diabetes.30

Figure 38. Pure human pancreatic islets isolated from digested pancreatic tissues, as seen under
a microscope. Image reprinted from reference 31 with permission of Baishideng Publishing
Group Co.
To evaluate potential insulin secretagogue properties of B12-GLP-1, human islet insulin
secretion was monitored under standard conditions of static incubation in which human islets
were equilibrated in Krebs-ringer buffer (KRB) containing 2.8 mM glucose, followed by a
subsequent elevation of the glucose concentration to 16.7 mM with or without the test substance.
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The rise in glucose concentration will cause glucose stimulated insulin secretion (GSIS) in
healthy insulin producing islets and the addition of a GLP-1 based conjugate should increase the
GSIS. The initial GSIS was used to determine the viability of the human islets being tested.
Human islets used for basic research are not healthy enough for human transplantations, which
means they are not always viable for research purposes either.
The average of three batches of isolated human islets produced a GSIS of 2.2-fold
insulin secretion (see Figure 39). GSIS was potentiated an additional 45% by 15 nM 3 (total 3.2
fold stimulation). This effect of 3 was similar to that which was measured when islets were
instead treated with 15 nM GLP-1 (total 3.3 fold stimulation).

Figure 39. Static incubation assays using human pancreatic islets. Islets were exposed to KRB
containing 2.8 mM glucose for 30 min and were then exposed to KRB containing 16.7 mM
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glucose with GLP-1 or 3 or without test substance. GSIS resulted in a 1.4 fold insulin secretion
while a 3.2 fold increase was observed for 3, which is comparable to the GLP-1 (3.3 fold
increase).

3.3. Conclusion
We have reported on the synthesis, purification and in vitro characterization of a novel
B12-K34R-GLP-1conjugate. Experimentation with the lead B12-GLP-1 conjugate in vitro
demonstrated B12 attachment has a minimal effect on the insulinotropic nature of K34R-GLP-1
(EC50 4.1 nM vs. 4.4 nM). We analyzed various steps in the physiological pathway of GLP-1
stimulated insulin secretion to come to this conclusion. Initially we used a luciferase based assay
to indirectly determine the ability of 3 to produce an increase in intercellular cAMP levels. The
ability of B12-GLP-1 to stimulate CICR was than monitored by Fura-2 assay. Finally we used
transplanted human islets to confirm the ability of B12-GLP-1 to stimulate insulin secretion. This
is the first reported study of how B12 conjugation affects a peptide’s in vitro activity. The data
collected for the B12-GLP-1 conjugate in vitro are very encouraging. The next step is in vivo
experimentation to determine the biological activity of the B12-GLP-1 conjugate, which is
scheduled to occur in October 2012 in the lab of collaborator Dr. Christian Roth in Seattle
Children’s Hospital, WA, US.
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Chapter 4 Synthesis of a B12 Derivative Capable of Amide Bond Formation
4.1 Introduction
The increasing use of B12 for the delivery of therapeutics has encouraged the reexamination of potential conjugate sites of B12.1-4 Several positions are available on B12
for conjugation, including the 5’-hydroxyl group of the ribose, the cobalt (III) ion, the
phosphate moiety and propionamides off the corrin ring (if modified to a carboxylic acid
first) (see Figure 40).5-7 Numerous groups have explored modifications of B12 that allow
for more facile, higher yielding or stable conjugate formation with continued recognition
by B12 dietary transport proteins.1, 3, 8-23 All such modifications to date suffer from issues
including reduced or complete loss of interaction with one or more of the B12 binding
proteins, stability issues that result from the production of ester or carbamate bonds, low
yielding conjugation reaction due to the nature of the functional group, or require
problematic purification of the modified B12 for subsequent conjugation.1, 3, 8-23 These
limitations have been well investigated24-26 and reviews of such sites has been reported,2730

however, in brief for purposes of perspective for the work described herein:
Conjugation resulting in the recognition of all three transport proteins has been

most successful with B12 at two major sites: 1) the 5’-hydroxy group of the ribose group
and 2) the peripheral corrin ring e propionamide (see Figure 40). The side chain e
carboxylic acid derivative, produced from hydrolysis of the propionamide, allows for a
variety of modifications,31-33 but the synthesis of the derivative is low yielding and
requires a laborious purification, the result, in part, of the formation of b and d carboxylic
acid isomers in addition to the desired e carboxylic acid derivative.34-38 The 5’-hydroxyl
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group of the ribose is a versatile site according to structure-activity relationships,
however conjugates produced have typically been synthesized, as mentioned above,
through carbamate or ester bonds.

Figure 40. Potential sites available for carboxylic acid formation that also maintain, at
least in part, B12 uptake protein recognition and binding are indicated in red. The atom
numbering scheme used for future NMR discussion (see section 4.2.2) is also indicated.
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We report the selective oxidation of the 5’-hydroxyl group of B12 to the
corresponding carboxylic acid using a hypervalent iodine reagent, 2-iodoxybenzoic acid
(IBX). IBX (see Figure 41) has never been utilized for the oxidation of such a complex
molecule as B12. The work reported here expands the range of successful use of the
environmentally friendly oxidizing agent.39

Figure 41. The structure of 2-iodoxybenzoic acid (IBX).

4.2 Results and Discussion
4.2.1 Synthesis of B12 5’-carboxylic acid (4)
The B12 5’-carboxylic acid (4) was synthesized utilizing a modified method of
Giannis et al., which incorporates the addition of an O-nucleophile to aid IBX in the
transformation of a primary alcohol to a carboxylic acid (see Figure 42).40, 41
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Figure 42. Purposed mechanism for the formation of 4 utilizing IBX and 2hydroxypyridine (HYP).
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The use of the O-nucleophile N-hydroxysuccinimide (NHS) was initially
attempted, but resulted in an inability to isolate the carboxylic acid, likely due to the
formation of the activated NHS ester that has been reported as a dominating product of
this reaction.40, 41 2-hydroxypyridine (HYP) was used as the O-nucleophile. To optimize
the reaction conditions, a series of experiments were performed where co-oxidant,
temperature and time were varied (see Table 2).
Table 2. Optimization of the Reaction Conditions for 4.
Entry

Co-Oxidant

Temp (oC)

Time (hr)

Yield (%)

1

None

50

2

17

2

HYP

50

2

23

3

HYP

50

3

26

4

HYP

50

4

28

5

HYP

50

5

22

6

HYP

60

2

30

The best result was obtained in the presence of 2.6 equivalents of IBX and 5
equivalents of HYP in DMSO at 60 oC. These conditions resulted in the oxidation of B12
to the 4 in two hours with a 30% yield. It was determined that a 30% yield was optimal
for the IBX reaction, in this case, as increase in temperature, IBX/HYP ratios or time
resulted in an increase in byproducts and/or decomposition of the B12 (especially at
temperatures in excess of 60 oC), and which also co-eluted with the desired carboxylic
derivative, complicating purification. The 30% yield is ~ three times that previously
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reported for the preparation of the e-carboxylic acid derivative and with far easier
separation (vide infra). 34-38
The crude reaction was precipitated from DMSO by diethyl ether addition and
dissolved in H2O prior to purification by ion exchange chromatography using a SAX
column. After a 5 minute hold at 100% water, a gradient from 100% water to 35%
MeCN:phosphate buffer pH 2 (50:50 v/v) over 5 minutes was necessary for the
separation and elution of 4 (see Figure 43). Slight increases in pH above 2 resulted in a
loss of pure product isolation. The HPLC purification allowed for the recovery and reuse
of B12 starting material, albeit with the oxidized 5’-aldehyde also present (see Figure 43).
4 was identified as the peak at retention time (Tr) 13.5 mins. Purity of 4 was at least 95%
as assayed by RP-HPLC.

Figure 43.

The RP-HPLC spectra of 4 (Tr = 13.5 mins.) monitored at 360 nm.

Unreacted B12 and 5’aldehyde co-elute at ~ Tr = 6 mins as indicated by MALDI-ToF MS.
MALDI-Tof mass spectrometry analysis of 4 demonstrated the anticipated
molecular ion peak [M-CN]+ of 1343.5 m/z (see Figure 44).
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Figure 44. MALDI-ToF MS spectrum of HPLC peak at Tr =14 mins indicating 4 ([MCN]+ 1343.5 m/z) with angiotensin as an internal reference.

Electronic absorption spectroscopy (EAS) was used to determine the oxidation
state of the metal center, nature of the axial ligands bond to the metal center and yield of
CA (εCA361 = 27500 M-1 cm-1) (see Figure 45).

99

Figure 45. Absorbance spectrum of 4 in 35 % HPLC mobile phase B.

4.2.2 1D and 2D NMR analysis of 4
The structure of 4 was determined by assignments obtained from 1H NMR (see
Figure 46) and 1H-13C heteronuclear (HSQC and HMBC) correlations (see Figures 47
and 48). The 1H NMR spectra of 4 revealed the loss of 2 protons (δH = 3.75 and 3.92),
when compared to the spectrum of B12 (CNCbl) (see Figure 49). A comparison of the
HSQC of B12 and 4 indicates the protons lost in 4 were originally attached to the R5
carbon (δC = 63.3) (see Figure 50). HMBC was then chosen to further establish the
addition of a carbonyl at the R5 position (see Figure 48), however it was established that
the R5 carbon shows no connectivity to any of the ribose protons and so was assigned by
HSQC.42
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Figure 46. 500 MHz 1H NMR spectrum of 4.

.
Figure 47. 500 MHz 1H-13C HSQC NMR spectrum of 4.
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Figure 48. 500 MHz 1H-13C HMBC NMR spectrum of 4.
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Figure 49. 500 MHz 1H NMR spectrum of B12 (CNCbl).

103

Figure 50. Portion of HSQC of 4 (right) and B12 (left) highlighting the loss of protons
(δH = 3.75 and 3.92) due to oxidation at the R5 carbon (δC = 63.3) in the 4.

4.2.3 Synthesis and Characterization of B12-5’-carboxylic acid
benzylamine (5)
A simple amine containing organic molecule, benzylamine, was conjugate to the
derivative to help with the identification of the R5 carbon by NMR. In the presence of 10
equivalents of ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) and 20 equivalents
1-hydroxybenzotriazole (HOBt) in DMF with 1% H2O, the desired conjugate was
produced within 1 hour at 40% yield (Figure 51).
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Figure 51. Synthesis of 5.

5 was purified using the same purification method as established for the
carboxylic acid (see Figure 52) and characterized by MALDI mass spectrometry (see
Figure 53) as well as 1D (see Figure 54) and 2D NMR (see Figure 55 and 56).

Figure 52. Purification of the conjugate was established by RP-HPLC using an SAX
column with a gradient from 100% water to 35% MeCN: phosphate buffer pH 2.
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Figure 53. MALDI-ToF MS spectrum of 5 ([M-CN+H]+ 1432.5). Angiotensin was used
as an internal reference (not shown).
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Figure 54. 500 MHz 1H NMR spectrum of 5.

Figure 55. 500 MHz 1H-13C HSQC NMR spectrum of 5.
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Figure 56. 500 MHz 1H-13C HMBC of 5.

Figure 57.

Analysis of 5 by 2D heteronuclear NMR spectroscopy. A. The atom

numbering scheme for the benzylamine attached to the R5 of B12 by an amide bond. B.
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Signal assignments made from HSQC. C. Signal assignments made from HMBC (Both
1

H and 13C assignment for CA were made by HSQC).

Addition of the benzylamine connectivity of the R5 carbon was established by
HMBC (see Figures 56 and 57). Specifically the protons of CA (δH = 4.42 and 4.50 ppm)
showed direct connectivity to the R5 carbon (δC = 173.8 ppm) as well as CB (δC = 140.8
ppm) and CC (δC = 131.4 ppm) of the benzylamine (see Figure 57). The complete
assignment of 4 and 5 can be found in Table 3.
Table 3. 1H and 13C chemical shifts for the B12 5’-carboxylic acid (B12CA), B12 5’carboxylic acid benzylamine (B12CABA) and B12 (CNCbl) in D2O [500 MHz].
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4.3 Conclusion
In conclusion, we have developed a convenient synthesis for the site-specific
oxidation of B12 using IBX and HYP. This new carboxylic acid derivative is highly
suited to the production of bioavailable amide bound conjugates. The one step
purification is simplistic and the synthesis results in a 30% yield within 2 hours, which is
far in excess of any previously reported B12 carboxylic acid derivative.9 The resulting
derivative has the potential to form high yielding conjugates and we believe will be of
considerable use for the field of B12 conjugation.
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Chapter 5 Experimental Procedure
5.1 Materials and Methods
Chemicals and solvents were purchased from Sigma–Aldrich or Fluka and were
used without further purification. Powdered bovine insulin was purchased from Sigma–
Aldrich. Glucagon-like peptide (7-36) amide with a K34R amino acid substitution and
N-terminal FMOC protection (FMOC-K34R-GLP-1) was purchased from NEOBiolab
(Cambridge, MA). DMSO was dried over 4 Ǻ molecular sieves (200–400 mesh, Sigma)
under dry dinitrogen. Dialysis tubing (2000, 3500, and 7000 Da cutoff) was purchased
from Pierce. H2O was distilled and deionized to 18.2 mΩ using a Barnstead Nano
Diamond ultra-purification machine. RP-HPLC purification was carried out on an
Agilent 1100 system with a variety of Agilent columns discussed below.
MALDI-TOF MS was performed on a Bruker Autoflex III Smartbeam machine
with laser intensity ranging from 50–73%. The matrix used for MALDI-ToF was 10 mg
α-cyano-4-hydroxycinnamic acid (CHCA) dissolved in dH2O/CH3CN (1:1 v/v)
containing 0.1% TFA. Angiotensin I was used as an internal control (1296 m/z). B12insulin conjugates were reduced with 10 mM DTT to determine B12 attachment to AChain or B-Chain. Trypsin digestion of B12-insulin conjugates was accomplished with the
addition of 0.02 moles trypsin to a 1 mole of B12-insulin to determine what fragment of
B-chain B12 attachment occured. EAS were obtained on a Varian Cary 50 Bio
spectrometer in a 1 mL quartz cuvette (Sigma) between 200 nm and 600 nm. All
centrifugation was done at 4000 rpm for 10 minutes using a Sorvall centrifuge with a
swinging rotor (Sorvall Heraeus 75006441 K). 96-well plates were coated with rat tail
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collagen from BD Biosciences prior to assays. CMRL-1066 modified culture medium
was obtained from Mediatech. Fetal bovine serum (FBS), Dulbecco’s modified eagle
media (DMEM), Pluronic F-127 and Fura-2 acetoxymethyl ester (Fura-2AM) were
purchased from Invitrogen Life Technologies, Carlsbad, CA. Insulin secretion was
determined using a Mercodia Ultrasensitive Rat Insulin ELISA Kit #10-1247-10.
Measurements of intracellular [Ca2+] were performed using a FlexStation 3 microplate
reader using SoftMaxPro software from Molecular Devices. A Lipofectamine 2000 kit
was purchased from Invitrogen for transfections. A luciferase assay kit was purchased
from Promega, Madison, WI.
5.2 Experimental Procedures
5.2.1 Synthesis of B12-B1Insulin (1)
The activation of the 5’-hydroxyl group of B12 was achieved using a previous
reported method.1 B12 (10 mg, 0.007 mmol) and CDT (1.7 mg, 0.010 mol) were stirred in
DMSO (1 mL, dried) under dry dinitrogen for 1 h. The activated B12 was used without
further purification. A variation of the literature procedure reported by Kim et al. was
used for the BOC protection of insulin.2 BOC (4.0 mg, 0.0187 mmol) and NHS (4.4 mg,
0.04 mmol) dissolved in DMSO (100 μL) containing 0.05% TEA (v/v) stirred for 0.5 h
prior to being added to a stirring solution of insulin (5.0 mg, 0.00087 mmol) dissolved in
DMSO (1 mL) containing 0.05% TEA (v/v). After 0.5 h, an excess of activated B12 (2.4
mg, 0.0017 mmol) was added to the BOC protected insulin solution. The reaction stirred
for 4 h and was isolated using diethyl ether (Et2O) and centrifugation. The red solid was
dissolved in 25/75 (v/v) CH3CN/H2O containing 0.1% TFA and purified using analytical
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RP-HPLC with an Eclipse XDB-C18 column (5 μm, 9.4 X 250 mm); flow rate: 1 mL/min,
solvent A: dH2O/0.1% TFA; solvent B: CH3CN/0.1% TFA; method 0-10 min 75/25%
A/B to 47.5/52.5% A/B. Collected 1 was then spiked with 50% TFA (0.5 ml) and stirred
for 0.2 h to remove the BOC protection. 1 was dialyzed against 5 L dH2O in snakeskin
tubing (7000 Da cutoff) to remove residual free insulin and BOC. The dialysis bag
content was then concentrated by lyophilization overnight yielding a light pink powder
(0.31 mg, 5%). HPLC Tr = 8.5 mins; MALDI-ToF: calculated for C317H464CoN79O89PS6
Insulin-[B12-CN+H]+ 7090.9 m/z, found 7090.5 m/z; MALDI-ToF of reduced of 1:
calculated for insulin’s B-Chain + [B12]+ 4754.5 m/z, found 4754.5 m/z; MALDI-ToF of
reduced and digested 1: calculated for Insulin’s B23-B30 + [B12]+ 2285.9 m/z, found
2285.8 m/z. Yield was calculated from EAS using ε361 =27,500 M-1cm-1.
5.2.2 Synthesis of B12-B29Insulin (2)
Powder bovine insulin (5.0 mg, 0.00087 mmol) was dissolved in DMSO (1 mL)
containing 0.05% TEA (v/v). An excess of activated B12 (2.4 mg, 0.0017 mmol) was
transferred to the unprotected insulin and reacted for 4 hours. FMOC-OSu (0.5 mg,
0.0015 mmol) in DMF (1 mL) was added to the reaction mixture. The reaction mixture
stirred for 2 h and was isolated using Et2O and centrifugation. The red solid was then
dissolved in a 25/75 (v/v) CH3CN/H2O containing 0.1% TFA and purified using
analytical HPLC. Piperidine (10% v/v) was added to the pink fraction. Dialysis (7000 Da
cutoff) against H2O (5L) removed residual free insulin and FMOC. The dialysis bag
content was then concentrated by lyophilization overnight yielding a light pink powder
(0.62 mg, 10%). HPLC Tr = 8.5 mins; MALDI-ToF: calculated for C317H464CoN79O89PS6
Insulin-[B12-CN+H]+ 7090.9 m/z, found 7090.5 m/z; MALDI-ToF of reduced of 2:
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calculated for insulin’s B-Chain + [B12]+ 4754.5 m/z, found 4754.5 m/z; MALDI-ToF of
reduced and digested 2: calculated for Insulin’s B1-B22 + [B12-CN+H]+ 3844.6 m/z,
found 3844.6 m/z. Yield was calculated from EAS using ε361 =27,500 M-1cm-1.
5.2.3 Synthesis of B12-K34R-GLP-1(7-36) amide (3)
B12 (10 mg, 0.007 mmol) was activated at the 5’-hydroxyl group using CDT (1.7
mg, 0.010 mmol) in DMSO (1 mL, dried) under dry dinitrogen for 30 mins.

The

activated B12 solution (0.096 mL, 0.0007 mmol) was subsequently added to a stirring
solution of FMOC-K34R-GLP-1 (1.0 mg, 0.0028 mmol) dissolved in DMSO (0.1 mL)
with 0.6% TEA (v/v). The reaction stirred for 3 hrs at RT before H2O w/ 0.1% TFA
(20% v/v) was added to the reaction to lower the pH. A solution of FMOC-OSu (0.028
mmol) in DMF was added and allowed to proceed an additional hr. The reaction was
extracted with the addition of diethyl ether. Purification of the B12-FMOC-K34R-GLP-1
conjugate was accomplished by RP-HPLC using an Agilent C18 column and HPLC
method solvent A: dH2O/0.1% TFA; solvent B: CH3CN; 0-25 min 75/35% A/B to
35/65% A/B. The pH of the solution was adjusted to pH 8 with NH2HCO3 immediately
following isolation by HPLC. The removal of the N-terminal FMOC protection was
accomplished with the addition of 10% piperidine after 10 minutes. The solution was
transferred to 3500 MWCO dialysis tubing and dialyzed against H2O for 18 hours,
changing solution every 4-6 hours. 3 was collected as a light pink solution (0.10 mg,
10%). HPLC Tr = 19.5 mins; MALDI-ToF: calculated for K34R-GLP-1-[B12-CN+H]+
4680 m/z, found 4682 m/z; Yield was calculated from EAS using ε361 =27,500 M-1cm-1.
5.2.4 Synthesis of B12-5’-carboxylic acid (4)
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B12 (10.0 mg, 0.007 mmol), 2-iodoxybenzoic acid (5.37 mg, 0.019 mmol) and 2hydroxypyridine (3.51 mg,0.037 mmol) were dissolved in DMSO (1 mL). The reaction
temperature (50-60oC) and time (2-5 hrs) were varied as outlined in Table1. The crude
reaction was precipitated by diethyl ether addition and dissolved in H2O prior to
purification. The derivative was purified by ion exchange chromatography using a SAX
column. After a 5 minute hold at 100% H2O, a gradient from 100% H2O to 35% MeCN:
phosphate buffer pH 2 (50:50 v/v) over 5 minutes was necessary for the separation and
elution of the 4. 4 was then neutralized and mixed with amberlite XAD4 resin overnight.
The resin, now red suggesting 4 binding, was collected and washed with H2O to remove
any salt prior to MeOH extraction of the 4. The MeOH was collected and lyophilized
yielding a red powder (3 mg, 30% for 2 hrs at 60oC). HPLC Tr =14 mins; MALDI-TOF
MS: calculated for C62H86CoN13O15P [M-CN]+ 1343.5, found 1343.5; See chapter 4 table
3 for NMR assignments.
5.2.5 Synthesis of B12 5’-carboxylic acid benzylamine (5).
4 (10.0 mg, 0.007 mmol), benzylamine (7.8 mg, 0.073 mmol), 1-EDC (14.0 mg,
0.073 mmol) and HOBt (19.7 mg, 0.146 mmol) were dissolved in DMF (1 mL) with 1%
H2O at rt for 1 hr. Isolation and purification were achieved as described for the 4 (4.0
mg. 40%). HPLC Tr= 10 mins. MALDI-TOF MS: calculated for C69H93CoN14O14P [MCN+H]+ 1432.5, found 1432.5; δH = 7.42, 7.41, 7.41, 7.39, 7.38 corresponding to the
aromatics of benzylamine and 4.46 corresponding to CA. δC = 140.8, 131.4, and 46.4
corresponding to CB , CC , and CA respectively. See chapter 4 table 3 for B12 related NMR
assignments.
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5.3 In vitro Investigation of 3
5.3.1 Cell Cultures
Human embryonic kidney (HEK-293) cells stably expressing the human GLP-1
receptor were a gift of Novo Nordisk A/S (Bagsvaerd, Denmark). HEK-GLP-1R cells
were cultured in DMEM containing 10% FBS, penicillin/streptomycin, and G418. The
cells were maintained at 37 °C in a humidified incubator gassed with 5% CO2 and were
passaged by trypsinization once per week.
Human islets of Langerhans, obtained posthumously from anonymous donors,
were provided under the auspices of the Integrated Islet Distribute Program of National
Institutes of Health, National Center for Research Resources, and National Islet Cell
Resource Centers. Primary cultures of human islets were maintained in a humidified
incubator containing 95% air and 5% CO2 at 37 °C in CMRL-1066 modified culture
medium containing 10% (v/v) FBS.
5.3.2 Luciferase Assay
For GLP-1 activity, HEK-GLP-1R cells were plated in a rat tail collagen coated
96 well plate at a density of 55,000-65,000 cells/well and incubated overnight at 37oC.
The next day, the cells were transfected with RIP1-CRE-Luc using Lipofectamine 2000
according to the manufacturer’s instructions. The cells (HEK-GLP-1R-RIP1-CRE-Luc)
were cultured in DMEM containing 10% FBS overnight, then exposed for 4 h to serumfree culture medium containing 1% BSA and the test substance. Cells were then lysed
and assayed for luciferase-catalyzed photoemissions using a luciferase assay kit and
luminometer.
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5.3.3 Fura-2 Assay
The experiment was performed using a monolayer of fura-2 loaded HEK-GLP-1R
cells grown on rat tail collagen coated Costar 3904 plate. Fura-2 was loaded in a
standard extracellular solution (SES) containing: 138 NaCl mM, 5.6 mM KCl, 2.6 mM
CaCl2, 1.2 mM MgCl2, 10 mM HEPES pH 7.4 and 11.1 mM glucose. The SES was also
supplemented with 20 μl per ml FBS, 1 μl per ml Pluronic F-127 and 1 μM fura-2 AM.
Spectrofluorimetry was performed using excitation light at 355/9 and 375/9 nm
(center/bandpass) delivered using a 455 nm dichroism mirror. Emitted light was detected
at 505/15 nm and the ratio of emission light intensities due to excitation at 355 and 375
was calculated.
5.3.4 Insulin Secretion in Human Pancreatic Islets
Insulin secretion was determined by static incubation. After overnight culture in
CMRL-1066 medium, human islets were transferred to MilliCell-PCF culture plate filter
inserts at a density of 40 islets/insert. The inserts were mounted within individual wells
of a 24-well cell culture plate and each well of the plate was filled with 1 ml of Krebsringer buffer (KRB) containing 24 mM sodium bicarbonate and the indicated
concentrations of glucose (pH 7.4). Culture plates containing islets were placed within a
cell culture incubator gassed with 95% air and 5% CO2 at 37 °C. Prior to the start of an
experiment, islets were exposed to KRB with 2.8 mM glucose for 30 min. The inserts
were then transferred between adjacent wells on the plate to measure basal and stimulated
insulin secretion. For each test solution, the duration of exposure was 30 min. A 200 μl
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fraction of each solution was then collected and assayed for insulin content by an
enzyme-linked immunosorbent assay after appropriate dilution of samples.
5.4 In vivo Experimentation of 1 and 2
Male Sprague Dawley rats (279 ± 31; ± SD; n=12) were rendered insulindeficient via subcutaneous injection of streptozotocin (STZ; 80 mg/kg BW) dissolved in
citrate buffer (100 mM; pH 4.2). Blood glucose concentration was assessed after four
days to ensure fasting levels of greater than 15 mmol/L. Maintenance of animals and
experimental protocols were conducted in accordance with federal regulations and
approved by the Murdoch University Animal Ethics Committee. Animals were fasted
overnight prior to the first blood sample being taken from the lateral tail vein and
assessed for glucose concentration (One-touch Verio).

Compounds were then

administered by oral gavage using a flexible feeding tube and blood samples collected 60,
120, 150, 180, 210 and 240 min post gavage from the lateral tail vein. AUC
transformations were conducted using the trapezoidal method in SigmaPlot, which was
then subtracted from pre-gavage[mmol] x 240min; higher numbers represent a greater
reduction in glucose concentration following oral gavage. Statistical significance was
then assessed on this data using a one-way ANOVA with repeated measures (condition)
after testing for normality (Shapiro-Wilk) and equal variance. Tukey post Hoc testing
was used to assess differences between condition.
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Chapter 6 Future Work
6.1 Vitamin B12
Major strides towards establishing the role of B12 as a carrier for oral delivery of
protein therapeutics have been achieved. The full potential of the B12 dietary uptake
pathway, however, has not been completely realized. Further exploration into the
transport proteins in terms of their role in protecting peptides/proteins in the stomach and
intestines, and the potential loss of the peptide/protein to TCII in the blood stream needs
to be done.
One of the major barriers facing oral drug delivery of peptides and proteins is the
acidic/proteolytic environment of the GIT.1 Previous reports have discussed the inability
of the transport proteins in aiding in the protection of peptides/proteins from these
elements.1 The previous authors, however, had no data to support such claims and our in
vivo work with B12-insulin suggests there is a protecting effect from the transport
proteins.2 In situ experimentation with the HC-B12 peptide/protein complex or IF-B12
peptide/protein complex in the presence of simulated stomach and intestinal conditions
would help to establish this important ability of the transport proteins. The production of
simulated stomach and intestinal conditions has been well established and can be
followed from literature.3
Knowledge of whether there is loss of insulin activity through TCII-B12 based
binding to the TCII receptor CD320, as opposed to the desired binding to the insulin
receptor CD220 (see Figure 58), needs to be investigated. If, upon oral delivery to the
circulatory system, a significant proportion of the conjugate binds to the CD320 and the
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rest goes to the target CD220, then modification of the conjugate to minimize CD320
binding would immediately improve the response of the oral B12-insulin conjugate and
ensure an optimal system had been obtained.

Figure 58. Rendering of B12-insulin (yellow-blue) bound by TCII (red and dark blue)
produced by collaborator Dr. Damien Allis at Syracuse University. It is possible for such
a structure to bind either the TCII receptor CD320 or the insulin receptor CD220 as
indicated. The image was altered from 2 with permission of The Royal Society of
Chemistry (RSC) on behalf of the Centre National de la Recherche Scientifique (CNRS).

The effect of different B12 modifications on the binding affinity of the three
transport proteins has been extensively documented,4-6 with studies showing conversion
of the b propionamide group into a carboxylic acid (see Figure 59) reducing binding of
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B12 by human TCII.6-8 To investigate the binding of TCII, a B12 b carboxylic acid based
insulin conjugate( B12 b acid-insulin) was synthesized with the intent of comparing its
activity to that of previously reported, orally active B12-insulin in a rat model.
Recognition by IF is not completely removed for such a modification, making the B12 b
acid-insulin an intriguing and worthwhile study of CD320 vs. CD220, since if positive
results were obtained, the final conjugate could still be used in oral form.6

Figure 59. Structure of B12 with side chain propionamides indicated. Conversion of the
propionamide at the b position to a carboxylic acid is cited as reducing TCII protein
binding of B12.7, 8
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Previous reports of the synthesis and purification of the b monocarboxylic acid
show it is a very time consuming processes.7, 9-11 By utilizing a microwave reactor, the b
monocarboxylic acid was synthesized in the Doyle lab in three min. Subsequently a onestep RP-HPLC purification method was established using a C8 column with a step
gradient of 2% B for 3 min, 10% B 3.1 to 8 min, 15% B 8.1-13.0 min and 20-80% B 13.1
to 20 min with A: H2O and B: MeOH (See Figure 60). The difficulty with purification is
a result of the number of byproducts in the reaction. Carboxylic acid formation can occur
at one (mono), two (di), or three (tri) propionamide positions (b, d, or e).

The

tricarboxylic acid elute first, followed by the dicarboxylic acids and the individual
monocarboxylic acid. B12 fragments are also byproducts which elute from Tr 15-31 min.
The peak at 13 minutes corresponds to the b monocarboxylic acids as determined by
literature comparison and 1D and 2D NMR.

Figure 60. RP-HPLC of B12 b carboxylic acid derivative.
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The ability of TCII to bind our synthesized b-carboxylic acid derivative was
explored by collaborators at Arrhus University in Denmark.

The Nexo group had

recently demonstrated that the B12 transport proteins are species specific and that some
species have only two transport proteins (IF and TCII) with altered TCII binding
properties.

Experimentation with human and mouse TCII established the b

monocarboxylic acid derivative had reduced binding with human TCII, as literature
would suggest, but was still bound by mouse TCII. Furthermore, the binding studies with
the B12 b carboxylic acid-insulin conjugate (AKP2 in Figure 61) vs. the B12-insulin
conjugate (AKP1 in Figure 61) were shown to bind at comparable levels in mouse and
human TCII. This result was very interesting and suggested an interaction between
insulin and TCII that negated the ability of TCII to bind the b carboxylic acid, which
should be further studied. These studies also demonstrated the need to evaluate the
animal model used for further exploration into the potential loss of protein/peptide to
TCII binding.
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B12 USA

B12 DK
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0.00
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Acid
AKPI
AKP2
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0.25
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0,0078 0,063
0,5
Competitor nmol/L

4
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Figure 61. Competitive binding study of human TCII vs. mouse TCII with B12-Insulin
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(AKP1), B12 b carboxylic acid-insulin (AKP2), B12 b carboxylic acid (Acid) and control
B12 from two sources (B12 USA and B12 DK).
6.2 Glucagon-like Peptide-1
The next step for the B12-GLP-1 conjugate will be to assess its in vivo
bioavailability and uptake upon oral administration. Bioavailability will be assessed
through food intake and body weight gain following subcutaneous injection in male
Sprague dawley rats (SD). The uptake and bioavailability of orally administered B12GLP-1 will be determined in an obese diabetic model, Zucker diabetic fatty (fa/fa) rats
(ZDF).

In these experiments, bioavailability of the conjugate will be assessed by:

changes in food intake and weight gain relative to baseline and controls; and amelioration
of the rodent’s insulin response to glucose stimulation as compared to GLP-1 and vehicle
treated controls.
The therapeutic use of GLP-1 is limited by a short half-life (1-2 min), due
primarily to degradation by the enzyme DPP-IV.12

Exendin-4 (Ex-4) is a DPP-IV

resistant GLP-1 agonist currently approved for the treatment of T2D (as exenatide, brand
name Byetta).13 A drawback of Ex-4 based therapy is that, as a peptide, it needs to be
administered subcutaneously (s.c).1 An orally active Ex-4 may offer advantages in areas
of patient acceptance/adherence to a regimen.14 Since native GLP-1 is secreted by the
intestinal L cells, an orally delivered GLP-1 agonist would also have the highly
significant possibility of mimicking the natural physiological effects of native GLP-1
more closely, in particular by interacting with the vagal afferent fibers of the
gastrointestinal (GIT) tract (not affected by the s.c administered form).15, 16

127

A B12-exendin-4 conjugate would be synthesized using CDT coupling chemistry
between the B12 ribose 5’-hydroxyl group and lysine K12 residue of Ex-4. No significant
reduction in peptide activity has been shown when conjugation occurs at K12 of Ex-4.17
Ex-4 will be purchased with FMOC protection at the N-terminus to aid in selective
conjugation and the FMOC protection will be removed prior to biological testing.
Purification will be achieved by RP HPLC using a C18 column. B12-exendin-4 will be
characterized by electronic absorption and circular dichroism (CD) spectroscopy,
MALDI-ToF mass spectrometry and B12 binding studies with IF and TCII.

These

experiments will produce data confirming the conjugate is pure, coupled correctly, has
remained folded through the chemical coupling procedure and the B12 is still recognized
by the transport proteins needed for oral delivery. To confirm the biological function of
B12-exendin-4 and to gauge the effects of B12 conjugation on Ex-4, in vitro bioassays
(CRE-luciferase in HEK 293-GLP-1R cells, insulin secretion in human islets monitored
by ELISA, and Ca2+ stimulation in HEK293-GLP1R cells) will be performed, as for B12GLP-1 previously investigated (see Chapter 3).
6.3 C-peptide
The B12 uptake pathway is not without its pitfalls.1 The limitations of the B12
uptake pathway are known and include a limited uptake capacity. Therefore, the oral
delivery pathway of B12 may be better suited for a non life threatening peptide, such as Cpeptide, which requires very little to produce a desired effect. Recent studies have shown
the health benefits of C-peptide replacement therapy in patients with type I DM.18
Recombinant protein expression of a C-peptide mutant will allow for conjugation to B12.
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An attempt to orally delivery C-peptide could be a great step forward in the treatment of
complications associated with diabetes.
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pathway in drug delivery
3.

Molecular modeling
considerations

4.

Expert opinion

Importance of the field: Vitamin B12 (B12) is a rare and vital micronutrient for
which mammals have developed a complex and highly efficient dietary
uptake system. This uptake pathway consists of a series of proteins and
receptors, and has been utilized to deliver several bioactive and/or imaging
molecules from 99mTc to insulin.
Areas covered in this review: The current field of B12-based drug delivery is
reviewed, including recent highlights surrounding the very pathway itself.
What the reader will gain: Despite over 30 years of work, no B12-based drug
delivery conjugate has reached the market-place, hampered by issues such
as limited uptake capacity, gastrointestinal degradation of the conjugate or
high background uptake by healthy tissues. Variability in dose response
among individuals, especially across ageing populations and slow oral uptake
(several hours), has also slowed development and interest.
Take home message: This review is intended to stress again the great potential, as yet not fully realized, for B12-based therapeutics, tumor imaging and
oral drug delivery. This review discusses recent reports that demonstrate
that the issues noted above can be overcome and need not be seen as
negating the great potential of B12 in the drug delivery field.
Keywords: B12, cobalamin, haptocorrin, intrinsic factor, peptides, transcobalamin
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1.

Introduction

The consumption of vitamin B12 (B12; cobalamin) is essential for the survival of all
living cells. B12 is produced naturally by bacteria and all other species must acquire
the vitamin through their diet. There are two major biologically active forms of B12:
methylocobalamin and adenosylcobalamin. Methionine synthase uses methylocobalamin to produce the amino acid methionine from homocysteine, and
methylmalonyl-CoA mutase uses adenosylcobalamin as a cofactor to produce succinyl CoA, an important molecule in the TCA cycle [1]. Mammals have developed a
complex uptake pathway for B12 involving a series of transport proteins [1-3]. For the
purposes of this review, the uptake pathway is discussed only superficially. For a
more in-depth discussion of the transport proteins, the reader is referred to recent
reviews by Banerjee et al. [1] and Randaccio et al. [4].
B12 is a water-soluble vitamin (molar mass 1355.38 g/mol as cyanocobalamin)
with a highly complex structure, comprising a midplanar corrin ring composed of
four pyrroline elements linked to a central cobalt(III) atom (see Figure 2 later).
The corrin ring is similar to the more commonly known porphyrin structure but
with key differences. Corrin rings have a greater degree of saturation compared
with porphyrins and the increased number of sp3 carbons confers greater flexibility
to the corrin. In addition, there is greater asymmetry to the corrin ring, the latter the
result of a 15-carbon ring over the porphyrin 16-carbon structure [1].
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.

An overview is provided of B12 structure, chemistry, and
uptake proteins and receptors.
An overview is given of the use of the B12 dietary
pathway in drug delivery.
Methods and highlights in the use of B12 conjugates to
utilize/target specific B12 proteins and
associated receptors.
In the section on general uses of B12 in drug delivery,
oral delivery is discussed, especially of proteins and
peptides, and general small molecule delivery by oral
and invasive means is discussed.

This box summarizes key points contained in the article.

Several functional groups are readily available for modification on B12. Only a few modification sites, however, maintain
the recognition needed to utilize the full B12 uptake pathway
necessary for oral delivery (see Figure 1). Other modifications
can be used to target specific proteins while reducing
affinity for others, a fact recently exploited to target haptocorrin (HC)-positive tumors [5]. An in-depth discussion of
modification sites can be found in Section 2.
B12 is initially released from food by the action of peptic
enzymes and the acidic environment of the gastrointestinal
system [6]. It is then bound and transported by two glycoproteins, HC and intrinsic factor (IF) [2]. Haptocorrin is secreted
by salivary glands and released also by the gastric mucosa.
Haptocorrin has a high affinity for B12 under acidic conditions (pH < 3) and so protects B12 from acid hydrolysis.
The HC:B12 complex travels from the stomach to the duodenum, where the increased pH (> 5) decreases the affinity of
HC for B12 [7]. Haptocorrin is also enzymatically digested
here. On release from HC, B12 binds to the second of the
two gastric transport glycoproteins, IF.
Intrinsic factor is a 43.4 kDa glycosylated protein that is
secreted from the gastric mucosa and the pancreas [2]. The
IF protein facilitates transport across the intestinal enterocyte,
which occurs by receptor-mediated endocytosis at the apically
expressed IF--B12 receptor (cubilin) [8]. Cubilin works to
transport B12 in concert with an anchoring protein amnionless (Am) [6]. Following transcytosis, and between 2.5 and
4 h after initial ingestion, B12 appears in blood plasma bound
to the third trafficking protein, transcobalamin II (TCII) [3].
The holo-TCII is cellularly internalized by the TCII receptor
(TCII-R). B12 is released by the degradation of TCII by lysozyme. Another receptor, megalin (MG), can reabsorb filtered
holo-TCII from primary urine. The TCII-R and megalin
receptors then ensure widespread delivery and maximal use
of B12 [1].
Knowledge of the binding between B12 and its various
transport proteins is critical if the system is to be successfully
translated from bench to bedside. In the last 5 years there has
been an explosion of critical structural data related to the B12
2

uptake pathway, with the publication of the IF [9], TCII [10]
and cubilin(5--8)-IF-B12 [8] structures. One missing piece in
the B12 puzzle is the crystal structure of HC. Indeed, a real
understanding of the functions of HC remains elusive, with
suggestions it may play a bacteriostatic role in the mouth
and bloodstream [11]. What is true now is that researchers
have a better understanding of how B12 interacts with its
transport proteins, and how these transport proteins interact
with their receptors. The implications this can have on drug
delivery and sites of potential conjugation can then be better
detailed, rationalized and hence optimized.
Along with the wealth of knowledge from the experimental
field is the recent use of modern theoretical approaches to
B12-based drug design. The foundational work for B12 molecular modeling studies has all but been completed with the
publication of several recent papers providing both force field
parameters and charge density information at levels of theory
comparable to, or exceeding, the quality of the force fields
within which the parameters have been used [12-17]. With
very little modification, a family of B12 structures can be
turned into topologies for force field parameter assignments.
This has opened the door to a wider range of B12 molecular
modeling studies, including studies of the periplasmic binding
protein BtuF [16] and the TonB-dependent transporter
BtuB [17]. Computational approaches have shown themselves
to be a powerful interpretive tool for explaining the various
structures involved in B12 transport and providing a useful
tool for rational drug design.
Based on the results of recent years, it is clear there is great
hope for a B12-based bioconjugate to reach the marketplace sooner rather than later. This review details and expands
on the points made in this introduction and discusses the
future of the field.

Review of the B12 dietary pathway in drug
delivery

2.

Modifiable points -- solvent-accessible pocket
The solvent-accessible surface of B12 is critical when considering B12-based bioconjugates. The key point to be made
upfront is that there is solvent accessibility. For TCII this solvent exposure is ~ 6.5% (~ 80 Å2). For IF this exposure is
twice as high at ~ 13% (~ 163 Å2), with HC the least accessible at 3.2% (~ 40 Å2) [18]. This exposure allows for select sites
to be utilized when designing a B12 conjugate, for general
pathway acceptance or for selecting specific parts thereof.
B12 and the molecule of interest can be: i) coupled directly
together; ii) held apart by ‘spacer’ units to produce distance
between the B12 and drug; or iii) carriers can be conjugated
to B12 with the desired drug contained, unconjugated, within
this carrier. Several functional groups are readily available for
modification on B12, including propionamides, acetamides,
hydroxyl groups, the cobalt(III) ion and the phosphate moiety.
Only a few modifications are capable of maintaining the
recognition of all three transport proteins needed to utilize
2.1
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Figure 1. Uptake pathway for B12 from oral consumption to cellular entry. Although B12 has been cited as a potential carrier
of drugs for several years, there are several limitations, including uptake capacity (~ 2.5 µg/day for an adult human [45]), that
have limited its use in drug delivery so far.
Am: Amnionless; CB: Cubilin receptor; HC: Haptocorrin; IF: Intrinsic factor; MG: Megalin; TCII: Transcobalamin II; TCII-R: Transcobalamin II receptor.

the full B12 uptake pathway effectively in an oral manner. This
limitation is a result of the manner by which the B12 is bound
by the transport proteins and a strong indicator even in the
absence of structural information on the similar solvent accessibility of B12 positions on binding in all cases. The size of the
drug is important when considering the location for conjugation, as are the transport proteins being utilized, because the
three transport proteins are not created equally. Conjugation
of drugs resulting in the recognition of all three transport
proteins has been successful with B12 at four major sites: i) to
the peripheral corrin ring e-propionamide [19]; ii) through the
5¢-hydroxy group of the ribose unit of the a-‘tail’ [20];
iii) through the 2¢-hydroxy group of the ribose unit of the
a-‘tail’ [21]; and iv) to the cobalt cation (see Figure 2) [22].
Examination of the recently published crystal structures of
B12 bound with TCII [10] and IF [9] provides a better understanding of why such positions are available for conjugation
without complete loss of recognition. TCII was the first transport protein crystallized [10]. The structure revealed several
important details about points of modification on B12,
including the presence of hydrogen bond formation between
various residues in TCII and B12’s phosphate moiety and

the side chains of the corrin ring. The further stability found
to occur with the replacement of the Co’s axial ligand with a
histidine residue from TCII [10] was also rationalized. However, this latter substitution is not necessary for the binding
of TCII and will not occur if a stable Co--C bond has been
formed, such as the Co--CN in cyanocobalamin. The crystal
structure [10] and molecular dynamics studies [14] have also
shown that TCII does not completely encompass B12 on
binding, and leaves an exposed section of the vitamin accessible to solvent. The 1.4 nm solvent-accessible pocket of B12
bound to TCII shows that the phosphate and ribose hydroxyl
groups are left protruding into the solvent, but only the ribose
5¢-hydroxyl tail is open to the environment enough such that
it can easily accommodate the conjugation of large molecules
(see Figure 3). Depending on the size of the conjugate, the
three other sites have been shown to accommodate molecules
without interference with TCII binding. It has been established that recognition and uptake of the vitamin still occur
on modification of the b-axial position of the B12’s
cobalt, the a-axial ribose tail and several exterior carboxylic
acid groups (produced by hydrolysis of side-chain
propionamides) [10,19,22].
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Figure 2. Structure of vitamin B12. Molecular structure of XCbls: the central cobalt(III) atom is six-coordinated, with the
equatorial positions filled by the nitrogen atoms of the corrin macrocycle. The (conventionally) ‘lower’, ‘a’-axial site is
occupied by an imidazole nitrogen atom from a 5¢,6¢-dimethylbenzimidazole base whereas the ‘upper’, ‘b’-axial site can be
occupied by various X groups (e.g., CN-, CH3-, Ado-, NO2-, SCN-, SeCN-, SO3- and thiourea). The corrin ring incorporates seven
amide side chains, three acetamides (a, c, g) and four propionamides (b, d, e, f). The four pyrrole rings are usually indicated
as A, B, C and D, as shown. Areas lightly shaded in pink have been commonly used for conjugates that maintain HC, IF and TCII
binding. The area shaded in yellow, namely the b-propionamide, has been used, on conversion to the carboxylic acid, for HCspecific targeting. This HC-specific targeting is important where background TCII-R uptake prevents selectivity of cancerous
tissue over healthy tissue.
Haptocorrin; IF: Intrinsic factor; TCII: Transcobalamin II; TCII-R: Transcobalamin II receptor.

The crystal structure of IF was published in 2007 [9].
This ~ 60 kDa protein is highly glycosylated and proved difficult to crystallize. The IF-B12 complex has several similarities to the previously discussed TCII-B12 complex, including
several of the same hydrogen bond formations between the
protein and the vitamin. The IF-B12 complex does not incorporate a histidine residue in the b-axial position, however,
and ~ 13% of the B12 is solvent-accessible compared with
only 6.5% of the B12 in the TCII-B12 complex [18]. The
crystal structure revealed a possible mechanism, involving
pH, for the transfer of B12 from IF to TCII, allowing
researchers a better understanding of the last few steps of the
B12 pathway [9].
While attention has concentrated on maintaining the binding between the transport proteins and B12 bioconjugates, little is known about what impact, if any, modifications to the
B12-transport protein complex might have on subsequent
receptor binding. Until recently the structure of a holoprotein
complex bound to a B12 receptor was unknown. In 2010,
Andersen et al. published the structure of cubilin(5--8)-IF-B12
(see Figure 4) [8]. This publication provided an outline of
how the holo-complex interacts with the receptor, allowing
4

researchers a new tool to determine the implications of
conjugation on receptor binding.
Targeting specific transport proteins
On delivery to the bloodstream, a B12 conjugate typically will
be acquired by the TCII protein. In cancer therapy/imaging,
the hypothesis in B12-based targeted delivery has historically
been that increased TCII-R expression (as much as 3- to
26-fold in certain patients [6]) in a variety of cancers such as
testis, breast, ovarian, thyroid, uterine, and brain cancer
would provide sufficient selectivity over healthy tissue. This
characteristic of B12 led to the production of both small molecule organic and inorganic B12 bioconjugates with various
applications in medicinal chemistry. Although the bioconjugates are discussed in more detail in the next section, it should
be noted here that the major problem associated with these
bioconjugates has been background uptake by healthy tissue.
In an attempt to overcome background uptake, HC has
been targeted more recently. Cytoplasmic or membraneassociated HC has been suggested to be de novo expressed [5]
or overexpressed [23] in certain cancer lines. To target HC
over TCII, Waibel et al. disrupted the interactions between
2.2
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Solvent-accessible 5′ ribose-OH and phosphate positions

Cobalt (III) inaccessibility in the TCII-B12 crystal structure

Figure 3. The solvent-accessible pocket of TCII bound to vitamin B12. The left pair of images show the 5¢ ribose and phosphate
positions (cyan) accessible through a 1.4 nm gap in the solvent-accessible surface of TCII (red = a-domain, blue = b-domain,
green = a/b linkage). The images on the right show the inaccessibility of the cobalt(III) coordination position in the crystal
structure (a position at which functionalization has been shown to occur without a deleterious change to binding affinity in a
few instances, indicating a TCII structural change at this position must occur to accommodate the steric bulk of a ligand. See
text and [10]).

B12 and TCII by utilizing the b-propionamide site after modification to the b-monocarboxylic acid (the yellow shading
seen in Figure 2) [5]. This method negates the possibility of
oral uptake but demonstrated greater tumor targeting by
reducing prevalent TCII-based uptake of the conjugates into
healthy cells. This is a considerable breakthrough for B12based cancer therapeutics because it demonstrates that one
of the oft-stated problems of using B12 systems, namely nonspecific cell uptake, can be addressed, at least towards cancer
cell lines with de novo HC expression. Images obtained with
single-photon-emission computed tomography (SPECT)
agents targeting HC and TCII are shown in Figure 5.
2.3

General uses of B12 in drug delivery
Increased solubility

2.3.1

The solubility behavior of a drug is one of the key physicochemical properties that can determine clinical efficacy and
is often the cause of the failure of a drug to reach the market [24]. For orally administered drugs, the compound needs
to be highly soluble or become immersed in the intestinal
fluid to allow for absorption (assuming enterocyte passage is
also feasible). For intravenously administered agents, sufficiently high solubility in the plasma is vital to diminish undesirable precipitation in the systematic circulation. In its native
form, B12 is a highly soluble vitamin [10.2 mg/ml] that can be
used to increase the solubility of compounds that would
otherwise have little ability to be used as a drug.
Oral delivery
Few peptide/protein-based drugs have the ability to survive
the gastrointestinal tract and/or cross the intestinal wall to
make it to the bloodstream. Therefore, delivery of a pharmaceutically viable amount of peptide/protein is unachievable
through simple oral dosing. At present, administration of
2.3.2

these compounds is done through subcutaneous injections.
This approach is time-consuming, painful, inconvenient,
and can lead to allergic reactions near the sight of injection,
as well as lower patient compliance. The improved ease of
administration associated with the oral-enteric pathway provides an attractive means for the delivery of many pharmaceutical drugs because higher patient compliance is likely [25,26].
As a highly soluble, non-toxic vitamin with an extremely
effective uptake pathway, B12 makes for an attractive vehicle
for the oral delivery of drugs [26]. Although great strides have
been taken in the field, the use of the uptake pathway is not
without disadvantages, including a limited oral uptake
capacity (1 -- 2 µg of B12 per day [27]) and the inability to
protect peptides/proteins from proteolytic degradation [28].
However, recent results, both experimental and theoretical,
offer new strategies to overcome these issues, and these are
discussed below.
Delivery of small molecules
For years, B12 has been utilized for the delivery of imaging
agents and therapeutic drugs for the treatment and diagnosis
of rapidly proliferating cells owing to the increased need for
B12 in such cells (see Table 1). Early investigators demonstrated that cobalt radionuclides (57Co, 58Co, 60Co) could
be used to label B12 for imaging [29-31]. The half-life of the
radionuclides, however, required the dosage for humans to
be too small for successful external images and the radioactive
compounds were shown to accumulate in the liver, pancreas
and kidneys, leading to organ damage [32]. In an attempt to
overcome these issues, some extra radionuclides, including
111
In (2.8 days; 0.245 MeV-g) [32], 131I (8 h; 364 keV-g,
606 keV-b) [33] and 99mTc (6.02 h; 140 keV-g) [34], have
been conjugated to B12 for labeling purposes since these
early days. Unfortunately, these experiments still resulted in
2.3.3
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Figure 4. Cubilin(5--8)-IF-B12 structure. This structure, published in 2010 (see Protein Data Bank accession code 3KQ4),
shows for the first time the interaction between holoIF (pink and green) and CUB5--8 domains (blue with calcium
as red spheres). The structure provides a road map to study
B12 conjugates bound to IF to explore the implications of B12
modification on IF binding and subsequent receptor interactions. The structure also offers up potential mutagenesis
sites on IF for use of IF as a delivery agent itself. Neither of
these two latter points has been studied extensively so far.
Image modified with permission from [8].
IF: Intrinsic factor.

undesired organ accumulation, limiting the amount of
drug delivered to cancerous cells and demonstrating high
background uptake in healthy cells [31-34].
In 2009, Siega et al. determined it was possible to deliver
Gd3+ to cancer cells by conjugation to B12. By using the metal
chelating agent DTPA, a B12--Gd3+ conjugate was constructed. The Gd3+ moiety conjugated to the 5¢ ribose of the
B12 did not affect the binding of the B12 transport proteins.
Viability tests on human myelogenous leukemia K562 cells
incubated with the conjugate showed a significant decrease
in cell viability compared with those incubated with the B12
parent compound and/or the Gd3+ ion alone [35]. Given that
this system utilized conjugation at the 5¢-ribose position,
allowing TCII recognition, it can be postulated that this
system, if tested in vivo, will give poor tumor specificity.
Nitric oxide (NO) has been demonstrated as a potential
candidate for antitumor therapy owing to its ability to cause
both necrosis and apoptosis [36]. In 2002, Bauer et al. set
out to demonstrate that conjugation of NO to B12 would
result in a greater anticellular effect against malignant cells
compared with normal cells. Nitrosylcobalamin (NO--B12)
is a B12 derivative with NO as the b-axial ligand. Once the
conjugate was in the cell NO was detached from B12, causing
inhibition of cellular metabolism and directly damaging
6

DNA, leading to apoptosis. The antiproliferative efficacy of
the conjugate was determined in 22 human tumor cell lines
and two non-cancer cell lines. It was determined that tumor
cell lines were more sensitive to the conjugate than the normal
cell lines. The conjugate was determined to inhibit tumor
growth in vitro and in vivo by activation of the extrinsic
apoptotic pathway [36].
Colchicine is a highly toxic compound that has been used
as a therapeutic agent for a wide variety of diseases since the
sixteenth century [37]. In recent years, it has been investigated
as a potential anticancer drug. It has a similar mode of action
as taxanes but is far more water-soluble, making it more
accessible to biological applications. Unfortunately, colchicine does not have the ability to distinguish healthy from
cancerous cells and colchicine chemotherapy results in overwhelming systematic toxicity [37]. In 2004, Grissom and
co-workers used B12 to deliver colchicine to cancerous cells.
To make the B12 conjugate, the colchicine analogue 2
(2-(4-acetylphenoxy)-N-acetophenocolchicine) was synthesized. To make the B12 conjugate, the colchicine analogue
2(2-(4-acetylphenoxy)-N-acetophenocolchicine) was synthesized. Compared with the unmodified colchicine, the analogue retained activity with only a minimal loss of toxicity.
Using an acid labile hydrazone linker, the analogue was
then attached to the b-axial ligand of B12. The linker allowed
for a pH-dependent release of colchicine in acidic conditions. Once taken into the cell by means of the B12 receptors,
colchicine was released to interact with microtubules but
showed a 10-fold decrease in toxicity [38]. As noted before,
this system in vivo would again be predicted to suffer from
TCII-based non-selective uptake/accumulation.
A progression of papers has recently appeared in the use of
B12 to deliver Pt drugs, focusing on cisplatin and analogues
thereof. In this instance it was shown that B12 can act as a
ligand for cisplatin by the formation of a cyanidebridged species between the b-axial ligand of B12 and Pt [39].
Alberto and co-workers showed that the B12--cisplatin conjugate retains a labile chloride ligand that can be exchanged
with ligands such as guanine, allowing the conjugate to
behave in a similar way to cisplatin [40]. In 2008, Alberto
and co-workers continued their initial work with the cisplatin
derivatives and synthesized several prodrugs around the
{B12-CN-Pt-R} moiety (see Figure 6) [22].
Using an in vitro adenosylation assay from Salmonella
enteric, the group was able to show that Co III was reduced
to Co II and the Pt II complex was released [22]. As the Pt II
complexes were shown to be released, B12-mediated delivery
of Pt complexes showed promise. In 2010, the in vitro
cytotoxicity of the {B12-CN-Pt-R} conjugates was published [41]. The preliminary results suggested a lower
activity (IC50 between 8 and 88 µM) than for cisplatin
alone. It is hypothesized that the limited B12 uptake capacity, discussed earlier, is most probably to blame. Studies
on the effects of the uptake capacity on concentration are
underway [41].
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Figure 5. SPECT/CT scans of mice 24 h after intravenous injection of B12-99mTc conjugates designed to be non-binders to TCII
(HC binder) and binders to TCII. A, C. HC targeting compound. B, D. TCII binding compound. Note increased tumor specificity
obtained with HC targeting. Color scale relates activity.
Reproduced with permission from [5].
HC: Haptocorrin; IF: TCII: Transcobalamin II.

2.3.4

Delivery of peptides/proteins

Table 2 lists the peptide/protein B12 conjugates reported so

far. A comprehensive review of this area has been reported
recently and the reader is referred there [42]. Instead, herein
is discussed the use of molecular dynamics in the development
and understanding of B12-based drug delivery systems using a
B12-insulin conjugate system (see Table 2) as an example of
the power of this approach.
3.

Molecular modeling considerations

Molecular modeling serves invaluably in both predictive and
interpretive capacities in modern drug design. The field is limited in application only by either the availability of proper theoretical descriptions of biologically relevant molecules (largely
in the form of molecular force field parameters and topologies,
limitations addressable by parameter generation and validation)
or the absence of experimental data on which to base proper
analyses. For molecular dynamics studies, the limitation is
largely in the form of absent crystallographic or solutionphase structural information against which to identify structural candidates and test new designs. As applied to the study
of bioconjugates, the atom-level description of molecular
phenomena afforded synthetic chemists by even modest

computational efforts reveals a great deal about the binding
environment of a molecule. The potential difficulties of designs
based on the placements of steric bulk (that prohibit binding of
the native molecule) or physical inaccessibility of targeted functionalization (that changes the binding of the native molecule)
can be visualized. Insights into possible molecular designs not
readily obvious from either crystallography or macroscale
sample characterization without synthetic efforts that survey
possible candidate positions can also be highlighted.
As a complement to many of the experimental studies of functionalization positions [43,44], molecular modeling studies reveal
the extent to which the modification potential of the B12 framework itself is greatly limited for new bioconjugate designs by the
nature of its binding within its transport proteins. Using the
binding of B12 to TCII (the complex for which the best structural information is available [1,3,10]) as a basis for all subsequent
bioconjugate design work (as a disruption at any step in the
transport pathway for B12 is probably deleterious for any bioconjugate design), several design considerations were revealed.
These molecular modeling studies provide both a reinforcement
of previous experimental work and insights into approaches for
potential new B12-based delivery designs based on functionalization positions deemed accessible, themselves based on the
geometry of the B12--TCII binding interaction.
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300.0
585.3
598.2
126.9
263.7
281.8
281.8
300.4
236.0

118.0
82.0
475.2
479.0
157.3
536.08

Cisplatin
Cisplatin-2’deoxyguanosine
Cisplatin-methylguanosine
131
I
trans-PtCI(NH3)2
trans-PtCI2(NH3)
Cis-Ptcl2(NH3)
PtCl3
[99mTc(CO)3(OH2)3]*

V02(OH/H)
VO2
Fluorescence
Khodamine 6G
Gd3+

Rhodamine isothiocyanate

NA

Cobalt atom
Cobalt atom
Ribose-5’-OH
RibosE-5’OH
Ribose-5’-OH

Cobalt atom
Cobalt atom
Cobalt atom
Pt(ll) center
Cobalt atom
Cobalt atom
Cobalt atom
Cobalt atom
b-acid

Cyano ligand

b-acid
b-acid
b-acid
d-acid
b- and d-acid
Cobalt atom
Ribose-5¢-OH
Cobalt atom
Cyano ligand

Conjugation site

trans-1,4-diaminocyclohexane (CDT)
trans-1,4-diaminocyclohexane (CDT)
Anbydrideof DTPA(NA)
AnbydrideofTTHA(NA)
HPMA(NHS/T5TU)

1,4-diaminobutane (EDAC)
1,4-diaminobutane (EDAC)
Diaminobutane (HOBt/ EDAC)
Diaminobutane (HOBtf EDAC)
Diaminobutane (HOBt/ EDAC)
Direct
1,6-diaminohexane (CDI)
4-chlorobutyricacid chloride (EDAC/NH5)
Imidazolecarboxylic acid (NA)
picolinic acid (NA)
2,4-dipicolinic acid (NA)
serine (NA)
N,N-dimethylglycine (NA)
Imidazolecarboxylic acid (NA)
2,4-dipicolinic acid (NA)
serine (NA)
N,N-dimethylglycine (NA)
Cyano ligand (NA)
Cyano ligand (NA)
Cyano ligand (NA)
Cisplatin (NA)
Cyano ligand (NA)
Cyano ligand (NA)
Cyano ligand (NA)
Cyano ligand (NA)
Propyl-PAMA-OEt (EDACorTBTU)
Ethyl-PAMA-OEt (EDAC or TBTU)
Butyl-PAMA-OEt (EDAC or TBTU)
Pentyl-PAMA-OEt (EDAC or TBTU)
Hexyl-PAMA-OEt (EDAC or TBTU)
3-hydroxy-2-methyl-l-propyl-lH-pyridin-4-one(NA)
3-hydroxy-2-methyl-l-propyl-lH-pyridin-4-one(NA)

Linker (coupling agent)

Diabetes treatment
Diabetes treatment
Imaging
Imaging
Imaging
Imaging
Imaging

Imaging of TCII receptors
Imaging of TCII receptors
Antitumor therapy
Antitumor therapy
Antitumor therapy
Antitumor therapy
Imaging
Delivery
Radiodiagnosis
Radiodiagnosis
Radiodiagnosis
Radiodiagnosis
Radiodiagnosis
Linker for biomolecules
Linker for biomolecules
Linker for biomolecules
Linker for biomolecules
Oral anticancer
Proof of principle
Proof of principle
Imaging
Delivery
Delivery
Delivery
Delivery
Imaging
Imaging
Imaging
Imaging
Imaging

Use

[5]

2008

[51]

[35]

2009
2010

[50]

2009

[49]

[33]
[22]

2007
2008

2008

[39]

2005

[48]

[36]
[47]
[38]
[48]

2002
2003
2004
2004

2004

[31]
[31]
[46]

Ref.

1997
1997
2000

Year

NHS: N-hydroxysuccinimide; EDAC: l-etbyl-3-(3-dimethylaminopropyl)carbodiimide; CDI: l,l’-carbonyldiimidazole; NA: Not available; CDT: l,l’-carbonyl-di-(l,2,4-triazole); DTPA: diethylenetriamine-N,N;N‘,N‘’, N“‘pentaacetic acid; DCC: N,N‘-dicyclohexylcarbodiimide; TTHA: Triethylenetetramine-N,N,N‘,N“,N“‘,N‘"‘-hexacetic acid; TBTU: Q-(Benzotriazol-l-yl)-N,N,N‘,N‘-tetramethyluronium tetrafluoroborate; TSTU: (N,N,N‘,N‘Tetramethyl-0-(N-succinimidyl))uronium tetrafluoroborate; HPMA: Lysine-modified-hydroxypropyl-methacrylamide.

288

452.0
467.7
144.2
144.2
288.5
30.0
792.0
399.4
162.0

Small molecules
99m
Tc-DTPA
111
ln-DTPA
b-nido-carborane
d-nida-carborane
bis-nido-carbarane
NO
Cy5 dye
Colchicine
[99mTco4]-

[Re(OH2)(CO)3]

Size

Molecule

Table 1. B12-small molecule conjugates.
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Figure 6. X-ray crystal structures of Pt conjugates of B12. Images were generated from deposited CIF files CCDC-261001 and
CCDC-261002. Both structures display the Co-C-N-Pt ‘core’. Both compounds display micromolar activity but both were less
effective than cisplatin directly, the result, it is hypothesized, of limited B12 uptake [41].

Any design of B12 bioconjugates must ultimately consider
all of the steps in the B12 transport pathway. In these considerations, it is known that B12 binding to its transport proteins
(HC, IF and TCII) must be conserved. The availability of
partial or complete molecular geometries for TCII [10] and
IF [9] reveals that these two proteins are largely similar in
geometry and binding mode, and indicates that HC is likely
to bind B12 in a similar manner. As the initial computational
study of B12-insulin [44] bioconjugate began with preliminary
experimental results that indicated successful transport (as
determined by cellular glucose uptake), the molecular modeling study focused on TCII. As part of any subsequent design
based on B12 delivery, the characterization of the binding
mode of B12 and the flexibility of the a/b domain ‘clamshell’
mechanism of binding by TCII (see Figure 7) produce an elegant picture of one set of readily accessible ‘bestpractice’ approaches for bioconjugate design. This is a very
straightforward model of how adhering to this set of
approaches is likely to produce viable candidates for a wide
variety of delivery targets.
In the previously reported molecular dynamics studies of
TCII with B12 [15], B12-insulin [44] and a B12 bioconjugate
modified with a short peptide tether [14], the simulations
revealed the extent to which the B12 is itself the hydrogenbonding glue that binds the TCII into the encapsulation
structure observed in diffraction studies (Figure 7). This
work indicated that the interaction between side chains at
the surface--surface interface between the a- and b-domains
is not a major contributor to the stability of the complex. It
also indicated that TCII in the absence of B12 probably consists of two, poorly interacting fragments linked by a short
tether (obviously the design best suited to binding and protecting a large biomolecule that cannot easily migrate into
the binding pocket of a less flexible or more inherently

structured protein). As a tool for directing design, the result
of the molecular dynamics simulation showed that modifications to the B12 are best performed for the generation of
new bioconjugates at positions on the B12 molecule at the
a/b domain interface. Appropriate modifications at this interfacial region are not expected to interfere with the individual
B12-a domain and B12-b domain interactions that produce
the encapsulated complex and, further, are made viable
because the ‘clamshell’ design of this complex results in a
a/b breathing motion in the MD simulations that makes
this interfacial region accessible under ambient conditions
and amenable to accommodating small tethering fragments
to couple B12 to some arbitrary molecular beyond the
solvent-accessible surface of TCII (see Figure 8).
The MD simulations provided atom-level explanations for
all of the bioconjugate design work on B12 performed so far.
This study specifically shows why certain chemical modifications produce viable candidates and some modifications
produce B12 bioconjugates that, by their disruption of the
B12-transport protein binding interaction, do not. Modification at the cobalt (Co) is shown to be a reasonable approach
for bioconjugate design because the Co coordination site lies
at the a/b interface and small changes to side chains on the
a-domain reduce steric congestion for coordinated ligands.
This is obvious for small molecules, given the known binding
of B12-CN and B12-CH3. Whereas the cobalt is more embedded than the ribose 5¢-hydroxyl position used as the point of
conjugation in the B12-insulin bioconjugate, the use of a
small, flexible tether that is linked to one molecule and is
Co-coordinated should serve as a reasonable mechanism
for new Co-tether designs, a result supported by previous
experimental work [44].
The MD simulation work also predicts that, owing to the
mechanism of encapsulation and the solvent accessibility of
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Size

Conjugation site

e-acid
e-acid
ribose-5’-OH
ribose-5’-OH

1.2
0.9
5.7
5.7

LHRH
DP3
Insulin
Encapsulated insulin delivery
B12 coated-dextran nanoparticles
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amide (CDI)

EGS (EDAC)
Amide (EDAC)
Disulfide (SPDP)
Hindered thiol (SMPT)
Thioester (NHS ester of iodoacetic acid)
Transglutamase cleavable tetrapeptide (EDAC)
EGS (EDAC)
Amide (EDAC)
Disulfide (2-iminothiolane)
Hindered thiol (SMPT)
Thioester (NHS ester of iodoacetic acid)
Transglutamase cleavable tetrapeptide (EDAC)
Amide (DCC/NHS)
Amide (EDAC) hexyl (EDAC)
amide (CDI, CDT)

Phosphaye-amine (EDAC)
Phosphaye-amine (EDAC)
GABA (EDAC)
glutaroyl (CDI)
disulfide (SPDP)
Amide (EDAC)
Hydrazide (EDAC)
Amide (EDAC) hydrazide (EDAC)

Linker (coupling agent)§

2007

70 -- 75% drop in plasma glucose

1995

1995

1995

2000
2000
2007

1971
1971
1979
1994
1995

Year

NA
NA
antibody response
24 -- 28% activity*
61 -- 66% activityz
29 -- 85% activityz
ND-100% activityz
ND-34% activityz
17 -- 22% activityz
ND
30% IF recognition
65% IF recognition
54% IF recognition
81% IF recognition
60% IF recognition
ND
ND
ND
37% IF recognition
65% IF recognition
48% IF recognition
45% absorbed
23% absorbed 42% absorbed
26% drop in glucose

Use

[58]

[57]
[57]
[20]

[56]

[56]

[55]

[52]
[52]
[53]
[54]
[55]

Ref.

*compared with native IFN-con.
z
compared with unconjugated G-CSF and EPO.
§
linker chosen on basis of greatest yield and/or activity. ND = not determined.
BS, HS: Bovine and human serum; IFN-con: Consensus interferon; G-CSF: Granulocyte colony stimulating factor; EPO: Erythropoietin; ANTIDE: N-Ac-D-Nal(2)D, D-Phe (pCl), D-Pal(3),ser, Lys (Nic), D-Lys(Nic), Leu, Lys(IPr),
Pro, D-Ala-NH2; LHRH: Luteinizing hormone-releasing hormone; DP3: Octapeptide (Glu-Ala-Ser-Ala-Ser-Tyr-Ser-Ala); GABA: y ami no butyric acid; EDAC: l-ethyl-3-(3-dimethylaminopropyl)carbodiimide;
CDI: 1,1’carbonyldiimidazole; SPDP: N-succmimidyl 3-(2-pyridyldithiio)-propionateJ; SMPT: 4-[(Succinimidyloxy)-carbonyl]-a-methyl-a-(2-pyridyldithio)toluene; NHS: N-hydroxysuccinimide;
DCC: N,N¢-dicyclohexylcarbodiimide, CDT: l,l’-carbonyl-di-(l,2,4-triazole)T; EGS: Ethylene glycol bis(succmimidylsuccinate; EDAC: l-ethyl-3-(3-dimethylaminopropyl)carbodiirnide.

e-acid

1.6

ANTIDE-3

e-acid

e-acid

1.6

34.0

ANTIDE-1

EPO

Directly conjugated and encapsulate insulin delivery
BS Albumin
66.0
Phosphate
YG-globulin
150.0
Phosphate
HS albumin
66.0
e-acid
IFN-con
22.0
ribose-5’-OH
G-CSF
19.6
e-acid

Molecule

Table 2. B12-protein/peptide bioconjugates.
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Figure 7. The binding of B12 within TCII. Substructures (domains) are differentiated by color. The a- and b-domains at the B12
binding position interact only through hydrogen bonding (and by way of a 10-residue covalent linkage), while numerous
interactions between both domains and the B12 have been characterized experimentally and through previous molecular
dynamics simulations. TCII structure based on [10].
TCII: Transcobalamin II.

30°

Cobalt accessible

30°

B12 encapsulation

Ribose 5′-hydroxy accessible

Figure 8. The time-averaged structure of B12-TCII from a 50 ns MD simulation. The accessibility of the B12 for chemical
functionalization but potentially limited B12 binding inhibition is shown by way of solvent-accessible surface representations
at both the cobalt (left) and ribose (right) positions.

several regions of B12, the cobalt and ribose 5¢-hydroxyl positions need not be mutually exclusive as targets for bioconjugate design. Instead, with the accessibility of both positions
attributed to the breathing motion of the a/b groups constrained largely by their strong binding to the B12 molecule,
the possibility exists for three-component bioconjugates.
This result was hinted at, but was not obvious from, the static
model of the B12--TCII binding interaction in the crystallographic study. The success of such designs is dependent on
the modes of delivery and the differences in where and
when the degradation of the combined product occurs. This

route does offer a promising path for new work in B12 delivery
approaches that are strongly supported from the synergy of
experimental precedent and supportive computational work.
With the availability of force field parameters and the
reported success of B12 MD simulations in several instances,
one of the few issues in B12 bioconjugate design hampering
continued and more thorough progress is the lack of
structures for proteins within the B12 transport pathway.
Although the success of the B12-insulin bioconjugate
indicates that, even in the presence of a large tethered
molecule, the solvent-accessible binding positions on the
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B12 are conserved in the members of the transport protein
family, greater subtlety in the modes of chemical modification and targeted B12 design will come most easily through
MD simulations that follow a B12 bioconjugate design
through each step in the pathway, for which a modeling
protocol is only as complete as the experimental characterization of all components. Within even the narrow selection
of B12 modification positions hinted at by the solventaccessible crystal structure maps and MD simulations of
the native TCII-B12 complex, a wealth of bioconjugate
design can be envisioned. Completeness in all-computational approaches to B12 bioconjugate design simply awaits
adequate models of HC and IF, the members of the transport pathway either partially characterized (IF) or still
unavailable (HC).
4.

Expert opinion

B12 and the B12 uptake pathway play a fundamental role in
biology and have been explored extensively from a structural
and mechanistic viewpoint. The unique structure of B12 and
the exquisite relationship with its binding proteins have
driven researchers for several decades and continue to this
day to offer up exciting new questions and new avenues of
research. One of these avenues is the use of B12 in drug
delivery, from small molecule in vivo imaging agents to the
oral delivery of large proteins. Inherent restrictions of the
B12 pathway, namely dose limitations and the demand
across cells, healthy or otherwise, for the vitamin, have so

12

far prevented the realization of a B12 bioconjugate pharmaceutical reaching the market. Despite this, several groups are
working to address the challenges of the field, with recent successes including HC-specific targeting overcoming TCII
background and the use of polymeric carriers attached to
B12 to increase drug payload.
The future of the field then lies in expanding on these successes. The authors envisage building B12 bioconjugates with
multiple payloads, using multiple sites on the B12 molecule
simultaneously. The use of B12 to deliver protein vaccine
components also has great potential. By targeting the immune
response, potentially low doses need be delivered that require
concentrations within the boundaries of the B12 uptake pathway capacity. The use of the B12 uptake proteins themselves
has also not been explored. Coating a viral particle that
requires an enteric IgA response with HC, for example, may
offer gastrointestinal protection and ultimately provide for
an oral vaccine for such a virus. The very investigation of
the role of HC in blood serum and its structure will also be
a highlight of the coming years in the B12 field. The take
home message of this review is that this is an exciting time
for B12-based drug development, with many of the barriers
thought to be road blocks to successful clinical trials
being overcome.
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resolution. Proc Natl Acad Sci USA
2007;104:17311-16
The crystal structure of intrinsic factor
was published, providing researchers

..

10.

Alpers D, Russell-Jones G. Intrinsic
factor, haptocorrin and their receptors.
In: Banerjee R, editor, Chemistry and
biochemistry of B12. New York: John
Wiley & Sons; 1999. p. 411-40
An important chapter in the seminal
text on B12.

Waibel R, Treichler H, Schaefer N, et al.
New derivatives of vitamin B12 show
preferential targeting of tumors.
Cancer Res 2008;68:2904-11
An important paper describing a new
strategy for targeting tumor cells with
minimum uptake in normal cells by
blocking the interactions between
B12 and TCII.

cobalamin (vitamin B12) pathway in the
rat intestine. Pharm Res 2000;17:825-32

with another key to the uptake
pathway of B12.

14.

.

Brown K, Zou X, Marques H.
NMR-restrained molecular modeling of
cobalt corrinoids: cyanocobalamin
(vitamin B12) and methylcobalt
corrinoids. Theochem 1998;453:209-24
An important early theoretical work
on corrinoids.

15.

Allis D, Fairchild T, Doyle R. The
binding of vitamin B12 to
transcobalamin (II); structural
considerations for bioconjugate design -a molecular dynamics study. Mol BioSyst
2010;6:1611-18

16.

Kandt C, Xu Z, Tieleman D. Opening
and closing motions in the periplasmic
vitamin B12 binding protein BtuF.
Biochemistry 2006;45:13284-92

17.

Gumbart J, Wiener M, Tajkhorshid E.
Coupling of calcium and substrate
binding through loop alignment in the
outer-membrane transporter BtuB.
J Mol Biol 2009;393:1129-42

18.

Wuerges J, Fedosov S, Randaccio L,
et al. Vitamin B12 transport proteins:
Crystallographic analysis of beta-axial
ligand substitutions in cobalamin bound
to transcobalamin. Life 2007;59:722-29

19.

Alsenz J, Russell-Jones G-J, Westwood S.
Oral absorption of peptides through the

Expert Opin. Drug Deliv. [Early Online]

20.

..

Petrus A, Fairchild T, Doyle R. Vitamin
B12 as a carrier for the oral delivery of
insulin. ChemMedChem 2007;2:1-5
Oral delivery of insulin using B12.

21.

Wang X, Wei L, Kotra L.
Cyanocobalamin (vitamin B12)
conjugates with enhanced solubility.
Bioorg Med Chem 2007;15:1780-87

22.

Ruiz-Sanchez P, Mundwiler S,
Alberto R. Syntheses and characterization
of vitamin B12--Pt(II) conjugates and
their adenosylation in an enzymatic assay.
J Biol Inorg Chem 2008;13:335-47

23.

Carmel R. Extreme elevation of serum
transcobalamin I in patients with
metastatic cancer. N Engl J Med
1975;292:282-4
A key finding in haptocorrin research
and the driving force behind much
current research.

..

24.

Leuner C, Dressman J. Improving drug
solubility for oral delivery using solid
dispersions. Eur J Pharm Biopharm
2000;50:47-60

25.

Fasano A. Novel approaches for oral
delivery of macromolecules. J Pharm Sci
1998;87:1351-6

26.

Gaucher G, Satturwar P, Jones M-C,
et al. Polymeric micelles for oral drug
delivery. Eur J Pharm Biopharm
2010;76:147-58

27.

Fedosov S, Grissom C, Fedosova N,
et al. Application of a fluorescent
cobalamin analogue for analysis of the
binding kinetics. FEBS J
2006;273:4742-53

28.

Cooperman J. Distribution of radioactive
and nonradioactive vitamin Bl2 in
normal and malignant tissues of an
infant with neuroblastoma. Cancer Res
1972;32:167-72

29.

Bose S, Seetharam S, Seetharam B, et al.
In vitro and in vivo inactivation of
transcobalamin II receptor by its
antiserum. J Biol Chem
1996;271:4195-200

30.

Wooley K, Collins D, Morton K.
Uptake of Co-57-vitaminB-12 by murine
tumors of many histologic types.
Clin Res 1993;41:73

31.

Collins D, Hogenkamp H.
Transcobalamin II receptor
imaging via radiolabeled

13

Vitamin B12 in drug delivery

diethylene-triaminepentaacetate
cobalamin analogs. J Nucl Med
1997;38:717-23
32.

33.

Expert Opin. Drug Deliv. Downloaded from informahealthcare.com by Syracuse University on 12/04/10
For personal use only.

34.

35.

36.

37.

38.

39.

40.

41.

14

Collins D, Hogenkamp H, Gebhard M.
Tumor imaging via indium 111-labeled
DTPA-adenosylcobalamin.
Mayo Clin Proc 1999;74:687-91
Ruiz-Sanchez P, Mundwiler S,
Alberto R, et al. Iodination of cisplatin
adduct of vitamin B12 [{B12}-CN-{cisPtCl(NH3)2}]+. J Organomet Chem
2007;692:1358-62
Mundwiler S, Waibel R, Alberto R,
et al. Picolylamine-methylphosphonic
acid esters as tridentate ligands for the
labeling of alcohols with the fac-[M(CO)
3]+ core (M = 99 mTc, Re): synthesis
and biodistribution of model compounds
and of a 99 mTc-labeled cobinamide.
Nucl Med Biol 2005;32:473-84
Siega P, Wuerges J, Randaccio L, et al.
Release of toxic Gd3+ Ions to tumour
cells by vitamin B12 bioconjugates.
Chem Eur J 2009;15:7980-89
Bauer J, Morrison B, Grane R,
et al. Effects of interferon on
transcobalamin II-receptor expression
and antitumor activity of
nitrosylcobalamin. J Natl Cancer I
2002;94:1010-19
Levy M, Spino M, Read S. Colchicine:
a state-of-the-art review.
Pharmacotherapy 1991;11:196-211
Bagnato J, Eilers A, Grissom C, et al.
Synthesis and characterization of a
cobalamin-colchicine conjugate as
a novel tumor-targeted cytotoxin.
J Org Chem 2004;69:8988-96
Mundwiler S, Kunze S, Alberto R,
et al. Cyanide-bridged vitamin
B12--cisplatin conjugates. Chem Eur J
2005;11:4089-95
Ruiz-Sanchez P, Mundwiler S,
Alberto R. Syntheses of fluorescent
vitamin B12-Pt(II) conjugates and their
Pt(II) release in a spectroelectrochemical
assay. Chimia 2007;61:190-3
Ruiz-Sanchez P, Ferrari S, Alberto R,
et al. Vitamin B12 as a carrier for
targeted platinum delivery: in vitro
cytotoxicity and mechanistic studies.

..

42.

..

43.

J Biol Inorg Chem 2010 DOI 10.1007/
s00775-010-0697-z
Demonstrates the ability of B12 to act
as a prodrug and deliver cytotoxins to
the cell.

52.

Petrus A, Fairchild T, Doyle R.
Traveling the vitamin B12 pathway: oral
delivery of protein and peptide drugs.
Angew Chem Int Ed 2008;47:1022-28
A recent review of the use of B12 for
the oral delivery of various peptides
and proteins.

Olesen H, Hippe E, Haber E, et al.
Nature of vitamin B12 binding: II.
Steric orientation of vitamin B12 on
binding and number of combining sites
of human intrinsic factor and the
transcobalamins. Biochim Biophys Acta
Protein Struct 1971;243:66

53.

Ahrenstedt S, Thorell J. The production
of antibodies to vitamin B-12.
Clin Chim Acta 1979;95:419-23

54.

Habberfield A, Kinstler O, Pitt C.
Conjugates of vitamin B12 and proteins
Patent. WOW09428015; 1994

55.

Russell-Jones G, Westwood S,
Habberfield A. Vitamin B12 mediated
oral delivery systems for
granulocyte-colony stimulating factor and
erythropoietin. Bioconjugate Chem
1995;6:459-65
One of the first papers to push
B12-protein conjugates for
oral delivery.

Pathare P, Wilbur D, Heusser S, et al.
Synthesis of cobalamin-biotin conjugates
that vary in the position of cobalamin
coupling. evaluation of cobalamin
derivative binding to transcobalamin II.
Bioconjugate Chem 1996;7:217-32

44.

Petrus A, Allis D, Doyle R. Exploring
the implications of vitamin B12
conjugation to insulin on insulin receptor
binding. ChemMedChem 2009;4:421-6

45.

Carkeet C, Dueker S, Lango J, et al.
Human vitamin B12 absorption
measurement by accelerator mass
spectrometry using specifically labeled
14C-cobalamin. P Natl Acad Sci USA
2006;103:5694-99

46.

Hogenkamp H, Collins D, Live D,
et al. Synthesis and characterization of
nido-carborane-cobalamin conjugates.
Nuc Med Biol 2000;27:89-92

47.

McGreevy J, Cannon M, Grissom C.
Minimally invasive lymphatic mapping
using fluorescently labeled vitamin B12.
J Surg Res 2003;111:38-44

48.

Kunze S, Zobi F, Alberto R, et al.
Vitamin B12 as a ligand for technetium
and rhenium complexes. Angew Chem
2004;116:5135-39
An important paper on B12-small
molecule conjugates for imaging/
therapy.

..

49.

Mukherjee R, Donnay E, Radomski M,
et al. Vanadium--vitamin
B12 bioconjugates as potential
therapeutics for treating diabetes.
Chem Commun 2008:3783-85

50.

Lee M, Grissom C. Design, synthesis,
and characterization of fluorescent
cobalamin analogues with high quantum
efficiencies. Org Lett 2009;11:2499-502

51.

Russell-Jones G, McEwan J,
McTavish K. Preliminary studies
on the selective accumulation of

Expert Opin. Drug Deliv. [Early Online]

vitamin-targeted polymers within
tumours. J Drug Target
2010; published ahead of print
May 6th, PMID: 20446757

..

56.

Russell-Jones G, Westwood S,
Farnworth P, et al. Synthesis of LHRH
antagonists suitable for oral
administration via the vitamin
B12 uptake system. Bioconjugate Chem
1995;6:34-42

57.

Alsenz J, Russell-Jones G, Westwood S,
et al. Oral absorption of peptides
through the cobalamin pathway in the
rat intestine. Pharmaceutical research
2000;17:825

58.

Chalasani K, Russell-Jones G, Jain A,
et al. Effective oral delivery of insulin in
animal models using vitamin B12-coated
dextran nanoparticles. J Control Release
2007;122:141-50

Affiliation
Susan M Clardy1, Damian G Allis1,
Timothy J Fairchild2 & Robert P Doyle†1
†
Author for correspondence
1
Syracuse University,
Department of Chemistry,
Syracuse, NY 13244-4100, USA
E-mail: rpdoyle@syr.edu
2
Murdoch University,
Chiropractic and Sports Science,
90 South Street,
Perth, WA 6150, Australia

View Online / Journal Homepage

MedChemComm

C

Dynamic Article Links <

Cite this: DOI: 10.1039/c2md20040f
www.rsc.org/medchemcomm

CONCISE ARTICLE

Examining the effects of vitamin B12 conjugation on the biological activity of
insulin: a molecular dynamic and in vivo oral uptake investigation†

Downloaded by Syracuse University on 03 April 2012
Published on 03 April 2012 on http://pubs.rsc.org | doi:10.1039/C2MD20040F

Susan Clardy-James,a Damian G. Allis,a Timothy J. Fairchild*b and Robert P. Doyle*a
Received 10th February 2012, Accepted 20th March 2012
DOI: 10.1039/c2md20040f
The practical use of the vitamin B12 uptake pathway to orally deliver peptides and proteins is much
debated. To understand the full potential of the pathway however, a deeper understanding of the
impact B12 conjugation has on peptides and proteins is needed. We previously reported an orally active
B12 based insulin conjugate attached at LysB29 with hypoglycemic properties in STZ diabetic rats. We
are exploring an alternative attachment for B12 on insulin in an attempt to determine the effect B12 has
on the protein biological activity. We describe herein the synthesis, characterization, and purification of
a new B12–insulin conjugate, which is attached between the B12 ribose hydroxyl group and insulin
PheB1. The hypoglycemic properties resulting from oral administration (gavage) of such a conjugate in
STZ diabetic rats was similar to that noted in a conjugate covalently linked at insulin LysB29,
demonstrating the availability of both positions on insulin for B12 attachment. A possible rationale for
this result is put forward from MD simulations. We also conclude that there is a dose dependent
response that can be observed for B12–insulin conjugates, with doses of conjugate greater than 109 M
necessary to observe even low levels of glucose drop.

Introduction
Oral delivery of therapeutic peptides and proteins at clinically
significant and controllable levels is a major challenge in current
medicinal chemistry.1 The oral delivery route aims to open up
new areas of peptide/protein therapeutics associated with the
removal for a need for injection and the concomitant promise of
greater patient quality of life and regimen adherence.2 The major
problems facing oral delivery of peptides/proteins is hydrolysis/
proteolysis in the gastrointestinal tract (GIT) and an inefficient
uptake mechanism for peptides/proteins from the GIT.3 We are
interested in the use of the vitamin B12 (B12) dietary uptake
pathway to address these hurdles and recently demonstrated
clinically relevant plasma concentration of a peptide hormone
(hPYY3-36) achieved through the B12 system in a rat model.4
B12 is vital for the survival of virtually all living cells. B12 is
synthesized naturally by certain bacteria and all other species
must acquire the vitamin exogenously through diet.5–7 Mammals
have a series of transport proteins in the GIT for the absorption
and cellular uptake of B12.5–7 The first transport protein, haptocorrin (HC), binds to B12 upon release from food, either in the
mouth or in the stomach and transfers it into the duodenum.8
a
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Once in the intestine, proteases cause the partial degradation of
HC, while a rise in pH promotes the interaction of B12 with
a second transport protein, intrinsic factor (IF). This results in
the transfer of 80% of bound B12 to IF.5 The IF–B12 complex
crosses the ileum via the cubam complex.9 IF digestion occurs
during transcellular passage allowing release of B12 to the serum
transport protein transcobalamin II (TCII).10 TCII is responsible
for cellular entry through the TCblR/CD320 receptor and is
postulated to facilitate blood–brain barrier transport.11
Previously, we reported on the development and characterization of an orally active B12–insulin conjugate with hypoglycemic properties in the streptozotocin (STZ)-induced diabetic rat
model.12 Results of this work stimulated further study into the
implications of the B12 conjugation on insulin’s ability to bind to
its receptor (INSR/CD220)13 using immune-electron microscopy
and molecular dynamics simulation.14 What is clear from the
results obtained to date is that (i) B12 can aid in delivering insulin
to rat blood serum at levels significantly greater than the
same administered concentration of ‘free’ insulin,12 and (ii) the
B12–insulin conjugate can still dock to CD220 and thus trigger
glucose uptake.13
The use of the B12 pathway to deliver a clinically relevant bolus
of insulin is not possible however, given both the limited uptake
capacity of the pathway and the relatively slow uptake time
for serum delivery (3 to 4 hours) and plasma maximum
(7 hours).15 The possibility of developing an oral, long acting
basal therapy is more feasible, where a low level of long acting
insulin is required and an initial uptake delay is not critical.
Med. Chem. Commun.
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The earlier results with insulin12 and PYY4 have been highly
encouraging and we have become focused on investigating and
improving in vivo residency of B12–insulin conjugates. Before
such an area can be fully explored however, knowledge of (i) the
effects of B12 conjugation on the two main sites suitable for such
on insulin (vide infra) and (ii) dose–response of B12–insulin
conjugates need to be addressed. These important factors are
discussed in this report.
Insulin has two primary sites available for conjugation (the
Na-amino group of phenylalanine B1 (PheB1) and the N3-amino
group of lysine B29 (LysB29)), which allow biological function to
be maintained.16 It is not completely understood which position
is more suitable for modification.16 Significant differences
between both positions upon B12 conjugation would be of great
importance given the limited B12 uptake capacity and the need
therefore to optimize such a conjugate. It is believed that
conjugation at the LysB29 position results in a reduction in
biological activity due to the close proximity to the insulin
receptor binding site.15–18 Therefore, moving B12 further away
from the binding site could result in an increase in biological
activity.15
We describe herein the synthesis, characterization, and purification of a new B12–insulin conjugate (1), which is attached at
insulin PheB1 (Fig. 1). We hypothesized that 1 may result in an
increase in insulin’s biological activity, while maintaining the B12
uptake capabilities due to the position of B12 attachment in
relation to the insulin receptor binding region. Our previously
investigated B12–insulin conjugate (B12 bound to insulin LysB29,
2)12 was used for comparison purposes (along with free insulin
controls). Both 1 and 2 were coupled at the B12–ribose hydroxyl
group through a carbamate linker. Hypoglycemic properties of 1
and 2 were evaluated in vivo in STZ induced diabetic rats.
Molecular dynamics simulation studies were used to help
rationalize the results. We also report dose dependence in STZ
diabetic rats for a B12–insulin conjugate.

Fig. 1 Molecular dynamic stimulation snapshot of TCII (red ¼ A-chain,
dark blue ¼ B-chain, green ¼ unstructured linkage) bound to 1 [B12
(yellow with light blue Co(III)) conjugated to the first amino acid (PheB1)
on the insulin B-chain (also yellow)].
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Results and discussion
Chemistry
The synthetic procedures for 1 and 2 were identical unless
otherwise noted. Reaction of B12 with 1,10 -carbonyl-di-(1,2,4triazole) furnished an activated ester at the 50 -hydroxyl group.
The activated B12 was then added to a slowly stirring solution
of bovine insulin. The site directed B12 conjugation utilizes
the established difference in reactivity of the amino groups
(LysB29 > GlyA1 [ PheB1) of insulin at pH 9.5.17 For 1, the
more reactive LysB29 and GlyA1 were initially protected with
tert-butyloxycarbonyl (BOC) to allow for specific conjugation of
B12 at the unprotected PheB1 residue as previously described by
Kim et al.17 2 was synthesized without need for a protecting
group due to the high level of reactivity of LysB29 under the
reaction conditions chosen.
Both reactions were extracted by ether precipitation and
centrifugation. The products were isolated by analytical reversephase HPLC. Purification proved challenging due to the similarity in hydrophobicity of unconjugated insulin and B12 conjugated insulin. For 1, the BOC protection was adequate to
produce a separation between B12 conjugated and free insulin
(see Fig. S2†). For 2, addition of an excess of FMOC-OSu was
used to aid in purification. The FMOC moiety increases the
retention time of the unconjugated (hence, unprotected) insulin
allowing for separation (Fig. 2). Following HPLC purification,
the protecting groups (BOC or FMOC) were removed with TFA
(1) or piperidine (2) and dialysed against 5 L of H2O overnight in
7000 MWCO dialysis tubing.
The exact site of conjugation was verified by matrix assisted
laser desorption ionization time of flight (MALDI-ToF) mass
spectrometry (MS) analysis of reduced and digested fragments of
1 and 2. The conjugates were first treated with dithiothreitol to
reduce the interchain disulfide bonds linking the A- and B-chain.
MS analysis of the reduced conjugates displayed m/z values
of 2339.0 and 4755.4 corresponding to unmodified A-chain and
B-chain bond to B12, respectively (Fig. 3).
To verify the specific B-chain site, reduced conjugates were
treated with trypsin, which cleaves peptides at the carbonyl side
of arginine or lysine, except when followed by a proline. Reduced
and digested 1 displayed a m/z of 3844.9 corresponding to B1–
B22 plus B12 indicating conjugation at the B1 site (Fig. 3). While,
reduced and digested 2 displayed a m/z of 2286.0 corresponding
to B23–B30 plus B12, indicating attachment at the B29 site
(see Fig. S2†).

Fig. 2 The RP-HPLC spectra of an FMOC protected insulin plus B12
reaction monitored at 360 nm (dash) indicating B12 is present and 254 nm
(solid) indicating insulin is present.
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Fig. 3 MALDI-ToF MS spectrum of DTT reduced 1 shows mass at
4754.5 m/z representing B12 attached to the B-chain of insulin. Reduced
and tryptically digested 1 (inset) produces a 3844.9 m/z fragmenting
consistent with B12 attached at the N-terminus of the B strand, as
expected with PheB1 conjugation. The addition of B12 to the B29 position
would produce a 2286.0 m/z fragment, absent in the spectra of 1. Also
absent is B12 attached to the A strand.

In vivo testing and molecular dynamics (MD)
Comparison between both conjugates was assessed by measuring
blood glucose concentration following oral delivery of 1 and 2
(Fig. 4). Area under the curve (AUC) transformation showed
a significant difference (p ¼ 0.03) between 1 and free insulin
control, consistent with that observed in our earlier report.12
Of interest here is that no significant difference in glucose drop
(p ¼ 0.53) was observed between 1 and 2. Both produced similar
and greater drops over free insulin of the same orally administered concentration. This data differs from previous literature15–18 that demonstrated conjugation position alters the
biological activity of insulin and was not what we expected. We
believe our findings may be explained by components of the B12
uptake pathway, making this result not in conflict with these
earlier findings but rather suggesting a unique result tied to the
use of B12 in insulin conjugation.
To help explain this result we conducted MD simulations on
the binding of 1 with the B12 transport protein TCII. Previous

Fig. 4 Relative (% pre-gavage) blood glucose concentration following
administration of free insulin (n ¼ 4), 1 (n ¼ 6) and 2 (n ¼ 6).
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MD simulations of 2 interacting with TCII13,14 indicated that the
lysine side chain alone provided an adequate tether length to
place the unstructured insulin B-chain region (residues B20–B30)
beyond the steric congestion of the B12 bound TCII structure.
Furthermore, the B20–B30 tail provides considerable length
for placing the most structured region of the insulin molecule
(the complete A-chain and B7–B19 B-chain region) far from the
a- and b-Domains of TCII, thereby not impacting the binding
geometry of the B12 in its internal TCII pocket or the interaction
of insulin with the insulin receptor.13
Formation of 1 does place the B12 several residues from this
structured insulin region, but the effective separation of the
structured insulin region from the TCII binding area is not
obvious from the components themselves given (i) the inability to
predict insulin unfolding of the B1–B7 region (the residues prior
to the first disulfide linkage to the A-chain) to accommodate the
B12 binding within its pocket and (ii) the inability to predict if the
phenylalanine side chain itself would serve as a source of steric
congestion to disrupt B12 binding in its pocket (in 2, the lysine
side chain is itself the tether region between B12 and insulin).
Given the structural similarities between the B12 transport
proteins TCII and IF (and presumed structural similarities
between both and haptocorrin),19 the TCII simulations serve
generally as a guide for predicting how the entire family of B12
transport proteins might behave upon B12 conjugation, at least
when tethered at the B12 ribose hydroxyl group. Insights into the
nature of the B12–insulin/TCII interaction upon PheB1 conjugation come from a 15 ns simulation of 1 interacting with the
TCII complex. A representative of the geometry of 1 during these
simulations is shown and labeled in Fig. 5.
The unstructured B20–B30 region of the insulin B-chain was
removed from such calculations. This unstructured loop points
away from the TCII when the B12 is linked at the B1 position

Fig. 5 A representative structure of 1 as bound within TCII. Significant
residues identified in the text are labeled, including one persistent
hydrogen bond between insulin B-chain residues B4 and B13 in the MD
simulation.
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requiring a considerable extension of the solvent box, which adds
to total atom count without providing useful information about
the TCII interactions with 1. The representative geometry in
Fig. 6 shows that the PheB1–CysB7 (B1–B7) region of the
B-chain is unfolded from its unmodified, native a-helix geometry. In the snapshot shown, the disruption of a-helical structure
extends slightly past the disulfide linkage (CysB7). This unfolding of the a-helix enables several local hydrogen-bonding interactions to form transiently throughout the 15 ns simulation. One
of the more persistent interactions is the newly formed hydrogen
bond between B4 and B13 (Fig. 5). The result of this unfolding is
that the B1–B7 residues become the long tether that separates the
insulin core from TCII upon binding of the B12–insulin conjugate. This tether originates from an otherwise stable a-helix and
is slightly longer than half of the length of the B20–B30 tether in
the previous study. The retention of the B12 within its binding
pocket with no observable deformation of this pocket indicates
that the B1–B7 tether is long enough to separate the two larger
fragments. As an MD simulation of the B12–insulin molecule
already bound in TCII, this simulation indicates only that, once
bound, there are no expected steric issues preventing retention of
the B12 in its binding pocket. Given the clamshell-like binding
mechanism proposed for the B12–TCII complex, it is presumed
that the B12 can bind with at least one domain of TCII first with
the insulin bound, after which the insulin B1–B7 unfolding is
a subsequent step in the enclosure of the complete B12 by TCII.
The 5.0 ns timesteps shown in Fig. 6 (shown without the TCII for
clarity) reveals the extent to which the PheB1–CysB7 is
completely uncoiled upon stable B12 binding in the TCII pocket.
It is this uncoiling induced upon binding by B12 uptake proteins
that possibly explains why both sites on insulin ultimately equate
in function and why such differences were not observed before.
Fig. 6 also reveals the extent to which this uncoiling in 1 is
extended into GlyB8–LeuB11, leaving only ValB12–CysB19 to
retain any preserved a-helical structure despite the reasonably
well-conserved overall structure of the conjugate. Looking then
at the 15 ns simulation, shown in 5 ns snapshots in Fig. 7, the
largest variation in local geometry is not observed at the B12 or

Fig. 6 5.0 ns snapshots of the 1 along the B-chain a-helix axis (V1) and
perpendicular to the a-helix axis (V2), with both views showing the
gradual uncoiling of the B-chain (PheB1 through LeuB11) over the
course of the simulation. Light blue ¼ insulin A-chain; yellow ¼ insulin
B-chain and B12. The TCII protein is not shown for clarity.
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Fig. 7 5.0 ns snapshots of the PheB1-linked B12–insulin/TCII complex.
Light blue ¼ insulin A-chain; yellow ¼ insulin B-chain and CN–Cbl;
red ¼ TCII a-Domain; green ¼ TCII a-/b-Domain linker; dark blue ¼
TCII b-Domain.

even the B12–insulin conjugate. Instead, the largest variation is
found in the unstructured loops of the a-Domain of TCII,
a result identical to that found in the previous B12–insulin
conjugate simulation study.13 This difference is most
clearly highlighted by comparing the simulation RMSDs of the
a-Domain with both these loops included (Fig. 8, dark red) and
excluded from the RMSD calculation (Fig. 8, light red). In the
case of the loop-excluded analysis, the hexagonal a-helix
framework of the a-Domain (the region responsible for forming
the cleft into which the B12 binds) shows very little change
through the simulation.
We then explored whether a dose-dependent response could be
observed for this pathway with a suitable B12–insulin conjugate.
Dose dependent effects of 1 on blood glucose were assessed in

Fig. 8 Backbone RMSD plots for the PheB1-linked B12–insulin/TCII
complex. The removal of the a-Domain a-helix-linking unstructured
loops in the TCII a-Domain RMSD analysis (light red) reveals the
persistence of the a-Domain B12 binding region compared to the overall
a-Domain RMSD analysis (dark red).
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Russell-Jones3. It is also possible that B12 conjugation is greatly
improving insulin stability, presumably as IF–B12–insulin
formed in situ. This hypothesis is consistent with the observed
glucose drop along with observed dose-dependent response.
Under this latter scenario, the blocking of uptake by a large
excess of B12 (>105 M) as observed in our earlier work12 would
still be attributed to loss of IF binding, but rather than loss of
cubam mediated uptake, the effect of such loss would be reduced
gastric protection.
If such a route to oral insulin through the insulin receptor is
made available by B12 conjugation it would be a paradigm shift
in our view of exploiting the B12 uptake pathway for oral protein
delivery.
Fig. 9 Relative (percentage change from pre-gavage) blood glucose
concentration following administration of 1 at concentrations of 109 M,
107 M and 105 M.

STZ-rats and the results are shown in Fig. 9. 1 was administered
at concentrations of 109 M (n ¼ 3), 107 M (n ¼ 3) and 105 M
(n ¼ 2). AUC was calculated for each dose as 1387  297, 795 
202 and 125  15 mmol L1 240 min below pre-gavage blood
glucose concentration for 109 M, 107 M and 105 M doses
respectively. AUC of raw data identified a significant difference
between 109 M and 105 M conditions, but there were no
significant differences between the other concentrations. The
data presented in Fig. 9 demonstrates the ability of the conjugate
to produce a dose dependent reduction in blood glucose. An
increase in concentration from 109 M to 105 M resulted in an
increase of 10–20% drop in blood glucose.
We report herein on the synthesis, purification and characterization of a new B12 insulin conjugate attached at the insulin
PheB1 position. The hypoglycemic properties resulting from oral
administration (gavage) of such a conjugate in STZ diabetic rats
was similar to that noted in a B12–insulin conjugate covalently
linked at the insulin LysB29 residue,12 demonstrating the availability of both positions of insulin for, at least, B12 attachment. A
possible rationale for this result is put forward from MD simulations, which suggest there is forced un-coiling of the insulin
molecule at either the N- or C-terminal B strand insulin regions,
depending on B12 conjugation site, upon B12 binding protein
interaction with 1 or 2. We also conclude that there is a dose
dependent response that can be observed for B12–insulin conjugates with doses of conjugate greater than 109 M necessary to
observe a drop in glucose. In our earlier report on the oral
activity of 2 we demonstrated that the blood glucose reduction
could be blocked by the addition of a large excess of free B12.
However, the administered amount of conjugate (100 nM) was in
great excess of the expected B12 uptake capacity of the rat
(100 nmole per dose),3 signifying an alternative and/or additional
mechanism for the response. Given the confirmed presence of an
insulin receptor (IR) in the intestine of several mammals20,21
including rat22,23 and human,24 it may be that there is an alternate
receptor at play in the uptake of B12–insulin. While the intestinal
IR was not the intended target for our conjugates it is possible
that the conjugation of B12 has resulted in a predominantly
monomeric insulin (necessary for IR binding) capable of interacting with the intestinal insulin receptor, as suggested by
This journal is ª The Royal Society of Chemistry 2012
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Abstract: Reaction of vitamin B12 (B12) with excess 2-iodoxybenzoic acid and 2-hydroxypyridine leads to selective oxidation of the
5′-hydroxyl group of the ribose tail of B12 in a 30% isolated yield.
The acid derivative was purified in one step by HPLC chromatography and characterized by MALDI-TOF mass spectrometry,
1
H NMR and 2D (HSQC and HMBC) NMR. The new carboxylic
acid derivative is perfectly suited to make stable amide-based B12
bioconjugates.

Interest in using vitamin B12 (B12) for the oral delivery of
peptides and proteins1 has encouraged us to further explore the available conjugate sites of B12. Modifications of
B12 that allow for more facile, higher yielding or stable
bioconjugate formation with continued recognition by B12
dietary uptake and transport proteins have been explored
by numerous groups.2–4 Several functional groups are
available on B12 for conjugation, including the 5′-hydroxyl group of the ribose tail, the cobalt(III) ion, the phosphate moiety, and suitably modified propionamides off
the corrin ring.5 All such modifications suffer from issues
including reduced or complete loss of interaction with one
or more of the B12 binding proteins, stability issues that result from the production of ester or carbamate bonds, low
yielding conjugation reaction due to the nature of the
functional group, or require problematic purification of
the modified B12 for subsequent conjugation.2–4 These
limitations have been well investigated6 and a review of
such sites has been reported,7 however, in brief for purposes of perspective for the work described herein: Conjugation resulting in the recognition of all three transport
proteins has been most successful with B12 at two major
sites: (i) the peripheral corrin ring e-propionamide, and
(ii) the 5′-hydroxyl group of the ribose unit of the a-‘tail’.
The side chain e-carboxylic acid derivative (Figure 1) allows for a variety of modifications,8 but the synthesis of
the derivative is low yielding and requires laborious purification, the result, in part, of the formation of b- and dcarboxylic acid isomers in addition to the desired e-isomer.9 The 5′-hydroxyl group has been cited as being a
more versatile site according to structure–activity relationships, however, the conjugates have typically been
synthesized as mentioned above, through carbamate or ester bonds.
SYNLETT 2012, 23, 000A–000D
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Figure 1 Potential sites available for carboxylic acid formation that
also maintain, at least in part, B12 uptake protein recognition and binding are indicated in red. The atom numbering scheme used for NMR
discussion is also indicated

The goal of this work was to create a simple route for the
production of a 5′-carboxylic acid derivative of B12 with
facile purification to ultimately produce stable amidelinked bioconjugates at this optimal position for conjugation, especially in regard to intrinsic factor binding (critical for oral uptake of B12 bioconjugates).10 Herein, we
report the use of the hypervalent iodine reagent, 2-iodoxybenzoic acid (IBX) for the selective oxidation of the
5′-hydroxyl group of B12 to the corresponding carboxylic
acid. This is the first time IBX has been utilized for the oxidation of such a molecule as B12 and expands the range of
use of this environmentally friendly oxidizing agent.11
The B12 derivative was synthesized through a modification of the method developed by Giannis et al., which incorporates the addition of an O-nucleophile to aid IBX in
the transformation of a primary alcohol into a carboxylic
acid (Scheme 1).12 The use of N-hydroxysuccinimide
(NHS) was initially attempted but resulted in the formation of a product mixture from which it was not possible
to isolate the carboxylic acid, likely due to the formation
of the activated NHS ester, which has been reported as a
dominating product of this reaction.12 Therefore, 2-hydroxypyridine (HYP) was used as the O-nucleophile. To optimize the reaction conditions, a series of experiments were
performed in which the co-oxidant, temperature, and time
were varied (Table 1). The best result was obtained in the

Downloaded by: Syracuse University Library. Copyrighted material.

Key words: vitamins, oxidation, 2-iodoxybenzoic acid, carboxylic
acids, cobalamin

LETTER

S. Clardy-James et al.

presence of 2.6 equivalents of IBX and 5 equivalents of
HYP in dimethyl sulfoxide (DMSO) at 60 °C.

Table 1 Optimization of the Reaction Conditions
Entry

Co-oxidant

Temp (°C)

Time (h)

Yield (%)

1

None

50

2

17

2

HYP

50

2

23

3

HYP

50

3

26

4

HYP

50

4

28

5

HYP

50

5

22

6

HYP

60

2

30

2). Slight increases in pH above pH 2 resulted in a reduction in the amount of pure isolated product. HPLC purification allowed the recovery and reuse of B12 starting
material, albeit with the oxidized 5′-aldehyde also present
(Figure 2). B12CA was identified as the peak at 13.6 minutes retention time. The purity of B12CA was at least 95%,
as assayed by RP-HPLC. MALDI-TOF mass spectrometry analysis of B12CA revealed the anticipated molecular
ion peak (m/z = 1343.5 [M – CN]+; Figure 3).

Scheme 1 Purposed mechanism for the formation of the 5′-carboxylic derivative utilizing IBX and HYP

These conditions resulted in the oxidation of B12 to the
5′-carboxylic acid derivative B12CA in two hours with a
30% yield (see the Supporting Information). It was determined that a 30% yield was optimal for the IBX reaction
in this case. An increase in temperature, IBX/HYP ratios,
or time resulted in an increase in the amount of byproducts
and/or decomposition of the B12 (especially at temperatures in excess of 60 °C), reducing the yield and complicating purification. The 30% yield is approximately three
times that previously reported for the preparation of the ecarboxylic acid derivative, with far easier separation (see
below).9
The crude reaction mixture was precipitated from DMSO
by ether addition and the precipitate was redissolved in
water prior to purification by ion exchange chromatography using a SAX column. After a 5 minute hold at
100% water, a gradient from 100% water to 35% MeCN–
phosphate buffer (pH 2; 50:50 v/v) over 5 minutes was
necessary for the separation and elution of B12CA (Figure
Synlett 2012, 23, A–D

Figure 2
The RP-HPLC spectra of 5′-carboxylic acid
(tR = 13.6 min) monitored at 360 nm. Unreacted B12 and 5′-aldehyde
co-elute at tR = ca. 5 min, as indicated by MALDI-TOF MS (see also
Figure S1 in the Supporting Information)

Electronic absorption spectroscopy (EAS) was used to establish the oxidation state of the metal center as Co(III),
with no indication of derivation of the axial ligands bound
to the metal center (εCA361 = 27500 M–1cm–1; see Figure 4)
The structure of B12CA was determined on the basis of 1H
NMR (see Figure S2) and 1H–13C heteronuclear (HSQC
and HMBC) correlations (see Figures S3 and S4). The 1H
NMR spectra of B12CA revealed the loss of two protons
(δH = 3.75 and 3.92 ppm), when compared to the spectrum
of B12 (CNCbl; see Figures S2 and S5). A comparison of
the HSQC of B12 and B12CA indicates the protons that are
absent in B12CA were originally attached to the R5 carbon
(δC = 63.5 ppm; see Figure S6). HMBC was attempted to
further establish the presence of a carbonyl at the R5 position (see Figure S4), however, it was not possible to assign the R5 carbon from the HMBC spectra because it
© Georg Thieme Verlag Stuttgart · New York
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Scheme 2 Synthesis of 5′-carboxylic acid plus benzylamine

Figure 5 Purification of the conjugate was established by RP-HPLC
using an SAX column with a gradient from 100% water to 35%
MeCN–phosphate buffer pH 2

Figure 4 Absorbance spectrum of 5′-carboxylic acid derivative in
35% HPLC mobile phase B

showed no connectivities to any of the ribose protons, and
so was assigned by HSQC.13
A simple amine-containing organic molecule, benzylamine, was conjugated to the derivative to help with the
identification of the R5 carbon by NMR analysis. In the
presence of 10 equivalents of ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC) and 20 equivalents 1-hydroxybenzotriazole (HOBt) in N,N-dimethylformamide (DMF)
with 1% water, the desired conjugate was produced at
40% yield over the first hour (Scheme 2), thus establishing proof-of-concept for the new B12CA.
The conjugate was purified by using the same purification
method established for the carboxylic acid (Figure 5) and
characterized by MALDI mass spectrometry (Figure S7)
as well as 1D (Figure S8) and 2D NMR (Figures S9 and
S10) spectroscopy.
With the addition of the benzylamine, connectivity to the
R5 carbon was established by HMBC (Figure 6). Specifically, the protons of CA (δH = 4.42 and 4.50 ppm) showed
direct connectivity to the R5 carbon (δC = 173.8 ppm) as
well as to CB (δC = 140.8 ppm) and CC (δC = 131.4 ppm)

© Georg Thieme Verlag Stuttgart · New York

Figure 6 Analysis of the B12 5′-carboxylic acid benzylamine derivative by 2D heteronuclear NMR spectroscopy. (A) The atom numbering scheme for the benzylamine attached to R5 of B12 by an amide
bond. (B) Signal assignments made from HSQC. (C) Signal assignments made from HMBC (both 1H and 13C assignment for CA were
made on the basis of HSQC analysis)

of the benzylamine. The complete assignment of B12CA
and B12CABA can be found in Table S1.
In conclusion, we have developed a convenient site-specific oxidation of B12 using IBX and HYP. This new carboxylic acid derivative is highly suited to the production
Synlett 2012, 23, A–D
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Figure 3 MALDI-TOF MS spectrum of HPLC peak at
tR = 13.6 min, indicating B12CA (m/z = 1343.5 [M – CN]+) with angiotensin I (m/z = 1296.5) as an internal reference

S. Clardy-James et al.

of bioavailable amide bound bioconjugates. The one-step
purification is simple and the synthesis results in a 30%
yield within two hours, which is far in excess of any previously reported B12 carboxylic acid derivative.9 The resulting derivative has the potential to form high-yielding
conjugates and we believe will be of considerable use in
the field of B12 conjugation.
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